PROGRAMME

30th ECNP Congress | 2-5 September 2017 Paris
For the Science and Treatment of Disorders of the Brain

Programme
Social Media

At the ECNP Congress

For informational updates and news flashes during the congress, find us on Facebook and follow us on Twitter.

@ECNPtweets

myECNP

Floor plans
- Level 2: 1
- Level 3: 2

Welcome: 6

Scientific Programme
- Types of sessions: 8
- Poster sessions information: 11

Saturday
- Sessions: 15
- Keynote session: 19

Sunday
- Sessions: 21
- Posters: 34

Monday
- Sessions: 79
- Posters: 92

Tuesday
- Sessions: 137
- Posters: 150

Industry
- Introduction: 195
- List of partners: 196
- Industry sessions:
  - Satellite symposia: 209
  - Expert science exchange: 211

Exhibition
- List of exhibitors: 218
- Floor plan exhibition: 219

Information
- Congress information:
  - Accreditation: 221
  - For members: 223
  - For junior scientists: 224
  - Congress committees: 226
  - ECNP Meetings around the congress: 229
  - Info A-Z: 230
- ECNP general:
  - Projects and initiatives: 236
  - Membership: 237

Contact: 240
Dear colleagues,

When ECNP started over 30 years ago, its focus was medicines – the science behind them, and how best to use them in the clinic. Since then, that focus has expanded to encompass all brain function as it relates to human brain disorders and their treatment. From neuropsychopharmacology, the ECNP Congress now covers the spectrum of applied and translational neuroscience.

What has not changed though – and what distinguishes the ECNP Congress most of all – is the outstanding quality of the science on offer and the commitment to real-world treatments that unites it. For anyone interested in the future of CNS treatments, whether the most innovative fundamental research or the latest advances in the clinic, there will be no meeting like the ECNP Congress.

This reputation for the very best science is one we work hard to uphold, and this year is no exception.

We are honoured to be able to welcome John Krystal as keynote speaker during the official opening of the congress on Saturday. He will provide us with a fascinating insight into the role of glutamate in psychiatric disease. And we have a great line of up of six plenary speakers!

This year the congress again covers a widespread range of subjects within neuropsychiatry and applied neuroscience. Speakers will present and discuss forefront research and therapy strategies. Special emphasis will be given to the role of lifestyle and potential interventions in this domain, with symposia, brainstorming and educational update sessions on stress, sleep and exercise (S.19, S.21, S.27, E.06, BS.05, BS.06). A symposium on digital technology in bipolar disorders will open up discussions on the opportunities and risks of this new approach (S.28). Three poster sessions will provide a further stage for the presenting and discussion of latest data in the field.

The highly popular top paper sessions, introduced last year, will feature again on the programme. In these sessions, leaders in the field will discuss their selection of the most clinically important and cutting-edge papers, published in the past 12 months, in their discipline.

We also extend a special welcome to our junior colleagues. We hope this congress will be of added value for junior scientists, especially with the new findings symposia (S.12 and S.16), career development sessions and our Monday night ‘Science-on-the-rocks’ event.

Welcome to Paris. We hope you will enjoy the congress! Amusez-vous!

Celso Arango
President

Astrid Linthorst
Chair Scientific Programme Committee
In alphabetical order

**Brainstorming sessions (BS)**
Small, focused interaction sessions organised by ECNP members on a topic of their choice. The organiser of the session and a second expert in that specific field of interest will initiate the discussion.

**Career development sessions (CD)**
These practical sessions each feature a leading expert in the field. The expert is specifically invited to share with you his/her wealth of knowledge and experience. The topics are especially interesting for junior scientists, but sessions are open to all participants. Career development sessions are held daily during the poster sessions.

**Industry sessions**

**Satellite symposia (C)**
These scientifically oriented sessions are organised by and with educational financial support from industry. The programmes have been reviewed for balance and rigour by the Scientific Programme Committee and are accredited for European CME.

**Expert science exchange (CE)**
The expert science exchange provides the opportunity for focused, scientifically driven engagement between industry and participants. Each session has six presentations which can be attended separately. Each presentation has a limited capacity of 80 participants and admittance is given on a first-come-first-served basis. The sessions are organised by and with educational financial support from industry.

**Keynote session (KL)**
As the centrepiece of the keynote session, the keynote lecture features a world-renowned speaker who is especially invited to present on a topic of interest to all congress participants. The keynote session will take place on Saturday 2 September 2017, followed by the welcome reception. The 2017 keynote lecture will be presented by John Krystal, Yale University School of Medicine, USA, on ‘**Targeting glutamate in psychiatric disease**’.

**Nomenclature session (NS)**
A lunchtime session on Sunday, specially dedicated to the classification of psychotropic drugs by means of the Neuroscience-based Nomenclature. The topic is ‘Why and how psychotropic nomenclature was changed: presenting the NbN app – focus on the paediatric’.

**Patient session (ES)**
A special session dedicated to addressing patient issues and topics relevant to patient care and families. This year the session will focus on terrorism and the appropriate care after terrorist attacks.

**Plenary lectures (PL)**
The plenary lectures are presented by internationally eminent scientists. Six plenary lectures are scheduled, one of which will be delivered by the 2017 ECNP Neuropsychopharmacology Award winner, Michel Hamon.

**Poster sessions (P)**
For detailed information about the poster sessions, please see the next chapter ‘Poster sessions information’.

**Rapid-fire poster sessions (RF)**
These sessions will give 18 of the highest-scoring poster presenters the chance to present their data in a 5-minute presentation. Rapid-fire poster presenters will be selected based on the quality of their abstract, and receive this extra benefit in addition to their participation in the general poster sessions with a poster board.

**Symposia (S)**
Symposia are divided into five tracks:

- **CT** Clinical Treatment track: the latest in therapies and clinical applications
- **CR** Clinical Research track: cutting-edge discoveries in clinical neuroscience
- **TR** Translational Research track: the latest translational and cross-disciplinary research
- **PR** Preclinical Research track: break-through research in basic neuroscience
- **ET** Educational track: up-to-date insights and practice-oriented education.

The sessions in the educational track focus on a continuous dialogue between the participants and the presenters. Different angles of a subject are discussed and state-of-the-art summaries are provided, with emphasis on new information relevant for clinical practice. A ‘key pad’ system is used to make the sessions more interactive.

The symposia are scheduled in six parallel sessions, daily at 09.00-10.40 and 15.00-16.40 (on Saturday only from 16.50-18.30). In each symposium, four speakers present on a specific topic.
New findings symposia
Two fixed symposia, one scheduled in the preclinical research track and one in the translational research track. Eight speakers per symposium are selected from the participants at the ECNP Workshop for Junior Scientists in Europe, which is held every year in March in Nice, France.

Regulatory spotlight session
A special regulatory dialogue session with the European Medicines Agency (EMA). Designed for open and active engagement amongst EMA stakeholders, the session provides an excellent platform for scientific and regulatory exchange.

TNM symposia
These are the three symposia based on the Targeted Network Meetings (TNMs), held last year in Vienna, Austria.

Top paper sessions (TP)
During six 30-minute top paper sessions speakers will discuss four papers published in the past 12 months, which they consider clinically most important and cutting-edge in their discipline. These sessions are a great way to get up to speed with the latest developments in different disciplines.

Welcome reception
Following the Keynote session on Saturday, participants are invited to the welcome reception held at the congress venue where they will have the opportunity to meet and interact with colleagues. A drink and a small bite will be served.

Poster sessions are held Sunday, Monday and Tuesday at 12.15-13.45, in the poster area. The posters are grouped into eight topics.

Poster sessions are scheduled during the lunch break to allow ample time for participants to discuss the data presented. Poster presenters will be at their paper poster for further explanation and discussion, and to answer any questions you might have. Additional emphasis is placed on the posters by awarding the most outstanding posters with Poster Awards, and the best abstracts for posters by junior scientists with Travel Awards. A number of poster presenters, who are resident of a European country with a developing economy (CDE), have received a CDE Grant to support travel expenses for the 30th ECNP Congress.

All poster presenters have submitted an e-poster in addition to presenting a paper poster. Special terminals are available in the poster area to view these e-posters. One terminal will contain all the awarded posters.

Activities related to the posters

<table>
<thead>
<tr>
<th>Time &amp; Location</th>
<th>Sunday, Monday, Tuesday</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.40-11.15 Poster area (podium)</td>
<td>Travel Award ceremony</td>
</tr>
<tr>
<td>10.40-11.15 Poster area</td>
<td>Poster viewing* and coffee break</td>
</tr>
<tr>
<td>12.15-12.45 Poster area (podium)</td>
<td>Rapid-fire poster session</td>
</tr>
<tr>
<td>12.15-13.45 Poster area</td>
<td>Poster session</td>
</tr>
<tr>
<td>13.00-13.15 Poster area (podium)</td>
<td>Poster Award ceremony</td>
</tr>
<tr>
<td>13.15-13.45 Poster area (podium)</td>
<td>Career development session</td>
</tr>
</tbody>
</table>

* Posters that are on display can already be viewed during this time (it is not mandatory for poster presenters to be at their poster).
Poster topics
Every topic (P.1-P.8) is divided into several subtopics. In order to find the posters in your field of interest more quickly, all topics and subtopics are listed below.
All posters are listed in this programme book by subtopic, on the day that they are presented.

P.1 Basic and clinical neuroscience
  1.a Genetics and epigenetics
  1.b Neuroanatomy and neurophysiology
  1.c Neurodevelopment
  1.d Glia-neuron interaction
  1.e Neuro-endocrinology
  1.f Neuro-immune interaction
  1.g Neuropharmacology
  1.h Animal behaviour
  1.i Brain imaging and neuromodulation
  1.j Cognitive neuroscience
  1.k Epidemiology
  1.l Other

P.2 Mood disorders and treatment
  2.a Affective disorders: basic
  2.b Affective disorders: clinical
  2.c Bipolar disorders: basic
  2.d Bipolar disorders: clinical
  2.e Treatment: basic
  2.f Treatment: clinical
  2.g Other: basic
  2.h Other: clinical

P.3 Psychotic disorders and treatment
  3.a Psychotic disorders: basic
  3.b Psychotic disorders: clinical
  3.c Treatment: basic
  3.d Treatment: clinical
  3.e Other: basic
  3.f Other: clinical

P.4 Anxiety disorders, OCD, stress-related disorders and treatment
  4.a Anxiety disorders: basic
  4.b Anxiety disorders: clinical
  4.c Treatment: basic
  4.d Treatment: clinical
  4.e Other: basic
  4.f Other: clinical

P.5 Dementia and neurological disorders
  5.a Dementia: basic
  5.b Dementia: clinical
  5.c Neurological disorders: basic
  5.d Neurological disorders: clinical
  5.e Other: basic
  5.f Other: clinical

P.6 Addiction
  6.a Alcohol: basic
  6.b Alcohol: clinical
  6.c Drugs: basic
  6.d Drugs: clinical
  6.e Other: basic
  6.f Other: clinical

P.7 Child and adolescent disorders and treatment
  7.a Disorders: basic
  7.b Disorders: clinical
  7.c Treatment: basic
  7.d Treatment: clinical
  7.e Other: basic
  7.f Other: clinical

P.8 Other topics
  8.a Other topics: basic
  8.b Other topics: clinical

Publication
Abstracts from posters presented at the 30th ECNP Congress will be published after the congress in a supplement to the ECNP journal European Neuropsychopharmacology. Abstracts of posters ending with a number higher than 300, have not been accepted for publication in the journal.

All abstracts are available on http://2017.ecnp.eu, congress information terminals at the venue, the ECNP app, and e-poster terminals.
Benefits related to the ECNP Congress

- Significantly reduced registration fees for the ECNP Congress.
- Exclusive access to the Members’ and Faculty lounge at the ECNP Congress.
- ECNP members can bring one junior scientist to the ECNP Congress for €100.
- The possibility to host a brainstorming session at the next congress.

Access to the latest information and research

- Free online subscription to the ECNP journal *European Neuropsychopharmacology*.
- Ability to join an ECNP Network.
- Access to the ECNP members’ website.
- Access to a member directory (‘find a member’), to connect to a wide network of ECNP members.

More opportunities

- Input into ECNP policy, by means of voting at the General Assembly.
- Serve on an ECNP committee and help shape ECNP’s future.
- Apply for an invitation to the ACNP Annual Meeting.

For more information, go to www.ecnp.eu/membership
**Elucidating the genetic architecture of psychiatric disease**

*Chairs:* Suzanne L. Dickson, Sweden
Andreas Meyer-Lindenberg, Germany

*S.01.01* Novel GWAS strategies to study schizophrenia genetics
t.b.a.

*S.01.02* Genetics of autism spectrum disorder: impact on neuroanatomy and synaptic plasticity
Thomas Bourgeron, France

*S.01.03* Anorexia nervosa and body mass index: combined GWAS and functional ex-vivo studies
Anke Hinney, Germany

*S.01.04* Exome or whole genome sequencing in bipolar disorder
Tadafumi Kato, Japan

**Aggression in conduct disorder is associated with altered top-down cortical processing mechanisms: a translational perspective**

*Chairs:* Jeffrey Glennon, The Netherlands
Essi Viding, United Kingdom

*S.02.01* Top-down cortical control mechanisms in animal models of aggression
Jeffrey Glennon, The Netherlands

**Role of oxytocin in social behaviour and stress coping**

*Chairs:* Gitte Moos Knudsen, Denmark
Inga Neumann, Germany

*S.03.01* When she’s gone: oxytocin reverses partner loss-induced passive stress coping
Oliver Bosch, Germany

*S.03.02* The effects of intranasal oxytocin after trauma
Miranda Olff, The Netherlands

*S.03.03* The role of serotonin and reward circuit architecture in oxytocin promoted social cognition: neuroimaging insights
Vibe G. Frokjaer, Denmark

*S.03.04* Translating oxytocin neuroscience to the treatment of anxiety disorders
Rene Hurlemann, Germany
**SYMPOSIUM**

16.50-18.30 | Grand Amphitheatre

**Rapid onset of action in the treatment of depression: evidence and mechanisms**

**Chairs:** Elias Eriksson, Sweden  
Tomi Rantamäki, Finland

**S.04.01**  
16.50  
Neurobiological mechanisms underlying rapid-acting antidepressant actions: BDNF the key?  
Lisa Monteggia, USA

**S.04.02**  
17.15  
NMDAR inhibition-independent antidepressant actions of ketamine metabolites  
Panos Zanos, USA

**S.04.03**  
17.40  
Re-examining the antidepressant potential and mechanisms of isoflurane  
Tomi Rantamäki, Finland

**S.04.04**  
18.05  
Combined use of antipsychotic and antidepressant drugs in treatment-resistant depression: scientific rationales  
Torgny H. Svensson, Sweden

**SYMPOSIUM**

16.50-18.30 | Havane

**Neuronal autophagy: concepts and treatment options**

**Chair:** Christian Behl, Germany

**S.05.01**  
16.50  
Basic mechanisms of autophagy and pharmacological induction  
David Rubinsztein, United Kingdom

**S.05.02**  
17.15  
Neuropeptide Y stimulates autophagy in hypothalamic neurons  
Claudia Cavadas, Portugal

**EDUCATIONAL UPDATE SESSION**

16.50-18.30 | Bordeaux

**E.01**

**EPA educational session – New insights in the negative symptoms of schizophrenia**

**Moderator:** Silvana Galderisi, Italy

**E.01.01**  
16.55  
Concept and neurobiology of negative symptoms in schizophrenia  
Armida Mucci, Italy

**E.01.02**  
17.40  
Developments and challenges in the assessment of negative symptoms in schizophrenia  
Sonia Dollfus, France

**KEYNOTE SESSION**

18.45-20.00 | Grand Amphitheatre

**Chair:** Celso Arango, Spain

**KL.01.01**  
Targeting glutamate in psychiatric disease  
John Krystal, USA

**WELCOME RECEPTION**

20.00-21.00 | Level 2

Participants are invited to the welcome reception to meet and interact with colleagues. A drink and a small bite will be served.
European Neuropsychopharmacology
Neuroscience Applied

Journal benefits
- Free online access for subscribers and ECNP members
- Easy online submission via Journal website (ees.elsevier.com/neuropsychopharmacol)
- Mobile optimised website for easy viewing

www.europeanneuropsychopharmacology.com
@els_psychiatry
facebook.com/elsevierpsychiatry

BS.01 BRAINSTORMING SESSION
07.45-08.45 | Room 341
Clinical implementation of chemogenetics, a revolutionary brain directed treatment
Chair: Pierre Blier, Canada
Experts: Roger Adan, The Netherlands
Dimitri Kullmann, United Kingdom

BS.02 BRAINSTORMING SESSION
07.45-08.45 | Room 342B
α7 Nicotine acetylcholine receptor (α7nAChR) negative allosteric modulators: next generation anxiolytics
Chair: Judith Homberg, The Netherlands
Experts: Christopher Lowry, USA
Jens Mikkelsen, Denmark

BS.03 BRAINSTORMING SESSION
07.45-08.45 | Room 343
Prevention of mental disorders: the role of treatment in pregnancy
Chair: Jaanus Harro, Estonia
Experts: Megan Galbally, Australia
Ian Jones, United Kingdom

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**S.06**

**SYMPOSIUM**

09.00-10.40 | Havane

**Novel approaches to cocaine addiction**

*Chairs:* Jean-Antoine Girault, France
  Wim van den Brink, The Netherlands

**S.06.01**

Synaptic basis of cocaine addiction

09.00  
Vincent Pascoli, Switzerland

**S.06.02**

Cocaine-induced chromatin modifications are associated with increased gene expression and DNA-DNA interactions of autism-candidate 2

09.25  
Olivia Engmann, Switzerland

**S.06.03**

Habit formation in humans with cocaine addiction

09.50  
Karen Ersche, United Kingdom

**S.06.04**

Plasticity in the lateral habenula underlying drug-evoked negative states

10.15  
Manuel Mameli, France

---

**S.07**

**SYMPOSIUM**

09.00-10.40 | Grand Amphitheatre

**Cognitive dysfunction across psychiatric disorders**

*Chairs:* Damiaan Denys, The Netherlands
  Dorien Nieman, The Netherlands

**S.07.01**

Cognitive functioning in subjects at clinical high risk for psychosis

09.00  
Paul Amminger, Australia

---

**S.08**

**SYMPOSIUM**

09.00-10.40 | Bleu

**Can genetic and epigenetic variation predict and mediate therapy response in anxiety disorders?**

*Chair:* Stefano Pallanti, Italy

**S.08.01**

SERT gene variation and response to exposure therapy in agoraphobia

09.00  
Koen Schruers, The Netherlands

**S.08.02**

Candidate genes involved in the aetiology and therapy response in panic disorder

09.25  
Angelika Erhardt, Germany

**S.08.03**

From candidate gene to (epi)genome-wide analyses of therapy response in child anxiety disorders

09.50  
Susanna Roberts, United Kingdom

**S.08.04**

From candidate gene to (epi)genome-wide analysis of therapy response in adult anxiety disorders

10.15  
Katharina Domschke, Germany
The role of brain connectivity in affective and psychotic disorders: implications for treatment

Chairs: Oliver Howes, United Kingdom
       Machteld Marcelis, The Netherlands

S.09.01 The effect of ketamine on fronto-temporal connectivity and implications for treating depression and schizophrenia
09.00 Andreas Meyer-Lindenberg, Germany

S.09.02 Altered functional brain connectivity in bipolar disorder and schizophrenia
09.25 Esther Opmeer, The Netherlands

S.09.03 Fronto-striatal connectivity in bipolar affective disorder and schizophrenia and relationship to treatment response
09.50 Oliver Howes, United Kingdom

S.09.04 The effect of risk factors for psychosis on brain connectivity
10.15 Machteld Marcelis, The Netherlands

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**AWARD CEREMONY**
10.40-11.15 | Poster area (podium)
Presentation ECNP Travel Awards

**COFFEE BREAK**
10.40-11.15 | Poster area and exhibition

**POSTER VIEWING**
10.40-11.15 | Poster area

Posters that are on display can already be viewed during this time. It is not mandatory for poster presenters to be at their poster, the poster sessions will start at 12.15. See pages 34-77 for details.

**PLENARY LECTURE**
11.15-12.00 | Grand Amphitheatre

Chair: Marion Leboyer, France

*Endophenotypes in schizophrenia*

Robert Freedman, USA

**LUNCH**
12.00-14.00 | Poster area and exhibition

**POSTER SESSION**
12.15-13.45 | Poster area

Poster presenters will be available at their paper poster for further explanation and discussion. See pages 34-77 for details.

**NOMENCLATURE SESSION**
12.00-14.00 | Bordeaux

**RAPID-FIRE POSTER SESSION**
12.15-12.45 | Poster area (podium)

Chair: Raymond Mongeau, France

RF.01.01 Optogenetic activation of prefrontal afferents in distinct hypothalamic regions facilitates aggressive behaviour

Biborka Bruzsik, Hungary

RF.01.02 Social cognition in schizophrenia patients and their siblings: the role of insula

Alice Caldiroli, Italy

RF.01.03 DNA methylation and adolescent trajectories of psychotic symptoms

Susanna Roberts, United Kingdom

RF.01.04 Repeated social stress in rats leads to contrasting patterns of structural plasticity in the amygdala and hippocampus

Deepika Patel, The Netherlands

RF.01.05 Mitochondria-targeted antioxidant SkQ1 reduces the death of dopaminergic neurons in the model of Parkinson’s disease in mice

Vsevolod Pavshintcev, Russia

RF.01.06 Cue reactivity and opioid blockade in amphetamine dependence: a randomised, controlled fMRI study

Joar Guterstam, Sweden
AWARD CEREMONY
13.00-13.15 | Poster area (podium)
Presentation ECNP Poster Awards

CAREER DEVELOPMENT SESSION
13.15-13.45 | Poster area (podium)
Abstract writing: how to pitch your results concisely and convincingly
Chair: t.b.a.
Presenter: Karen Ersche, United Kingdom

TOP PAPER SESSION
13.15-13.45 | Room 341
Highlights in neuropsychopharmacology
Chair: t.b.a.
Presenter: Filippo Drago, Italy

TOP PAPER SESSION
13.15-13.45 | Room 342B
Highlights in child and adolescent disorders
Chair: Abraham Weizman, Israel
Presenter: Mara Parellada, Spain

PLENARY LECTURE
14.00-14.45 | Grand Amphitheatre
Multimodal neuroimaging in neurodegenerative diseases
Gaël Chételat, France

COFFEE BREAK
14.45-15.00 | Poster area and exhibition

PRECLINICAL RESEARCH TRACK

SYMPOSIUM
15.00-16.40 | Havane
MicroRNAs in affective disorders
Chair: Philip Gorwood, France
S.11.01 miR-33 regulates GABAergic mechanisms of fear-inducing memories
Jelena Radulovic, USA
S.11.02 RGS2, SERT and NAT regulating microRNAs in anxiety disorders
Leif Hommers, Germany
S.11.03 MicroRNAs as biomarkers of antidepressant treatment response
Juan Pablo Lopez, Germany
S.11.04 Genome-wide association analysis implicates microRNAs in bipolar affective disorder
Andreas Forstner, Germany

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
New findings in applied neuroscience research I

**Chairs:** Livia De Picker, Belgium
Guy Goodwin, United Kingdom.

**S.12.01**
15.04
A “Brain-on-a-Chip” approach to characterizing glutamatergic and dopaminergic modulation of cortico-striatal networks
Benjamin Lassus, France

**S.12.02**
15.16
Ketamine restores changes in glutamate release, dendrite morphology and BDNF trafficking in the hippocampus of rats vulnerable to chronic mild stress
Paolo Tornese, Italy

**S.12.03**
15.28
Cadherin-13, a risk factor for neurodevelopmental disorders, modulates serotonin system development via radial glia interaction
Andrea Forero, Germany

**S.12.04**
15.40
A novel approach to map induced activation of neuronal networks using chemogenetics and functional neuroimaging
Tessa Roelofs, The Netherlands

**S.12.05**
15.52
AP2gamma transcription factor as a modulator of hippocampal neurogenesis in an animal model of depression
Eduardo Loureiro-Campos, Portugal

**S.12.06**
16.04
Compartmentalized perturbation of GABAergic synapses in the basolateral amygdala principal neurons
Rinki Saha, Israel

**S.12.07**
16.16
Role of the matricellular protein hevin in drug response
Raphaele Mongredien, France

**S.12.08**
16.28
Reward deficits triggered by glucocorticoids are driven by laterodorsal tegmentum ventral tegmental area dysfunction
Bárbara Coimbra, Portugal

New psychoactive substances: ‘legal highs’, cognitive lows?

**Chairs:** Kim Kuypers, The Netherlands
Jan M. van Ree, The Netherlands

**S.13.01**
15.00
Emerging novel psychoactive substances in Europe
Marta Torrens, Spain

**S.13.02**
15.25
Pharmacology of novel synthetic stimulants structurally related to the ‘bath salts’ constituent 3,4-methylenedioxypyrovalerone (MDPV)
Michael Baumann, USA

**S.13.03**
15.50
Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances
David Wood, United Kingdom

**S.13.04**
16.15
Behavioural toxicology and metabolomics of novel psychoactive substances (NPS) in controlled human studies
Johannes Ramaekers, The Netherlands

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**SYMPOSIUM** 15.00-16.40 | Bleu

**Relapse and relapse prevention following electroconvulsive therapy for depression: where are we now?**

_Chairs:_ Declan McLoughlin, Ireland  
Eduard Vieta, Spain

_S.14.01_ 15.00 Relapse after successful ECT: does the ResPECT experience fit the literature?  
Pascal Sienaert, Belgium

_S.14.02_ 15.25 Cognitive performance as a predictor for ECT outcome and relapse  
Esmée Verwijk, The Netherlands

_S.14.03_ 15.50 The KEEP-WELL trial (NCT02414932) – ketamine for depression relapse prevention following ECT  
Declan McLoughlin, Ireland

_S.14.04_ 16.15 The prolonging remission in depressed elderly (PRIDE) Trial (NCT01028508): results from the randomised phase  
Charles Kellner, USA

**SYMPOSIUM** 15.00-16.40 | Maillot

**The role of resilience in schizophrenia**

_Chair:_ John M. Kane, USA  
Til Wykes, United Kingdom

_S.15.01_ 15.00 The concept of resilience: definition and measurement  
John M. Kane, USA

**EDUCATIONAL TRACK**

**EDUCATIONAL UPDATE SESSION** 15.00-16.40 | Bordeaux

**Hoarding disorder: update on neurobiology, diagnosis and treatment**

_Moderator:_ Naomi Fineberg, United Kingdom

_E.03.01_ 15.05 Hoarding disorder: epidemiology, genetics and diagnostics  
David Mataix-Cols, Sweden

_E.03.02_ 15.50 Hoarding disorder: transdiagnostic and treatment aspects  
Danielle C. Cath, The Netherlands

**BREAK** 16.40-17.15

**Start industry sessions at 17.15**

**Updated programme:**  
http://2017.ecnp.eu / ECNP app / congress info terminals
P.1.a | GENETICS AND EPIGENETICS

P.1.a.001 Neurocognitive endophenotypes of schizophrenia and bipolar disorder and their possible association with variation in the candidate gene FKBP-5

P.1.a.002 The influence of childhood trauma, major depressive disorder and telomere length on HIV-associated neurocognitive disorders
J. Womersley*, G. Spies, S. Malan-Müller, G. Tromp, S. Hemmings, S. Seedat, South Africa

P.1.a.003 PDE7B, NMBR and EPM2A variants and schizophrenia: a case-control and pharmacogenetics study
H. Kim*, T.Y. Jun, South Korea

P.1.a.004 Financial hardship may trigger migraine through circadian dysregulation – a possible role for the CLOCK gene

P.1.a.005 Genome-wide gene-based tests replicate the association of the SORCS3 gene with neuroticism

P.1.a.006 Association of dopamine transporter gene SLC6A3 polymorphisms with remission and antidepressant therapy response in patients with depressive disorders
I.S. Losenkov*, I.V. Pozhidaev, D.Z. Osmanova, G.G. Simutkin, Russia

P.1.a.007 Gene expression biomarkers related to auditory hallucinations in peripheral blood of patients with schizophrenia
J. Gilabert-Juan*, G. Lopez-Campos, N. Sebastia-Ortega, S. Guara, J. Sanjuan, M.D. Molto, France

P.1.a.008 5-HTTLPR shows association with younger age at suicide: preliminary results from the Hungarian suicide biobank
J. Bakor, X. Gonda*, P. Dome, G. Faludi, E. Dinya, A. Laszik, Hungary

P.1.a.009 Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram

P.1.a.010 Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder
C. Fabbri*, A. Serretti, Italy

P.1.a.011 Effects of Val158Met polymorphism of catecholamine-O-methyltransferase on sensory gating in healthy subjects and schizophrenia patients
Z. Storozheva*, A.V. Kirenskaya, Russia

P.1.a.012 A new target for focusing on neurocognitive symptoms in depression: ATP6V1B2 rs1106634 is associated with hippocampal deficit and lifetime depression

P.1.a.013 The effect of valproic acid in the dorsal hippocampus in a rat model of post-traumatic stress disorder
N.G. Acet*, S. Ketenci, B. Aydin, H. Cabadak, Z. Gören, Turkey

P.1.a.014 Polymorphism (RS67175440) of DAT1 (SLC6A3) gene associated with an increased risk of Cloninger type 2 alcoholism in gender-specific manner
A.E. Nikolishin*, V.M. Brodiansky, N.A. Chuprova, M.G. Solovieva, A.O. Kibitov, Russia

P.1.a.009 Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram

P.1.a.010 Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder
C. Fabbri*, A. Serretti, Italy

P.1.a.011 Effects of Val158Met polymorphism of catecholamine-O-methyltransferase on sensory gating in healthy subjects and schizophrenia patients
Z. Storozheva*, A.V. Kirenskaya, Russia

P.1.a.012 A new target for focusing on neurocognitive symptoms in depression: ATP6V1B2 rs1106634 is associated with hippocampal deficit and lifetime depression

P.1.a.013 The effect of valproic acid in the dorsal hippocampus in a rat model of post-traumatic stress disorder
N.G. Acet*, S. Ketenci, B. Aydin, H. Cabadak, Z. Gören, Turkey

P.1.a.014 Polymorphism (RS67175440) of DAT1 (SLC6A3) gene associated with an increased risk of Cloninger type 2 alcoholism in gender-specific manner
A.E. Nikolishin*, V.M. Brodiansky, N.A. Chuprova, M.G. Solovieva, A.O. Kibitov, Russia

P.1.b | NEUROANATOMY AND NEUROPHYSIOLOGY

P.1.b.001 Effects of memantine on electrophysiological properties of rat barrel cortex neurons
A. Shamsizadeh*, Iran

P.1.b.002 The impacts of the interaction between gender and sexual orientation on the cerebral structures in homosexual and heterosexual people
S. Hu, D. Wang*, Y. Xu, J. Hu, China
**NEURODEVELOPMENT**

**P.1.c.001** Bioplasma promotes neuronal differentiation through cross-talk between superoxide and ERK pathway: new insights into age-related diseases

J.Y. Jang*, H. Rhim, S. Kang, South-Korea

**P.1.c.002** Validating a novel protocadherin 9 conditional knockout mouse model to study sensory cortex functioning

B.E. Hornix*, R. Kat, R. Havekes, M.J. Kas, The Netherlands

**P.1.c.003** Comparing the broad socio-cognitive profile of youth with Williams syndrome and 22q11.2 deletion syndrome


**P.1.c.004** Cerebellum and attention to the eyes in autism


**P.1.c.005** X-linked PCDH19 protein regulates cortical and hippocampal development, seizure susceptibility, cognition and autism-related behaviors

A. Cwetsch*, L. Perlini, S. Bassani, M. Passafaro, L. Cancedda, Italy

**P.1.c.006** Guanfacine as an alternative for autism spectrum disorder with hyperactivity symptoms

V. Muñoz Martinez*, L. Nuevo Fernandez, L. Mella Dominguez, B. Mata Saenz, L. Asensio Aguerri, G.A. Jimenez Londoño, Spain

**P.1.c.007** fMRI correlates of social cognition in attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and comorbid condition

D. Izarbe*, S. Lukito, O. O’Daly, D.J. Lythgoe, C. Murphy, V. Stoenceva, E. Simonoff, K. Rubia, United Kingdom, Spain

**NEUROENDOCRINOLOGY**

**P.1.e.001** What sexuality tells us about long-term outcome of eating disorders: a three years follow up study

G. Castellini*, L. Lelli, V. Ricca, Italy

**P.1.e.002** Serum VGF levels were significantly changed in mental disorders and may aid the diagnosis


**P.1.e.003** Comorbidity of depression in Schmidt syndrome

M. Manea*, G. Crisan, G. Scarisoareanu, V.M. Dumitru, Romania

**P.1.e.004** Vitamin D3 exerts a protective effect on glucocorticoid-induced neurotoxicity in rats via modulation of signaling through receptor activator of NF-κB

O. Lisakovska*, D. Labudzynskyi, S. Savosko, I. Shymanskyy, M. Veliky, Ukraine

**NEURO-IMMUNE INTERACTION**

**P.1.f.001** Elevation of plasma level of complement factor H in geriatric depression

C. Shin*, C. Han, Y. Ko, C. Pae, M. Park, South-Korea

**P.1.f.002** Effects of serotonin 5-HT1A and 5-HT2A receptor agonists and antagonists on the immune response in rats with high and low aggressiveness

E. Alperina*, G. Idova, E. Zhukova, Russia

**P.1.f.003** The relationship between depression and lower urinary tract symptoms is moderated by adverse life events and mediated by inflammatory mechanisms

G. Castellini*, V. Ricca, M. Maggi, Italy
A study of mechanisms behind extreme aggression: the possible existence of functional signaling mechanisms modulated by ACTH IgG

H. Værøy*, C. Adori, R. Legrand, N. Lucas, J. Breton, C. Cottard, J.C. Do Rego, C. Duparc, E. Louiset, H. Lefebvre, E. Western, S. Andersson, P. Dechelotte, T. Hökfelt, S. Fetissov, Norway

Variation in cytokines and C-reactive protein in different psychiatric disorders

Y. Sakai*, V.C. Iversen, N.H. Groven, S.K. Reitan, Norway

The association of neurobiological indices and the prognosis of therapy in schizoaffective patients with manic-delusional and manic-paraphrenic attack

I. Oleichik*, A. Iznak, S. Sizov, O. Yunilaynen, S. Zozulya, Russia

History of depression is associated with neuropsychiatric symptoms and augmented inflammatory markers in a cross sectional study on obese patients

G. Oriolo*, L. Huet, S. Dexpert, A. Aubert, B. Aouizerate, E. Magne, C. Beau, P. Ledagueneil, D. Forestier, D. Fuchs, R. Martin-Santos, L. Capuron, Spain

Selective inhibition of purinergic 2X7 receptors elicits antidepressant-like effect in chronic mild stress model in rats: role of innate immunity

F. Aricioglu*, C. Sahin Ozkartal, T. Bastaskin, E. Tuzun, C. Kucukali, T. Utkan, Turkey

Magnesium potentiates the facilitatory effects of citalopram on cognitive performance of old rats

G. Rusu*, G. Popa, A.C. Cristofor, L. Mittelau-Tartau, Romania

Effect of a single dose of methylphenidate on cognition in adults with attention deficit hyperactivity disorders and predictive therapeutic response

S. Ertle, L. Vanoli, A. Erb, F. Duval*, France

Sedative drugs activate signaling pathways implicated in rapid-acting antidepressant effects

S. Kohtala*, W. Theilmann, N. Matsui, A. Klein, T. Rantuamäki, Finland

Impact of selective manipulation of nucleus accumbens local microcircuits on D2-medium spiny neurons (MSN)-dependent increase in motivation


Contrasting effects by blocking orexin and NMDA receptors in telemetric EEG recordings in rats

B. Ferger*, P. Voehringer, H. Raith, J.R. Nicholson, C. Dormer-Ciosoek, Germany

D1 receptors, but not D2, mediate the locomotor activity and behavioral sensitization caused by 3,4-methylenedioxypyrovalerone (MDPV) in rats


5-HT1A biased agonists induce different hemodynamic responses: a pharmacological MRI study


Exploration of the concept of 5-HT1A receptor biased agonists: a multimodal imaging study

B. Vidal*, S. Fieux, J. Redouté, M. Villien, D. Le Bars, A. Newman-Tancredi, N. Costes, L. Zimmer, France

Ketamine and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via D3 receptor and mTOR pathway

L. Cavalleri*, E. Merlo Pich, C. Chiamulera, M.J. Millan, G. Collo, Italy
ANIMAL BEHAVIOUR

**P.1.g.012**  Effects of riociguat and biperiden on memory  
L.G.J.M. Borghans*, A. Sambeth, J.H.H.J. Prickaerts,  
J.G. Ramaekers, A. Blokland, The Netherlands

**P.1.g.013**  Stevens-Johnson syndrome induced by sodium valproate – a case report  
S. Nascimento*, F. Freitas, D. Pereira, T. Filipe,  
V. Viveiros, C. Costa, J. Gama, M. Prates, Portugal

**P.1.g.014**  Auditory steady state responses in rodents, a new tool for drug discovery in schizophrenia?  
C. Roucard*, B. Pouyatos, S. Gory-Faure, C. Touller,  
A. Evrard, R. Maury, C. Dumont, B. Mandé, A. Andrieux,  
Y. Roche, V. Duveau, France

**P.1.g.015**  Effects of repeated restraint stress on AT1 and Mas receptors content in medial amygdaloid nucleus  
W. Costa-Ferreira*, L. Gomes-de-Souza, G. Morais-Silva,  
C.C. Crestani, Brazil

**P.1.h.006**  Resveratrol attenuates neuroinflammation, maintains hippocampal BDNF levels and alleviates depressive-like behavior in aged rats  
Y. Yazir*, T. Utkan, G. Gacar, S. Furat Rençber,  
T. Demirtaş Şahin, S.S. Gocmez, Turkey

**P.1.h.007**  Latrophilin 3: a mouse model of attention deficit hyperactivity disorder  
N. Mortimer*, M. Ribasés, J. Ramos QUIroga, K. Lesch,  
O. Rivero, Germany, Spain

**P.1.h.008**  Rats exposed to maternal depression and antidepressant treatment during development show sex differences in social behavior  
D.J. Houwing*, A.S. Ramsteijn, L. Staal, J.M. Swart,  
J.D.A. Olivier, The Netherlands

**P.1.h.009**  Effects of post-learning REM sleep deprivation on hippocampal zif268 and mir-124 expression in mice  
S. Karabulut*, K. Korkmaz Bayramov, F. Ozdemir,  
E. Ergen, T. Topaloğlu, E. Tufan, K. Yazgan, A. Golgeli,  
Turkey

**P.1.h.010**  Scopolamine hydrobromide is indeed a proper memory impairments inductor in mice  
A. Podkowa*, K. Salat, K. Podkowa, A. Palucha-Poniewiera,  
K. Pytka, N. Malikowska, A. Furgała, Poland

**P.1.h.011**  AMN082, a positive allosteric modulator of the mGlu7 receptor, enhances the antidepressant-like activity of scopolamine in the tail suspension test  
K. Podkowa*, A. Podkowa, K. Salat, A. Pilc,  
A. Palucha-Poniewiera, Poland

**P.1.h.012**  Assessments of the behavioral disorder in the photothrombotic stroke model mouse  
Y. Ito*, M. Tsuboi, C. Iguchi, W.T. Rausch, Y. Kosuge,  
K. Ishige, Japan

**P.1.h.013**  Anxiety-like behaviour in adult mice as predictor of lifespan  
I. Martínez de Toda*, C. Vida, L. Sanz, M. De la Fuente,  
Spain

**P.1.h.014**  Analgesic and anti-inflammatory effects of a novel N-pyrrolylcarboxylic acid derivative  
H. Zlatanova*, S. Vladimirova, I. Kandilarov, I. Kostadinov,  
D. Delev, I. Kostadinova, Bulgaria
Optogenetic activation of prefrontal afferents in distinct hypothalamic regions facilitates aggressive behavior

Lipocalin-2 regulates adult hippocampal neurogenesis and contextual discriminative behaviour

Reinforcing properties of the glutamate receptors antagonists and karyotypic stability in rats
I. Barinova*, A.M. Potapkin, A.A. Lebedev, G.P. Kosyakova, P.D. Shabanov, Russia

Transcutaneous vagus nerve stimulation for treatment-resistant depression – the first experiences: a pilot study
A.Z. Antosik-Wójcińska*, M. Kaczmarczyk, Ł. Święcicki, Poland

Effects of electroconvulsive therapy on white matter integrity in severely depressed patients
J. Repple*, Germany

Altered functional connectivity of the amygdala during humor processing in patients with schizophrenia
P. Berger*, F. Bitsch, A. Nagels, B. Straube, I. Falkenberg, Germany

Emotion regulation in mood and anxiety disorders: a meta-analysis of fMRI cognitive reappraisal studies
M. Picó-Pérez*, J. Radua, T. Steward, J.M. Menchón, C. Soriano-Mas, Spain

Treatment-resistant depression in schizophrenia: clinical response predictors of repetitive transcranial magnetic stimulation (rTMS)
N. Maslenikov*, E.E. Tsukarzi, S.N. Mosolov, Russia

A human protocol for the study of persistent avoidance in obsessive-compulsive disorder
B. Vervliet*, I. Lange, M. Hammoud, M.R. Milad, Belgium

No association between serotonin 1a autoreceptors and amygdala reactivity in healthy volunteers
G.S. Kranz*, A. Hahn, C. Kraus, P. Baldinger-Melich, G. James, G. Grygiewski, M. Mitterhauser, W. Wadsak, S. Kasper, R. Lanzenberger, Austria

Social cognition in schizophrenia patients and their siblings: the role of insula
A. Caldirol*, M. Buoli, N. Van Haren, J. De Nijs, A.C. Altamura, W. Cahn, Italy

Impaired corticospinal excitability revealed by transcranial magnetic stimulation in patients with major depressive disorder
P. Vignaud*, E. Poulet, M. Suaud-Chagny, J. Brunelin, France

Increased glutamate/GABA ratio links the autism and schizophrenia spectra through a social disorganisation trait phenotype
T.C. Ford*, R. Nibbs, D.P. Crewther, Australia

Correlation between depression and volume of hippocampal subfields in the elderly with subclinical depression
S.K. Kim*, J.G. Lee, South-Korea

Neurophysiological effects of low and high frequency rTMS on long latency auditory evoked potentials
C. Nathou*, France

Glutamate levels in the medial prefrontal cortex during pregnancy

Inefficient cortical processing in creativity tasks in bipolar disorder: an fNIRS study
H. Devrimci Ozguven*, Y. Hosgoren Alici, E. Kale, I. Yenihayat, B. Baskak, Turkey

Previous antidepressant treatment is associated with increased brain connections in depressed patients: a case control study
Superficial white matter integrity in autism spectrum disorders

White matter connectivity related to amisulpride treatment response in patients with schizophrenia

Structural neuroimaging characteristics of adolescents at ultra-high risk for psychosis: a voxel-based morphometry study
A. Fortea*, J. Pariente, A. Calvo, D. Ilzarbe, E. De la Serna, J. Tor, M. Dolz, I. Baeza, G. Sugranyes, Spain

Hormone and menstrual cycle effects on sleep spindle parameters in oral contraceptive users and controls
P. Ujma*, E. Kristóf, R. Bódizs, M. Dresler, L. Genzel, Hungary

QEEG as a marker of radiation damage
F. Mucci*, K. Loganovsky, D. Marazziti, Italy

Etanercept treatment reverses the impaired spatial and emotional memory functions in different age groups of genetic absence epileptic WAG/Rij rats
T. Utkan*, T. Demirtaş Şahin, A. Karson, S.S. Gocmez, Turkey

Modification of EEG related to aversive olfactory stimulation
S. Tukaiev*, I. Zyma, M. Makarchuk, Ukraine

Identification of cognitive subtypes across the bipolar/schizophrenia diagnostic spectrum
A.J. Lynham*, I.R. Jones, J.T.R. Walters, United Kingdom

Examining cognition across the bipolar/schizophrenia diagnostic spectrum

Ephedrine HCL, curcumin and turmerone in neurogenesis and inhibition of beta-amyloid plaques in transgenic mice models
P. Keerthi*, Malaysia

Cognitive impairment after prenatal exposure to brain-specific anion transporter-1-specific monoclonal antibodies
Y.A. Zorkina*, E.A. Zubkov, O.I. Gurina, Russia

Modulation of spatial memory function by the basal forebrain GABAergic neurons
L. Kruashvili*, M. Burjanadze, M. Chighladze, T. Naneishvili, Georgia

Effects of medial septal lesions on learning strategy selection in the dual-solution plus-maze task
M. Chighladze*, M. Dashniani, T. Naneishvili, K. Rusadze, Georgia

Changes in EEG markers by TAK-063 in subjects with stable schizophrenia have different temporal relationships with changes in working memory
T.A. Macek*, M. McCue, J. Xie, K. Wesnes, P.H. Boeijinga, USA

Cognitive functions and signs of leptin resistance in patients with cerebrovascular disease and metabolic syndrome comorbidity
O. Kopchak*, Ukraine

Comparative study of the effects of donepezil and memantine on scopolamine-induced amnesia model in rats
D. Getova*, D. Dimitrova, Bulgaria

Characteristics of dynamic indicators of cognitive functions in patients with schizotypal personality disorder
A. Chepeliuk*, M.G. Vinogradova, Russia

Mental health among single and partnered parents in South Korea
S.I. Kim, K.A. Kong, Y.C. Kim*, South-Korea
**P.1.k.002** Risk factors for suicide in the late-life depression: age and sex-related differences  
J.W. Kim*, Y.S. Lee, South-Korea

**P.1.k.003** The Negev hospital-university-based (HUB) database of autism  

**P.1.k.006** Gender differences in the symptoms of major depressive disorder – results from a series of nationwide general population surveys in Korea  
S.M. Chang*, S. Won, S.J. Lee, South-Korea

---

**P.1.I.001** Low range magnetic field reduces anxiety degree in genetically epilepsy-prone rats  
N. Bukia*, G. Kekelia, M. Butskhrikidze, L. Machavariani, M. Svanidze, Georgia

**P.1.I.003** Managing psychotropic drugs in patients with renal impairment  
C. Ferreira*, S. Alves, M.J. Avelino, J.M. Jara, Portugal

**P.1.I.004** Physiopathology in early-onset bipolar disorder: inflammation and oxidative stress dysregulation  
G. Salazar*, F. Hernández, R. Vicente, C. Martínez, J. Vidal, A. Espliego, K. MacDowell, J.C. Leza, C. Arango, C. Moreno, Spain

**P.1.I.005** Neuropeptide Y and calcitonin gene-related peptide in CSF in Parkinson’s disease with co-morbid depression versus major depressive disorder  
A.A. Mathé*, S. Pålhagen, P. Svenningsson, Sweden

**P.1.I.006** A study of uric acid concentration in bipolar disorder and schizophrenia  
M. Malewska*, A. Permoda-Osip, A. Szeliga-Neyman, F. Rybakowski, J.K. Rybakowski, Poland

**P.1.I.007** Motivations of psychiatric outpatients to participate in research: assessment of factors influencing participation decisions  
I. Morán-Sánchez*, A. Luna, A. Rodríguez-Hernández, M.D. Pérez-Cárceles, Spain

**P.1.I.008** AMPA receptor subunit expression and receptor binding in patients with addiction: a systematic review of postmortem studies  
F. Ueno*, S. Matsushita, T. Tsuji, A. Endo, A. Gouraridis, S. Higuchi, M. Mimura, H. Uchida, Japan

**P.1.I.010** From schizotypy to schizophrenia: what about self boundaries?  

**P.1.I.011** AMPA receptors in schizophrenia: a systematic review of postmortem studies on receptor subunit expression and binding  
H. Tani*, T. Suzuki, S. Nakajima, T. Koizumi, M. Mimura, H. Uchida, Japan

**P.1.I.031** Metabolic, endocrine and central alterations in a chronic mouse model of food restriction  
P.2.a AFFECTIVE DISORDERS (BASIC)

P.2.a.001 Evaluation of the activity of bupropion in a mouse model of posttraumatic stress disorder using forced swim and elevated plus maze tests
N. Malikowska*, K. Salat, Poland

P.2.a.002 External validity of the forced swim test supported by meta-analysis of studies using different classes of antidepressant drugs
Y. Stukalin*, N.Z. Kara, H. Einat, Israel

P.2.a.003 NS-398 potentiates the antidepressant-like effect of MTEP in mice: involvement of pro-inflammatory cytokine pathways in the brain
M. Sowa-Kućma*, P. Misztak, P. Pańczyszyn-Trzewik, A. Pilc, G. Nowak, K. Stachowicz, Poland

P.2.a.004 Effects of deep brain stimulation of the medial prefrontal cortex in two animal models of treatment-resistant depression
P. Gruca*, M. Papp, M. Lason-Tyburkiewicz, E. Litwa, M. Niemczyk, K. Tota-Głowczyk, P. Willner, Poland

P.2.a.005 Chronic co-administration of mGluR5 antagonist (MTEP) with COX-2 inhibitor (NS398) affects DSCAM expression in prefrontal cortex and hippocampus in C57Bl/6J mice
K. Stachowicz*, M. Sowa-Kućma, P. Pańczyszyn-Trzewik, P. Misztak, G. Nowak, A. Pilc, Poland

P.2.a.006 Behavioral and hormonal effects of vitamin D3 hormone treatment in the adult female rats with experimental model of menopause
J. Fedotova*, S.G. Pivina, A.V. Suchko, Russia

P.2.a.007 Mood disorders in the offspring of antenatally depressed mothers in the Northern Finland 1966 Birth Cohort: relationship to parental mental disorder
T. Taka-Eilola*, P. Mäki, J. Veijola, Finland

P.2.a.008 Genome-wide analysis of IFN-α induced depressive-like behaviour in the cortex of mice: the role of inflammation and microglia
C. Malpighi*, V. Zonca, A. Knorr, A. Friebe, A. Cattaneo, Italy

P.2.a.009 Synapse numbers in the infralimbic cortex of rats subjected to long-term stress
D. Csabai*, O. Wiborg, B. Czéh, Hungary

P.2.b AFFECTIVE DISORDERS (CLINICAL)

P.2.b.001 The effects of rTMS on loudness dependence of auditory evoked potentials (LDAEP) and prediction of treatment response in depression

P.2.b.002 Pharmacological prophylaxis of postpartum exacerbation in depressive and anxiety symptoms: a retrospective chart review
F. Uguz, E. Subasi, F. Dalboy, M. Ak*, Turkey

P.2.b.003 MIN-117: a randomized, double-blind, parallel-group, placebo- and active-controlled study in patients with major depressive disorder
M. Davidson*, Israel

P.2.b.004 Changes of cognitive function in mild cognitive impairment with depression after the treatment of depressive symptoms
C. Han*, S.H. Kim, S. Yoon, C. Shin, J.E. Park, South-Korea

P.2.b.005 Toward a better characterisation and management of treatment-resistant depression in France through the network of expert centers (FondaMental)

P.2.b.006 The role of rare copy number variants in depression
K. Kendall*, E. Rees, I. Jones, G. Kirov, J. Walters, United Kingdom

P.2.b.007 N-acetylcysteine as an adjunctive treatment to reduce depressive symptom severity when C-reactive protein levels are increased
S. Odebrecht Vargas Nunes*, M. Porcu, H. Odebrecht Vargas, M. Urbano, Brazil
P.2.b.008 Effect of agomelatine and escitalopram on emotional experiences in outpatients suffering from major depressive disorder
G. Goodwin, E. Scott, I. Reis De Oliveira, A. McIntyre, Y.M. Mok, R.A. Emsley, T. Hall, M. Munafo, E. Corruble, F. Picarel-Blanchot*, U. Marx, V. Olivier, C. De Bodinat, France

P.2.b.009 Association of depression with the 10-year risk of cardiovascular mortality in primary care population in Latvia
R. Ivanovs*, A. Kivite, I. Mintale, J. Vrublevska, L. Berze, R. Logins, E. Rancans, Latvia

P.2.b.010 The effect of cognition in the well-being of patients with major depression

P.2.b.011 Obesity in patients with major depressive disorder is related to bipolarity and mixed features: evidence from the BRIDGE-II-MIX study
E. Petri, O. Bacci, M. Barbuti*, I. Pacchiarotti, G. Maccariello, J. Azorin, J. Angst, C. Bowden, S. Mosolov, E. Vieta, A. Young, G. Perugi, Italy

P.2.b.012 Depression-Associated Cardiac Failure (DACFAIL)
A. Menke*, C. Wurst, S. Stonawski, D. Lehrieder, K. Lechner, A. Sauter, C. Leistner, Y. Busch, P. Heuschmann, G. Gelbrich, C. Angermann, R. Werner, T. Higuchi, A. Buck, J. Deckert, S. Störk, Germany

P.2.b.013 The change of suicidal ideation over a 12-week naturalistic treatment of depression: comparison between young people and older adults
H.S. Kim, T.Y. Jun, H.J. Seo*, South-Korea

P.2.b.014 Agomelatine in the treatment of depressed patients with comorbid physical disorders
K.G. Kahl*, M.B. Westhoff-Bleck, K.W. Sühs, G. Eckermann, Germany

P.2.b.015 The relationship between major depressive disorder and leptin receptor polymorphism in adolescents
B. Acikel*, C. Eroglu, E. Kurar, S. Yilmaz, S. Herguner, Turkey

P.2.b.016 Cannabis use among depressive people: a study about one hundred thirty-six outpatients
B. Amamou*, S. Fathallah, A. Mhalla, F. Zaafane, L. Gaha, Tunisian Republic

P.2.b.017 Depression-Associated Cardiac Failure
A. Menke*, C. Wurst, S. Stonawski, D. Lehrieder, K. Lechner, A. Sauter, C. Leistner, Y. Busch, P. Heuschmann, G. Gelbrich, C. Angermann, R. Werner, T. Higuchi, A. Buck, J. Deckert, S. Störk, Germany

P.2.b.018 The change of suicidal ideation over a 12-week naturalistic treatment of depression: comparison between young people and older adults
H.S. Kim, T.Y. Jun, H.J. Seo*, South-Korea

P.2.b.019 Agomelatine in the treatment of depressed patients with comorbid physical disorders
K.G. Kahl*, M.B. Westhoff-Bleck, K.W. Sühs, G. Eckermann, Germany

P.2.b.020 The relationship between major depressive disorder and leptin receptor polymorphism in adolescents
B. Acikel*, C. Eroglu, E. Kurar, S. Yilmaz, S. Herguner, Turkey

P.2.b.021 Association of depression with the 10-year risk of cardiovascular mortality in primary care population in Latvia
R. Ivanovs*, A. Kivite, I. Mintale, J. Vrublevska, L. Berze, R. Logins, E. Rancans, Latvia

P.2.b.022 The effect of cognition in the well-being of patients with major depression

P.2.b.023 Obesity in patients with major depressive disorder is related to bipolarity and mixed features: evidence from the BRIDGE-II-MIX study
E. Petri, O. Bacci, M. Barbuti*, I. Pacchiarotti, G. Maccariello, J. Azorin, J. Angst, C. Bowden, S. Mosolov, E. Vieta, A. Young, G. Perugi, Italy

P.2.b.024 Depression-Associated Cardiac Failure (DACFAIL)
A. Menke*, C. Wurst, S. Stonawski, D. Lehrieder, K. Lechner, A. Sauter, C. Leistner, Y. Busch, P. Heuschmann, G. Gelbrich, C. Angermann, R. Werner, T. Higuchi, A. Buck, J. Deckert, S. Störk, Germany

P.2.b.025 The change of suicidal ideation over a 12-week naturalistic treatment of depression: comparison between young people and older adults
H.S. Kim, T.Y. Jun, H.J. Seo*, South-Korea

P.2.b.026 Agomelatine in the treatment of depressed patients with comorbid physical disorders
K.G. Kahl*, M.B. Westhoff-Bleck, K.W. Sühs, G. Eckermann, Germany

P.2.b.027 The relationship between major depressive disorder and leptin receptor polymorphism in adolescents
B. Acikel*, C. Eroglu, E. Kurar, S. Yilmaz, S. Herguner, Turkey

P.2.b.028 Association of depression with the 10-year risk of cardiovascular mortality in primary care population in Latvia
R. Ivanovs*, A. Kivite, I. Mintale, J. Vrublevska, L. Berze, R. Logins, E. Rancans, Latvia

P.2.b.029 The effect of cognition in the well-being of patients with major depression

P.2.b.030 Obesity in patients with major depressive disorder is related to bipolarity and mixed features: evidence from the BRIDGE-II-MIX study
E. Petri, O. Bacci, M. Barbuti*, I. Pacchiarotti, G. Maccariello, J. Azorin, J. Angst, C. Bowden, S. Mosolov, E. Vieta, A. Young, G. Perugi, Italy

BIPOLAR DISORDERS (BASIC)

P.2.c.001 Prevalence and characteristics of patients with bipolar disorder admitted to the mental health unit of a general hospital

BIPOLAR DISORDERS (CLINICAL)

P.2.d.001 Adjunctive antidepressants to mood stabilizers or atypical antipsychotics in bipolar depression and 1-year rehospitalization rates: a cohort study
Y. Shvartzman, A. Krivoy, A. Valevski, A. Weizman, E. Hochman*, Israel

P.2.d.002 Long-term lithium treatment of bipolar disorder influences very small embryonic-like stem cells and mRNA expression of pluripotency and glial markers

P.2.d.003 White matter abnormalities in late onset mania: do they predict outcome?
J. Ramirez-Bermudez*, O. Marrufo-Melendez, C. Berlanga-Flores, A. Guadamuz, D. Sanchez, C. Attriano, J. Taboada, Mexico

P.2.d.004 Structural brain differences between psychotic and non-psychotic bipolar patients
C.M. Esposito*, G. Fumagalli, S. Lanfranconi, S. Grassi, A. Caldiroli, M. Serati, M. Buoli, A.C. Altamura, Italy

P.2.d.005 Social cognition in bipolar disorder: exploring emotional intelligence
C. Varo*, E. Jimenez, B. Solé, C. Bonnin, C. Torrent, E. Valls, I. Morilla, G. Lahera, A. Martinez-Arán, E. Vieta, M. Reinares, Spain

Cannabis use among depressive people: a study about one hundred thirty-six outpatients
B. Amamou*, S. Fathallah, A. Mhalla, F. Zaafane, L. Gaha, Tunisian Republic

Association of depression with the 10-year risk of cardiovascular mortality in primary care population in Latvia
R. Ivanovs*, A. Kivite, I. Mintale, J. Vrublevska, L. Berze, R. Logins, E. Rancans, Latvia

The effect of cognition in the well-being of patients with major depression

Obesity in patients with major depressive disorder is related to bipolarity and mixed features: evidence from the BRIDGE-II-MIX study
E. Petri, O. Bacci, M. Barbuti*, I. Pacchiarotti, G. Maccariello, J. Azorin, J. Angst, C. Bowden, S. Mosolov, E. Vieta, A. Young, G. Perugi, Italy

Depression-Associated Cardiac Failure (DACFAIL)
A. Menke*, C. Wurst, S. Stonawski, D. Lehrieder, K. Lechner, A. Sauter, C. Leistner, Y. Busch, P. Heuschmann, G. Gelbrich, C. Angermann, R. Werner, T. Higuchi, A. Buck, J. Deckert, S. Störk, Germany

The change of suicidal ideation over a 12-week naturalistic treatment of depression: comparison between young people and older adults
H.S. Kim, T.Y. Jun, H.J. Seo*, South-Korea

Agomelatine in the treatment of depressed patients with comorbid physical disorders
K.G. Kahl*, M.B. Westhoff-Bleck, K.W. Sühs, G. Eckermann, Germany

The relationship between major depressive disorder and leptin receptor polymorphism in adolescents
B. Acikel*, C. Eroglu, E. Kurar, S. Yilmaz, S. Herguner, Turkey
P.2.d.006  Patient-centered care: assessing patient satisfaction in a tertiary outpatient unit of bipolar disorder

P.2.d.007  Bipolar type I and substance use disorders: safety, tolerability and effectiveness of asenapine adjunctive treatment

P.2.d.008  SLC1A2 and adverse childhood experiences interaction associates with white matter integrity in adult bipolar patients
I. Bollettini*, S. Poletti, C. Lorenzi, S. Brioschi, F. Benedetti, Italy

P.2.d.009  Body mass index associates with measures of white matter integrity in bipolar disorder
E. Mazza*, S. Poletti, I. Bollettini, C. Locatelli, F. Benedetti, Italy

P.2.d.010  Atherogenic index of plasma in manic, depressive, and euthymic stages of bipolar disorder
N. Karamustafalioglu*, T. Kalelioglu, P. Unalan, B. Kok, S. Sozen, O. Yuksel, M. Akkus, O. Yuksel, M. Leboyer, J. Houenou, France

P.2.d.011  Fronto-limbic connectivity during emotional processing in bipolar depression: the role of 5-HT1A promoter polymorphism
D. Ghiglino*, M. Riberto, B. Vai, S. Poletti, I. Bollettini, C. Colombo, C. Lorenzi, F. Benedetti, Italy

P.2.d.012  Could lithium prevent the bipolar disorder brain atrophy?

P.2.d.013  The brain–gut axis profiles in patients with bipolar depression: a preliminary study
S. Hu*, Q. Lu, J. Lai, T. Huang, Y. Xu, China

P.2.d.014  Interaction of temperament and character traits with reasons for living in suicidal bipolar depressed patients
A. Petek Eric*, I. Eric, P. Filakovic, Croatia

P.2.d.015  Is cognitive dysfunction in bipolar disorder related to sleep abnormalities?
R.H. McAllister-Williams*, A.J. Bradley, P. Gallagher, K.N. Anderson, United Kingdom

P.2.d.0301  Comparison of suicidal ideation, anxiety, hopelessness, social adaptation and psychosocial functioning in bipolar patients with suicide attempts
C. Akkaya*, A. Akkoyun, Turkey

P.2.e  TREATMENT (BASIC)

P.2.e.001  The efficacy of vortioxetine in a major depression case and follow-up of pruritus adverse effect
B. Yelken*, Turkey

P.2.e.002  Alterations of Nrf2 nuclear factor are associated with inflammation and oxidative stress in chronic mild stress animal model of depression
P. Pańczyszyn-Trzewik*, P. Misztak, G. Nowak, M. Papp, P. Gruca, M. Sowa-Kućma, Poland

P.2.e.003  Methodological limitations of comparative effectiveness research on antidepressants: a simulation study
A. Chevance*, F. Naudet, R. Gaillard, P. Ravaud, R. Porcher, France

P.2.f  TREATMENT (CLINICAL)

P.2.f.001  Lost in Translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy males
J.R. Kelly*, A.P. Allen, A. Temko, W. Hutch, P.J. Kennedy, N. Farid, E. Murphy, G. Boylan, J. Bienenstock, J.F. Cryan, G. Clarke, T.G. Dinan, Ireland

P.2.f.002  Sex differences should be considered in the administration of lithium carbonate to patients with metabolic syndrome
H. Yonezawa*, T. Nagamine, K. Nakamura, T. Takahashi, Japan

P.2.f.003  Five-year follow-up of excellent long-term lithium responders with severe renal impairment
M. Abramowicz*, A. Permoda-Osip, B. Nowak, P. Olejniczak, J.K. Rybakowski, Poland
P.2.f.004  Effectiveness and tolerability of vortioxetine for major depressive disorder
S.L. Romero Guillena*, B.O. Plasencia Garcia de Diego, R. Navarro, O. Santamaria, F. Gotor Sanchez-Luengo, Spain

P.2.f.005  Sleep deprivation with sleep phase advance in treatment-resistant depression: biological features of efficacy
E. Dopierała*, A. Jasińska-Mikołajczyk, E. Ferensztajn-Rochowiak, M. Chłopocka-Woźniak, J.K. Rybakowski, Poland

P.2.f.006  Effect of agomelatine on circadian rhythms in outpatients suffering from major depressive disorder over 6 weeks
G. Hajak, J. Landowski, U. Marx, V. Olivier, F. Picarel-Blanchot*, C. De Bodinat, S. Kasper, France

P.2.f.007  The impact of currently recommended antihypertensive therapy on depression and other psychometric parameters: a prospective, pilot study

P.2.f.008  Use of benzodiazepines in relation to onset and duration of untreated illness in psychotic and affective disorders
V. De Carlo*, B. Grancini, M. Vismara, B. Benatti, L. Cremaschi, C. Arici, L. Oldani, C. Palazzo, F. De Cagna, L. Degoni, E. Baldassarri, B. Dell’Osso, A. Altamura, Italy

P.2.f.009  Neurofeedback treatment on depressive symptoms and functional recovery and brain-derived neurotrophic factor in treatment-resistant major depression

P.2.f.010  Quetiapine – adjunctive treatment of major depressive disorder with anxiety symptoms
S. Bise*, G. Sulejmanpašić, D. Bégic, M. Ahmic, Bosnia and Herzegovina

P.2.f.011  All-cause mortality in treatment-resistant depression: a register-based cohort study in Sweden
J. Reutfors*, T. Andersson, L. Brandt, A. DiBernardo, G. Li, A. Westerlund, L. Wingård, R. Bodén, Sweden

P.2.f.012  Vagus nerve stimulation in patients requiring maintenance therapy after response to electroconvulsive therapy
S. Aaronson*, D.J. Kutzer, USA

P.2.f.013  Efficacy of dialectical behavior therapy compared to supportive therapy in adolescents with suicidal behavior
P. Santamarina Perez*, S. Romero Cela, I. Méndez Blanco, E. Font Martinez, M. Picado Rossi, E. Martínez Mallén, E. Moreno Pérez, A. Morer Liñán, Spain

P.2.f.014  Intravenous ketamine for depression and congruent psychotic symptomatology: description of two consecutive cases
N. Olazabal*, S. Bustamante, M. Madrazo, G. Priego, L. Osa, A. Catalan, A. O’Neil of Tyrone, M. Gonzalez-Torres, Spain

P.2.f.015  Effectiveness of inhaled loxapine (IL) in agitated patients diagnosed with personality disorder (PD) – a first approach
B. Patrizi*, M.V. Navarro Haro, M. Gasol, Spain

P.2.g  OTHER (BASIC)

P.2.g.001  A comparative survey between the levels of personal and perceived stigma among professionals working in the psychiatric care system
R.I. Nica*, M.C. Pîrlog, Romania

P.2.h  OTHER (CLINICAL)

P.2.h.001  Clinical and genetic risk factors associated with suicidality in Korean patients with mood disorders
S.I. Kim, H.Y. Choi, W.J. Lim, E.J. Kim, Y.C. Kim*, G.E. Kim, South-Korea

P.2.h.002  Increase of plasma levels of VEGF-D, but not VEGF-A and VEGF-C, after antidepressant treatment in depressed patients
A. Rigal*, R. Colle, C. Verstuyft, B. Feve, L. Becquemont, E. Corruble, France

P.2.h.003  Theory of mind and depersonalization in borderline personality disorder
S.L. Romero Guillena*, F. Gotor Sanchez-Luengo, B.O. Plasencia Garcia de Diego, Spain
**P.2.h.004** Suicide ideation, anger and impulsiveness in chronic pain patients before and after pain relief: an observational study
V. Mancini*, S. Marini, V. Lalli, M.R. Sergi, F. Gambi, A. Costantini, M. Di Giannantonio, Italy

**P.2.h.005** Correlation between the patient health questionnaire (PHQ-9) and the mini international neuropsychiatric interview (MINI) items in representative nationwide primary care sample in Latvia
J. Vrublevska*, M. Trapencieris, R. Ivanovs, E. Rancans, Latvia

**P.2.h.006** Is aggression a missed bipolar diagnostic feature in mixed depression?
N. Verdolini*, G. Perugi, L. Samalin, A. Murru, J. Angst, J.M. Azorin, C.L. Bowden, S. Mosolov, A.H. Young, M. Barbuti, G. Guiso, D. Popovic, E. Vieta, I. Pacchiarotti, Spain, Italy

---

**P.3.a.001** The relationship between alterations in metabolite levels in the DLPFC and clinical symptoms of patients with first-episode schizophrenia
M. Huang*, W. Guo, S. Lu, Y. Xu, China

**P.3.a.002** Polygenic risk profile score increases schizophrenia liability mostly through cognition pathways: mathematical causation models with polygenic risk
T. Toulopoulou*, X. Zhang, S. Cherny, R. Straub, K. Berman, D. Dickinson, P. Sham, D. Weinberger, Turkey, United Kingdom

**P.3.a.003** DNA methylation and adolescent trajectories of psychotic symptoms

**P.3.a.004** Abnormal visual scanning during reality evaluation and its relationship to magical ideation in schizophrenia
J.S. Lee*, M.W. Kim, J.J. Kim, South-Korea

---

**P.3.b.001** Birth seasonality in first episode psychosis
A. Toll, A. Mané, D. Bergé, V. Pérez - Solà, A.J. Palma Conesa*, Spain

**P.3.b.002** Maintenance to win: prospective observational study of extended-release injectable aripiprazole for maintenance therapy in psychotic outpatients
J.J. De La Gandara*, S. Mayo, Spain

**P.3.b.003** The effects of nutriose- glucomannan-antioxidant complex on the parameters of the metabolic syndrome in the schizophrenia patients treated with olanzapine
G.M. Djokic*, V. Djordjevic, A. Agic, A. Rankovic, P. Vojvodic, S. Djukic Dejanovic, Serbia

**P.3.b.004** Factors connected to insight in patients with schizophrenia
L. Kalisova*, J. Michalec, M. Simonova, Czech Republic

---

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
P.3.b.005 Blood biomarkers predict the cognitive effects of aripiprazole in patients with acute schizophrenia

P.3.b.006 Theory of mind, metabolic syndrome and schizophrenia
S.L. Romero Guillena*, R. Navarro, F. Gotor Sanchez-Luengo, O. Santamaria, B.O. Plasencia Garcia de Diego, Spain

P.3.b.007 Intact striatal dopaminergic modulation of reward learning and daily-life reward-oriented behaviour in relatives of individuals with psychotic disorder

P.3.b.008 Schizophrenia and adjunctive aripiprazole for antipsychotic-induced sexual dysfunction
G. Sulejmanpasic-Arslanagic*, S. Bise, Bosnia and Herzegovina

P.3.b.009 Cognitive effects of polypharmacy in psychotic disorders – less is more

P.3.b.010 Determining fasting glucose modifiers in acute-phase schizophrenia: a descriptive cross-sectional analysis
I. Carreira Figueiredo*, I. Cargaleiro, D. Pereira, P. Aguiar, Portugal

P.3.b.011 Evaluation of methylation changes in the first episode psychosis patients
S. Hira*, O. Ozcan, O.M. Ipcioglu, R. Tutuncu, H. Balibey, A. Ulcay, A. Ates, M. Gultepe, Turkey

P.3.b.012 A systematic review of methods for the assessment of antipsychotics adherence: focus on delusional disorder
A. Gonzalez Rodriguez*, F. Estrada, J.A. Monreal, D. Palao, J. Labad, Spain

P.3.b.014 The association between serum levels of brain-derived neurotrophic factor and cognitive impairment in chronic elderly schizophrenia inpatients

P.3.b.015 Catatonia is associated with worse cognitive performance in antipsychotic-naive patients with first-episode psychosis: a 3-month follow-up study
B. Colomer, J. Cuevas Esteban*, R. Vila Badia, A. Butjosa, N. Del Cacho, M. Pardo, J. Usall, Grupo Pep-prolactina, Spain

P.3.b.016 Early-onset inguinal hernia as risk factor for schizophrenia or related psychosis: a nationwide register-based cohort study
K. Melkersson*, L. Wernroth, Sweden

P.3.b.017 Neurophysiological correlates of negative symptom domains in schizophrenia
G.M. Giordano*, T. Koenig, A. Mucci, A. Vignapiano, A. Amodio, G. Di Lorenzo, C. Niolu, M. Altamura, A. Bellomo, Italy

P.3.b.018 Electrophysiological and neurocognitive correlates of the disorganization factor in schizophrenia
A. Vignapiano*, T. Koenig, A. Mucci, G.M. Giordano, A. Amodio, G. Di Lorenzo, C. Niolu, M. Altamura, A. Bellomo, S. Galderisi, Italy

P.3.c.001 Metabolic syndrome in chronic mental patients – are atypical antipsychotics that guilty?
J. Melim*, A. Batista, R. Araújo, F. Malheiro, S. Fonseca, Portugal

P.3.c.002 Nicotinic alpha7 receptor agonist and modulators improved social but not sensorimotor deficits on subchronic MK-801 model of schizophrenia in rats
G. Unal*, H. Zortul, A. Hazar-Yavuz, F. Aricioglu, Turkey

P.3.c.003 Nigella sativa extract improved sensorimotor gating deficit on acute ketamine model of schizophrenia in rats
G. Unal*, R. Keles, T. Taskin, F. Aricioglu, Turkey

P.3.c.004 Rapid augmentation of antipsychotic drugs by sodium nitroprusside (SNP) – behavioural assessment and effect on brain dopaminergic transmission in rats
J. Titulaer*, A. Malmerfelt, M. Marcus, T. Svensson, Sweden
**P.3.d.001**  Efficacy and safety of MIN-101: a new drug in development for the treatment of negative symptoms in schizophrenia – a 12 weeks RCT
* M. Davidson*, S. Jay, C. Staner, E. Luthringer, N. Noel, J. Reilly, M. Weiser, J. Rabinowitz, R. Luthringer, USA

**P.3.d.002**  Pharmacological management of antipsychotic-induced obesity – a systematic literature review

**P.3.d.003**  Aripiprazole once-monthly long-acting injectable in schizophrenia
* B.O. Plasencia García de Diego*, S.L. Romero Guillena, F. Gotor Sanchez-Luengo, Spain

**P.3.d.004**  Effectiveness of electroconvulsive therapy in patients with schizophrenia: a controlled, population-based mirror-image study

**P.3.d.005**  E-medicine: a smartphone application to antipsychotic switch
* T. Bottai*, D. Dassa, P. Raymondet, France

**P.3.d.006**  Antipsychotic treatment in hospitalized patients with schizophrenia and with the occurrence of aggressive behavior (2-years review)
* M. Zelman*, S. Godinova, M. Zholob, Slovak Republic

**P.3.d.007**  Neurocognitive and social functions, and economic games in recovered schizophrenic patients after antipsychotic treatment

**P.3.d.008**  Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials
* F. Corponi*, A. Serretti, S. Montgomery, C. Fabbri, Italy

**P.3.d.009**  Schizophrenia, hospitalisations and antipsychotic treatment: analysing LAI patterns in a brief hospitalisation unit
* J.M. Pascual*, J.M. Mongil San Juan, C. Rodriguez Gomez, J.M. Villagrán Moreno, Spain

**P.3.d.010**  Aripiprazole long-acting injection: a naturalistic study in a community setting
* C. Vannini*, G. Baroni, C. Montemiro, G. Martinotti, M. Di Giannantonio, M. Alessandrini, Italy

**P.3.d.011**  Inflammatory processes and schizophrenia: evidence from a twin study
* H.H. Stassen*, S. Braun, R. Bridler, E. Seifritz, M. Weisbrod, Switzerland

**P.3.d.012**  Sustained remission with cariprazine treatment: post hoc analysis of a randomized, double-blind, schizophrenia relapse prevention trial

**P.3.d.013**  Efficacy of cariprazine in subgroups of bipolar patients with manic episodes, mixed episodes, and with or without psychotic symptoms
* E. Vieta, S. Durgam, K. Lu, I. Laszlovszky, I. Saliu*, W. Earley, USA

**P.3.d.014**  Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients

**P.3.d.015**  Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia

**P.3.d.016**  Long-term complex therapy of schizophrenia with paliperidone palmitate in combination with psychosocial interventions in outpatient settings
* A. Savelyev*, T. Korman, T. Gritsevskaya, Russia

**P.3.d.017**  Comparison of stress levels between stabilised psychotic patients in a half-way house and a control group from the community
* P.M. Gabay*, M.D. Fernandez Bruno, A. Montenegro, Argentina

**P.3.d.018**  Clozapine-induced parotitis following eight years of clozapine treatment: a case study
* K. Todorova-Nenova*, Bulgaria
FDA guidelines for clozapine monitoring system in USA
R.S. Sultan*, M. Olfson, S.J. Garlow, E. Duncan, USA

Processing of visual perception in paranoid schizophrenia
Z. Beria*, G. Naneishvili, V. Kenchadze, N. Vachadze, Georgia

Effect of omega-3 supplementation during pregnancy and in offspring adolescence: an animal model of schizophrenia induced by poly(I:C)
E.D. Rosa*, L.P. Géa, B.S. Panizzutti, L.F. Oliveira, E.Z. Aguiar, C.S. Gama, Brazil

Proteomic profiling changes induced by physical activity in patients with schizophrenia

Art therapy for patients in acute psychotic episodes
T. Aladashvili*, E. Tavadze, Q. Gorgodze, L. Tsuleiskiri, Georgia

Haloperidol decreases the serum potassium level but has no effect on magnesium level
J. Noh*, M. Park, South-Korea

Compliance with psychotropic medications – a patient’s perspective
V. Videnova*, N. Manuseva, B. Stefanovski, V. Isjanovski, Macedonia

Factors predicting personal and social performance in patients with schizophrenia
S.H. Kim*, J.S. Yi, J.J. Kim, South-Korea

The Korean version of the University of California San Diego performance-based skills assessment: reliability and validity
J. Ryu*, South-Korea

Sleep disturbance in schizophrenia inpatients and related factors
S.K. Kim*, B.J. Jung, South-Korea

Predictors of serum level of magnesium among inpatients with schizophrenia: a cross-sectional survey

The report on current state and effectiveness of occupational therapy with mentally disabled people in Korea
S.M. Lee*, H.Y. Chung, M. Hong, South-Korea

Assessment of peripheral blood immune system cells in patients with schizophrenia and bipolar disorder: a computational deconvolution study
P. Karpiński, M. Sąsiadek, D. Frydecka, B. Misiak*, Poland
**ANXIETY DISORDERS (BASIC)**

**P.4.a.001** Social anxiety disorder among applicants to the psychiatry Master’s Degree program in Malaysia  
F.L. Azhar*, J.S. Gill, A.H. Sulaiman, Malaysia

**P.4.a.002** OX1 but not OX2 receptors modulate anxiety-like behaviours of pentylenetetrazol-induced kindled rats  
A. Roohbakhsh*, S. Asadi, E. Kordi, M. Fereidoni, A. Shamsizadeh, A. Moghimi, Iran

**P.4.a.003** Neural substrates of fear conditioning are modulated by GRB2 allelic variation: converging evidence from an independent replication  
U. Lueken*, M. Kuhn, Y. Yang, B. Straube, T. Kircher, H. Wittchen, B. Pfleiderer, V. Arolt, A. Wittmann, A. Ströhle, H. Weber, A. Reif, K. Domschke, J. Deckert, T. Lonsdorf, Germany

**P.4.a.004** Repeated social stress in rats leads to contrasting patterns of structural plasticity in the amygdala and hippocampus  
D. Patel*, S. Chattarji, B. Buwalda, The Netherlands

**P.4.a.005** Chronic social defeat stress: impact on sleep in susceptible mice  
F. Henderson*, V. Vialou, S. El Mestikawy, V. Fabre, France

**P.4.a.006** Different effects of anxiolytics phenazepam and fabomotizole on dipeptidylpeptidase-IV plasma activity in patients with anxiety disorders  
T. Syunyakov*, N.N. Zolotov, G.G. Neznamov, Russia

**P.4.a.008** Hypothalamic miR-132-3p changes in response to intracerebroventricular oxytocin: relevance for anxiety- and fear-related behaviour  
A. Bludau, R. Menon, G. Meister, I. Neumann*, Germany

**ANXIETY DISORDERS (CLINICAL)**

**P.4.b.001** Anti-basal ganglia antibodies (ABGA) and excitatory neurotransmitters in OCD  
S. Gnanavel*, P. Sharan, V. Subbiah, U. Sharma, N. Jagannathan, United Kingdom

**P.4.b.002** What sexual assault does to the brain? A longitudinal neuroimaging study  
W. El Hage*, France

**P.4.b.003** Altered functional connectivity of the subthalamus and the bed nucleus of the stria terminalis in obsessive-compulsive disorder  

**P.4.b.004** Psychosocial functioning of grown-up congenital heart disease patients after cardiac surgery  
A. Sydorenko*, I. Lebid, M. Markova, Ukraine

**P.4.b.005** Prescribing practices in obsessive-compulsive disorder in Italy  
D. Marazziti*, F. Mucci, A. Tundo, U. Albert, B. Dell’Osso, I. Moroni, Italy

**P.4.b.006** Anxiety associated with a reduction of cardiovascular mortality risk in primary care population in Latvia  
R. Ivanovs*, A. Kivite, I. Mintale, J. Vrublevska, L. Berze, R. Logins, E. Rancans, Latvia

**TREATMENT (BASIC)**

**P.4.c.001** Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects  

**P.4.c.002** Role of cerebral dopamine neurotrophic factor in the regulation of non-motor behaviour  

**Updated programme:**  
http://2017.ecnp.eu / ECNP app / congress info terminals
**P.4.d**  **TREATMENT (CLINICAL)**

**P.4.d.001** Efficacy and safety of agomelatine 25–50 mg/day versus escitalopram 10–20 mg/day in severe generalized anxiety disorder

**P.4.d.002** Evaluating self-knowledge and self-control workshops for patients with anxiety disorders
S.L. Romero Guillena*, M. Garcia Salguero, J.H. Jimenez Hernandez, Spain

**P.4.d.003** Augmentation of serotonin reuptake inhibitors with antipsychotic drugs in treatment-resistant obsessive-compulsive disorder: a meta-analysis
M. Dold*, M. Aigner, S. Kasper, Austria

**P.4.d.004** Double blind randomised sham controlled study to examine benefits of transcranial direct current stimulation in obsessive compulsive disorder
S. Manche Gowda*, India

**P.4.e**  **OTHER (BASIC)**

**P.4.e.001** Brain incorporation of different polyunsaturated fatty acids ratio and anxiety-like symptoms development in young rats supplemented with omega-3/-6
F.T. Kuhn*, M.E. Bürger, V.T. Dias, Brazil

**P.4.e.002** Neuromodulation of the hyperdirect pathway to study flexibility as an endophenotype of obsessive compulsive disorders
N. Benzina*, K. N'Diaye, L. Mallet, E. Burguiere, France

**P.4.e.003** Interaction between D2 dopamine and OX1R orexin receptors in predator-induced stress
I.Y. Tissen*, E.R. Bychkov, P.P. Khokhlov, A.A. Lebedev, P.D. Shabanov, Russia

**P.4.e.004** MicroRNA signature associated with enhanced vulnerability to develop psychiatric disorders: dissecting the mechanisms by using an in vitro model
N. Cattane*, N. Mariani, C. Pariante, A. Cattaneo, Italy

**P.4.f**  **OTHER (CLINICAL)**

**P.4.f.001** Brain structural correlates of subclinical obsessive-compulsive symptoms in healthy children

**P.4.f.002** Psychiatric disorders and domestic violence – specific consultation analysis
H. Prata Ribeiro*, Portugal
P.5.a  DEMENTIA (BASIC)

P.5.a.001  In vitro effects of newly developed cholinesterase inhibitors and ABAD modulators on mitochondrial respiration

P.5.b  DEMENTIA (CLINICAL)

P.5.b.001  Impairments of eye-tracking precedes working memory deficits in patients with dementia
T. Crawford*, S. Higham, United Kingdom

P.5.b.002  The impact of apolipoprotein E gene polymorphism on the cerebral blood flow in patients with mild cognitive impairment
L. Zhu*, L. Wenxiang, W. Zan, C. Jiu, S. Hao, B. Feng, Z. Zhijun, China

P.5.b.003  The PDE4-inhibitor roflumilast improves memory: findings from a translational perspective
M.A. Van Duinen, A. Sambeth, P.R.A. Heckman, M. Tsai, G. Lahu, T. Uz, A. Blokland*, J. Prickaerts, The Netherlands

P.5.b.004  The effect of heart rate variability on early Alzheimer’s dementia with severe depressive disorder: autonomic nervous system evaluation
D. Shin*, D. Bae, S. Park, J. Pyo, South-Korea

P.5.c  NEUROLOGICAL DISORDERS (BASIC)

P.5.c.001  Inactivation of the orphan G protein-coupled receptor Gpr88 in the dorsal striatum reverses the effects of dopamine depletion in a rat model of Parkinson’s disease

P.5.c.002  Mitochondria-targeted antioxidant SkQ1 reduces the death of dopaminergic neurons in the model of Parkinson’s disease in mice
V. Pavshintcev*, L. Podshivalova, O. Averina, M. Egorov, M. Lovat, Russia

P.5.d  NEUROLOGICAL DISORDERS (CLINICAL)

P.5.d.001  Influence of fluvoxamine on plasma interleukin-6 and on clinical improvement in Japanese major depressive disorder patients
R. Yoshimura*, A. Katsuki, K. Atske, H. Hori, R. Igata, Y. Konishi, Japan

P.5.d.002  The statistical analysis of the changes of the depressive mental states of Japanese patients with subacute myelo-optico neuropathy
T. Konishi*, Japan

P.5.d.003  Associational analysis between sleep-related variables and sleep positional difference of apnea-hypopnea index in obstructive sleep apnea syndrome

P.5.d.004  Myasthenia gravis: co-morbid psychiatric disorders and use of psychotropic medication
C. Machado*, B. Almeida, C. Fragoeiro, L. Monteiro, Portugal

P.5.f  OTHER (CLINICAL)

P.5.f.001  Characteristics of dizziness patients visiting ENT dizziness clinic first and referred to a psychiatrist
K.K. Lee*, K. Kim, S. An, J. Jung, South-Korea

P.5.d.002  Psychopathology variables in neck-pain patients

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**P.6.a**  **ALCOHOL (BASIC)**

**P.6.a.001** Changes in serotonin biosynthesis in the brain of rats with chronic alcohol intoxication  
O.I. Kharchenko*, O.S. Kostiuk, I.V. Kizub, O.M. Savchuk, L.I. Ostapchenko, Ukraine

**P.6.a.002** Behavioural study of low-affinity non-competitive NMDA-receptor antagonist hemantane in animal models of alcohol dependence  
L. Kolik*, A. Nadorova, S. Seredenin, Russia

**P.6.a.003** Effects of chronic alcoholisation and ethanol withdrawal on expression of OX1R orexin brain receptors in rats  
P.D. Shabanov*, E.A. Sekste, M.I. Airapetov, E.R. Bychkov, P.P. Khokhlov, A.A. Lebedev, Russia

**P.6.b**  **ALCOHOL (CLINICAL)**

**P.6.b.001** The calcium story: is calcium involved in relapse behaviour and craving?  
R. Schuster*, A. Koopmann, M. Grosshans, I. Reinhard, R. Spanagel, F. Kiefer, Germany

**P.6.b.002** Association of gamma-glutamyl transferase (GGT) with risk of alcohol use behaviours  
J.W. Kim*, B.C. Lee, I.G. Choi, South-Korea

**P.6.b.003** A double blind placebo controlled randomised clinical trial of pregabalin for alcohol dependence  
E. Krupitsky*, K. Rybakova, E. Skurat, A. Mikhailov, N. Neznanov, Russia

**P.6.b.004** Characteristics of cognitive impulsivity in alcohol use and gambling disorder: a meta-analysis on decision making assessed with the Iowa gambling task  
I. Kovács*, M. Richman, Z. Janka, A. Maráz, B. Andó, Hungary

**P.6.b.005** The impact of positive and negative emotional states vs. comorbid depression or anxiety diagnoses on alcohol consumption in male and female alcoholics  

**P.6.b.006** Analysis of brain white and gray matter characteristics in alcohol dependent patients and in their siblings  
N. Capraz*, E. Oztekin, N. Zorlu, F. Gelal, L. Besiroglu, A. Saricicek, Turkey

**P.6.c**  **DRUGS (BASIC)**

**P.6.c.001** The influence of co-administration of mephedrone and nicotine on anxiety- and memory-related behaviours and nicotine-induced sensitization in mice  
G. Biala*, K. Kaszubska, M. Kruk-Słomka, A. Michalak, B. Budzynska, Poland

**P.6.c.002** Impact of the route of administration in drug discrimination studies in rats  
V. Castagné*, C. Froger-Colléaux, A.M. Hernier, S. Paillard, K. Davoust, France

**P.6.c.003** Cholinergic nervous system can be modulated by the cyclooxygenase-2 inhibitor celecoxib via inhibition of enzyme acetylcholinesterase  
M. Pohanka*, Czech Republic

**P.6.c.004** Combination of pregabalin with morphine: reinforcing and inhibiting effects  
E. Vashchinkina*, O. Vekovischeva, O. Piippo, E.R. Korpi, Finland

**P.6.c.005** Electrodermal activity monitoring on inpatient detoxification unit  

**P.6.c.006** The effects of long-term MDMA use on responses to social exclusion and empathy  
M. Carlyle*, T. Stevens, C. Morgan, United Kingdom

P.6.d.002 The impact of excessive alcohol use upon prospective memory in early adolescence T. Heffernan*, United Kingdom


P.6.d.004 Use of classic and new psychoactive substances and academic outcomes among Italian university students R. Santacroce*, G. Martinotti, F. Sarchione, M. Lupi, E. Cinosi, M. Di Giannantonio, Italy

P.6.d.005 Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration – a translational study N. Jayaram-Lindström*, Sweden

P.6.d.006 Effects of gamma hydroxybutyrate (GHB) induced coma on long-term memory and brain function F. Raposo Pereira*, The Netherlands


P.6.d.008 Substance-induced psychotic disorders in an acute psychiatric inpatient unit A. Fernandez-Quintana*, C. Quiroga-Fernández, A. Novo-Ponte, M.D.C. García-Mahía, Spain

P.6.e.001 Dopamine, norepinephrine, glutamate antibodies in individual prevention of addiction T.V. Davydova*, L.A. Vetrile, T.I. Nevidimova, E.I. Masterova, I.A. Zakharova, D.N. Savochkina, V.G. Fomina, Russia

P.6.e.002 Factors associated with benzodiazepine dependence among elderly patients followed in outpatient psychiatry unit B. Amamou*, S. Fathallah, A. Mhalla, F. Zaafrane, L. Gaha, Tunisian Republic

P.6.f.001 Cognitive remediation improves executive functions, self-regulation and quality of life in residents of a substance use disorder therapeutic community E.M. Marceau*, J. Berry, J. Lunn, P.J. Kelly, N. Solowij, Australia

P.6.f.002 Is impulsivity the only trait that matters in addictive behaviour? G. Crisan*, M.M. Manea, A. Miron, A. Mitrofan, V.B. Savu, G. Scarisoreanu, V.M. Dumitru, Romania

P.6.f.003 Why do addicted people participate in research? I. Morán-Sánchez*, A. Luna, A. Rodríguez-Hernández, M.D. Pérez-Cárceles, Spain
P.7.a  DISORDERS (BASIC)

P.7.a.001  Examining the relationship between attention deficit hyperactivity disorder, behavioural features and obesity in Turkish children and adolescents
A. Onal Sonmez, B. Goksan Yavuz*, S. Aka, S. Semiz, Turkey

P.7.a.002  Morphology of the posterior superior temporal sulcus and social cognition in adults with high functioning autism
S. Hotier*, F. Leroy, J. Mangin, A. Gaman, I. Scheid, M. Leboyer, T. Zalla, J. Houenou, France

P.7.a.003  No association of D310 and D514 repeat polymorphisms of mitochondrial D-loop region with attention deficit hyperactivity disorder
S.W. Jung*, D.K. Kim, South-Korea

P.7.b  DISORDERS (CLINICAL)

P.7.b.001  Sodium oxybate improves excessive daytime sleepiness, cataplexy, and lowers IL-2 receptor levels in a 12-year-old boy: case report
W. Baek*, USA

P.7.b.002  A systematic review of shared psychotic disorder in children and young people
L. Vigo*, D. Ilzarbe, C. Losada, I. Baeza, M. Kyriakopoulos, United Kingdom

P.7.b.003  Differences in quantitative electroencephalograms between two subtypes of attention deficit hyperactivity disorder
J.H. Ha*, M.K. Song, D.H. Park, South-Korea

P.7.b.004  The impact of attention deficit hyperactivity symptoms on mindfulness
B. Goksan Yavuz*, A. Onal Sonmez, M. Yavuz, Turkey

P.7.b.005  The concept of latent social skills in autism and its predictive value for future development
M. Hrdlicka*, I. Dudova, S. Beranova, M. Vacova, T. Urbanek, Czech Republic

P.7.b.006  Similar familial underpinnings for full and sub-syndromal pediatric bipolar disorder: a familial risk analysis
J. Wozniak*, M. Uchida, S.V. Faraone, M. Fitzgerald, C. Vaudreuil, N. Carrellas, J. Davis, R. Wolenski, J. Biederman, USA

P.7.b.007  Rehabilitation in adolescents with autism spectrum disorder: a three-year longitudinal study
S. Marini*, T. D’Ambrogio, M.R. Sergi, F. Gambi, M. Di Giannantonio, G. Sorge, Italy

P.7.d  TREATMENT (CLINICAL)

P.7.d.001  Evaluation of the effectiveness of the serious game JeStiMulE for the improvement of social cognition in adults with autistic spectrum disorders
M. Antonini*, S. Serret, F. Maria, J. Bourgeois, E. Fontas, F. Askenazy, M. Benoit, M. Fouchet, France

P.7.d.002  Effects of a single low dose of methylphenidate on saccadic eye movements in adults with attention-deficit/hyperactivity disorder (ADHD)
F. Duval*, M. Mokrani, A. Erb, M. Sasseau, R. Carcagni, T. Weiss, L. Caruso, France

P.7.d.003  A pilot study: comparison of one-year outcomes of fluoxetine vs trauma-focused cognitive behavioural therapy of war-related PTSD in children
D. MartsenkoSkyyi*, Ukraine

P.7.d.004  Modafinil for attention-deficit/hyperactivity disorder (ADHD): an updated systematic review and meta-analysis
R. Lowenthal*, I. Tiar, A. Soares, M. Generoso, Q. Cordeiro, P. Shiozawa, Brazil

P.7.d.005  Risperidone versus placebo in the treatment of children and adolescents with autism spectrum disorders: a meta-analysis and systematic review
N. Maneeton*, B. Maneeton, S. Putthisri, P. Woottiluk, S. Likhitsathian, A. Narkpongphun, M. Srisurapanont, Thailand

P.7.d.301  Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicenter naturalistic study
M.L. Menard*, S. Thummel, M. Giannitelli, B. Olliac, O. Bonnot, C. Boule, D. Cohen, F. Askenazy, Etape Study Group, France
**P.7.e.001** Effects of traumatic experiences on suicidal ideation among Korean adolescents: the roles of depression and self-esteem
S.Y. Kwon, J.A. Nam, H.J. Park, J.C. Yu*, K.S. Choi, South-Korea

**P.7.f.001** Gender differences in the long-term impact of childhood abuse: a psychopathological investigation in a non-clinical sample
C. Appignanesi*, I. Pinucci, M. Fattorini, G. Castellini, V. Ricca, Italy

**P.7.f.002** Prospective, observational cohort study of JAKE™, an autism knowledge

**P.8.b.001** Psychotropic drugs prescriptions in patients older than 65
T. Poinsat*, C. Lachuer, R. Batista, France

**P.8.b.002** Prevalence and clinical correlates of intermittent explosive disorder in psychiatric outpatients
V. Gelegen, L. Tamam*, Turkey

**P.8.b.003** Body mass index reduction after bariatric surgery in patients with and without psychotropic medication: a retrospective study
E. Monteagudo*, J.M. Ginés, L. Martinez, M. Angelats, L. Pujol, E. Ribera, E. Pousa, V. Pérez-Solá, P. Salgado, Spain

**P.8.b.004** Quality of life and related factors in elderly people who live alone

**Updated programme:**
http://2017.ecnp.eu / ECNP app / congress info terminals
ECNP SCHOOLS
Week-long residential programmes providing outstanding young clinicians from across Europe with state-of-the-art training in treatment best practices.

AGENDA FOR 2018
- **8-13 April 2018**
  ECNP School of Child and Adolescent Neuropsychopharmacology
  Venice, Italy
- **24-29 June 2018**
  ECNP School of Neuropsychopharmacology
  Oxford, United Kingdom

www.ecnp.eu/school

FREE REGISTRATION AND ACCOMODATION

BS.04
BRAINSTORMING SESSION
07.45-08.45 | Room 341

New technologies for reducing placebo response and improving signal detection in CNS clinical trials

Chair: t.b.a.

Experts: Michael Detke, USA
Jonathan Rabinowitz, Israel

BS.05
BRAINSTORMING SESSION
07.45-08.45 | Room 342B

The ‘stressed’ hippocampus as target for treatment of comorbid epilepsy and depression

Chair: Christopher Pryce, Switzerland

Experts: Luciana D’Alessio, Argentina
E. Ron de Kloet, The Netherlands

BS.06
BRAINSTORMING SESSION
07.45-08.45 | Room 343

Breaking the link between insomnia and depression

Chair: Sue Wilson, United Kingdom

Experts: Tiina Paunio, Finland
Eus J.W. van Someren, The Netherlands

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**PRECLINICAL RESEARCH TRACK**

**SYMPOSIUM**
09.00-10.40 | Room 352AB

**New findings in applied neuroscience research II**

**Chairs:**
Mark J. Millan, France  
Joanna Slusarczyk, Poland

**S.16.01**
09.04
Understanding the circadian abnormalities associated with bipolar disorder and lithium treatment  
*Harshmeena Sanghani, United Kingdom*

**S.16.02**
09.16
Glucocorticoid receptor-dependent signalling in astrocytes as target of opioid action  
*Justyna Barut, Poland*

**S.16.03**
09.28
Tau-dependent suppression of adult neurogenesis in the stressed hippocampus  
*Chrysoula Dioli, Portugal*

**S.16.04**
09.40
Mineralocorticoid receptor and cognitive function in major depression  
*Michael Kaczmarczyk, Germany*

**S.16.05**
09.52
Pharmacokinetics to rediscover psychotropics; the case of risperidone  
*Georgios Schoretsanitis, Switzerland*

**S.16.06**
10.04
Acute psychosocial stress impacts the hemodynamic response latency: a novel brain-phenotype of acute stress and GR-sensitivity  
*Immanuel Elbau, Germany*

**S.16.07**
10.16
The dynamic brain response to stress is impaired in siblings of schizophrenia patients  
*Judith van Leeuwen, The Netherlands*

**S.16.08**
10.28
Can we weaken or rewrite maladaptive alcohol memories via reconsolidation?  
*Ravi Das, United Kingdom*

**TRANSLATIONAL RESEARCH TRACK**

**SYMPOSIUM**
09.00-10.40 | Grand Amphitheatre

**Sex differences at the intersection of stress, fear and depression**

**Chairs:**
Christina Dalla, Greece  
Kevin C.F. Fone, United Kingdom

**S.17.01**
09.00
Why can’t a woman be more like a man?  
*Osborne Almeida, Germany*

**S.17.02**
09.25
Sex differences in models of depression and antidepressant response  
*Christina Dalla, Greece*

**S.17.03**
09.50
Sex differences in neuroplasticity and neurosteroids effects  
*Luis M. Garcia-Segura, Spain*

**S.17.04**
10.15
Epigenetic regulation of sex differences in susceptibility to stress  
*Georgia Hodes, USA*

**Updated programme:**
http://2017.ecnp.eu / ECNP app / congress info terminals
SYMPOSIUM 09.00-10.40 | Maillot

Behavioural addictions: diagnosis, co-morbidity and neurobiology

Chairs: Marc Potenza, USA
Florence Thibaut, France

S.18.01 09.00 Brain imaging studies in pathological gamblers: are the underlying neural mechanisms similar to those of drug
Marc Potenza, USA

S.18.02 09.25 Clinical studies on comorbidity of internet gaming disorders with mood, anxiety and personality disorders
Aviv Weinstein, Israel

S.18.03 09.50 Incorporating pharmacological treatment strategies into sexual addiction
Florence Thibaut, France

S.18.04 10.15 Neuroimaging in compulsive sexual behaviours: impulsivity, compulsivity or true addiction?
Valerie Voon, United Kingdom

SYMPOSIUM 09.00-10.40 | Bleu

What is the impact of physical exercise interventions in schizophrenia?

Chairs: Hilleke Hulshoff Pol, The Netherlands
Berend Malchow, Germany

S.19.01 09.00 Exercise of an overlearned skill increases the integrity of white matter fiber tracts in patients and healthy individuals
Hilleke Hulshoff Pol, The Netherlands

S.19.02 09.25 Aerobic exercise interventions as feasible and effective interventions for schizophrenia
Berend Malchow, Germany

S.19.03 09.50 Influence of exercise in combination with clozapine and other antipsychotics in chronic refractory schizophrenia patients
William Honer, Canada

S.19.04 10.15 Physical exercise and risk for schizophrenia
Jarmo Hietala, Finland

SYMPOSIUM 09.00-10.40 | Havane

Regulatory spotlight session – Strategies for the development of medicines for autism spectrum disorders

Chairs: Manuel Haas, United Kingdom
Andreas Reif, Germany

S.20.01 09.00 Moving forward with translational research in autism – a regulatory-academic liaison

S.20.02 09.25 Regulatory perspective on the data to be gathered for the development of medicinal products for autism spectrum disorder
Sabine Lenton, United Kingdom

S.20.03 09.50 Qualification of novel methodologies a regulatory perspective
Maria Tome, United Kingdom

S.20.04 10.15 Strategies for the development of medicines for autism spectrum disorders - an industry perspective
Lindsay Ham, Switzerland

Updated programme: http://2017.ecnp.eu / ECNP app / congress info terminals
EDUCATIONAL TRACK

EDUCATIONAL UPDATE SESSION
09.00-10.40 | Bordeaux

How do genetic studies advance understanding and treatment of psychiatric disease?

Moderator: Martien Kas, The Netherlands

E.04.01 Genetics and schizophrenia
09.05 Jeremy Hall, United Kingdom

E.04.02 Genetics and affective disorders
09.50 Franziska Degenhardt, Germany

AWARD CEREMONY
10.40-11.15 | Poster area (podium)
Presentation ECNP Travel Awards

COFFEE BREAK
10.40-11.15 | Poster area and exhibition

POSTER VIEWING
10.40-11.15 | Poster area

Posters that are on display can already be viewed during this time. It is not mandatory for poster presenters to be at their poster, the poster sessions will start at 12.15. See pages 92-135 for details.

PLENARY LECTURE
11.15-12.00 | Grand Amphitheatre

Brain Prize Award lecture

Chair: Laurence Lanfumey, France

Synaptic plasticity in health and disease

Graham L. Collingridge, United Kingdom

LUNCH
12.00-14.00 | Poster area and exhibition

POSTER SESSION
12.15-13.45 | Poster area

Poster presenters will be available at their paper poster for further explanation and discussion. See pages 92-135 for details.

RAPID-FIRE POSTER SESSION
12.15-12.45 | Poster area (podium)

Chair: Guido van Wingen, The Netherlands

RF.02.01 Glutamate levels measured by glutamate voltammetry in the rat prefrontal cortex after treatment with N-methyl-D-aspartate receptor antagonists
Irina Ionescu, Germany

RF.02.02 Brain responses in the theory of mind network are modulated by intention type in schizophrenia
Florian Bitsch, Germany

RF.02.03 Hevin in the nucleus accumbens controls emotional responses
Marta Barrera Conde, Spain

RF.02.04 Reducing fear extinction deficits in a 5-HT2C receptor editing model of post-traumatic stress disorders
Mathilde Regue, France

RF.02.05 Study of the effects of caffeinated/sugared energy drinks on ethanol craving, in rats
Juliana Jorge Romano, Brazil

RF.02.06 Enduring effects of methylphenidate on sleep in children with Attention-Deficit/Hyperactivity Disorder: a double-blind randomized controlled trial
Michelle Solleveld, The Netherlands
PLENARY LECTURE
14.00-14.45 | Grand Amphitheatre
Chair: Celso Arango, Spain
ECNP Neuropsychopharmacology Award lecture
Presentation of the award to Michel Hamon by ECNP President Celso Arango.
A journey into serotonin: 40 years of discoveries and surprises
Michel Hamon, France

COFFEE BREAK
14.45-15.00 | Poster area and exhibition

PRECLINICAL RESEARCH TRACK

SYMPOSIUM
15.00-16.40 | Bleu
The stressed genome in affective disorders: a novel target for pharmacological intervention?
Chairs: Nadine Provençal, Canada
Johannes M.H.M. Reul, United Kingdom
S.21.01 15.00
Epigenetic effects of glucocorticoids exposure during hippocampal neurogenesis and their implication in psychiatric disorders
Nadine Provençal, Canada
S.21.02 15.25
Perinatal adversities and stress vulnerability in later life
Carmine M. Pariante, United Kingdom
S.21.03 15.50
Epigenetic signatures of early life adversities and vulnerability to psychopathology
Marco Andrea Riva, Italy
S.21.04 16.15
Glucocorticoid action in the brain: novel findings at the neuronal genome level
Johannes M.H.M. Reul, United Kingdom
**TRANSLATIONAL RESEARCH TRACK**

**SYMPOSIUM**

**S.22**

15.00-16.40 | Room 352AB

**GABA dysfunction in the pathogenesis of schizophrenia: from bench to clinic**

**Chairs:** Dimitri Kullmann, United Kingdom  
Philip Mcguire, United Kingdom

**S.22.01**

15.00  
Prepubertal parvalbumin protein loss precedes adult parvalbumin interneuron loss in MAM-treated rats: rescue by peripubertal diazepam  
Anthony A. Grace, USA

**S.22.02**

15.25  
Understanding complex inputs to an abnormal circuitry in the trisynaptic pathway in schizophrenia  
Francine M. Benes, USA

**S.22.03**

15.50  
GABA spectroscopy and cognitive functioning  
Gabriele Ende, Germany

**S.22.04**

16.15  
Alterations in GABA neurotransmission before the onset of psychosis  
Gemma Modinos, United Kingdom

**CLINICAL RESEARCH TRACK**

**SYMPOSIUM**

**S.23**

15.00-16.40 | Maillot

**New tools to understand and seek success at youth suicide prevention**

**Chair:** J. John Mann, USA

**S.23.01**

15.00  
Introduction to the session: current status of youth suicide prevention and why we need new tools  
J. John Mann, USA

**CLINICAL TREATMENT TRACK**

**SYMPOSIUM**

**S.24**

15.00-16.40 | Grand Amphitheatre

**Use of human brain implants to interpret brain activity and clinical applications to neurological disorders**

**Chair:** Nick F. Ramsey, The Netherlands

**S.24.01**

15.00  
Fully implanted brain signal recording device for communication in severe paralysis reveals feasibility of chronic home use of neuronal activity  
Mariska VanSteensel, The Netherlands

**S.24.02**

15.25  
Brain-computer interface using high-density intracortical microelectrode arrays for robotic limb control and reliable communication  
Beata Jarosiewicz, USA

**S.24.03**

15.50  
Use of sensing brain implants to better understand and regulate DBS in Parkinson’s disease: clinical results in patients  
Coralie De Hemptinne, USA

**S.24.04**

16.15  
The potential of near infrared light therapy in neurodegenerative disease  
t.b.a.
**CLINICAL RESEARCH TRACK**

**S.25**

**SYMMOSIUM**
15.00-16.40 | Havane

**Reward processing as cross-cutting phenomenon in psychiatric classifications**

**Chair:** Arnt Schellekens, The Netherlands

**S.25.01**
15.00
Striatal reward signalling across psychiatric diagnoses
Andreas Heinz, Germany

**S.25.02**
15.25
Disruption of reward-processing in addiction unravelled by image based meta-analysis of fMRI studies
Maartje Luijten, The Netherlands

**S.25.03**
15.50
Reward processing in bipolar disorders
Esther Jimenez, Spain

**S.25.04**
16.15
Neural correlates of reward processing in ADHD: what do we know and where do we go from here?
Anouk Scheres, The Netherlands

**EDUCATIONAL TRACK**

**E.05**

**EDUCATIONAL UPDATE SESSION**
15.00-16.40 | Bordeaux

**Tackling the challenge of treatment resistant depression**

**Moderator:** Siegfried Kasper, Austria

**E.05.01**
15.05
Pharmacological options for treatment resistant depression: what does the evidence suggest?
Hamish McAllister-Williams, United Kingdom

**E.05.02**
15.50
Neurostimulatory options for treatment resistant depression: which treatment for which patient?
Sarah Kayser, Germany

**BREAK**
16.40-17.15

**Start industry sessions at 17.15**

**Updated programme:**
http://2017.ecnp.eu / ECNP app / congress info terminals
P.1.a.015 Genetic association with suicidal ideation in patients with acute coronary syndrome
H.J. Kang*, K.Y. Bae, S.W. Kim, I.S. Shin, J.S. Yoon, J.M. Kim, South-Korea

P.1.a.016 Is the HTR3A rs1062613 polymorphism differently associated with reward-related dopamine release in fibromyalgia patients and healthy controls?

P.1.a.017 Translational identification of transcriptional signatures of major depression and antidepressant response

P.1.a.018 Gene expression in the brain of rats with increased aggression and signs of cognitive deficits caused by the early social isolation
N.A. Krupina*, E.A. Zubkov, Y.A. Zorkina, E.V. Orshanskaya, N.N. Khlebnikova, Russia

P.1.a.019 Epigenetic and transcriptional changes in the CRH gene are related to severity of suicide attempt and a general psychiatric risk score in adolescents
J. Jokinen*, A. Boström, H. Schiöth, M. Asberg, Sweden

P.1.a.020 A brainstem structural intermediate phenotype of CYP2C19 polymorphism
J.C. Stingl, A. Paul, M. Steffens, P. Beschoner, J. Bosch, L. Dommes, R. Viviani*, Germany

P.1.a.021 Study of polymorphic variants of tryptophan hydroxylase genes in patients with schizophrenia
V. Tiguntsev*, A.V. Semke, Russia

P.1.a.022 Assessment of DNA methylation status in HERV-K sequences in patients with first-episode schizophrenia
B. Misiak, F. Stramecki*, E. Szmida, P. Karpiński, P. Piotrowski, J.A. Besłej, D. Frydecka, Poland

P.1.a.023 Genetic diagnostics of neural tube defects (NTD)-associated congenital anomalies with next-generation sequencing technologies
L. Pappa*, Estonia

P.1.a.025 Dopamine receptors genes polymorphisms in Parkinson patients with levodopa-induced dyskinesia

P.1.a.026 Association between polymorphisms of the PCDH15 gene and schizophrenia in Korean population
Y. Choi*, W. Kang, E. Kim, J. Kim, South-Korea

P.1.a.027 Reduced glutamatergic metabolism in the anterior cingulate cortex in carriers of the Met-allele of the BDNF Val66Met polymorphism
L. Martens*, L. Fensky, L. Colic, M. Li, A. Richter, G. Behnisch, B. Schott, C. Seidenbecher, M. Walter, Germany

P.1.a.028 Identification of phenotypic predictors of pathogenic copy number variants in a psychosis population
C. Foley*, E. Heron, L. Gallagher, A. Corvin, Ireland

P.1.b.005 The weakening of amplified synaptic strength at preexisting synapses has not been modified by T3 hormone
S. Delibaş*, Y. Bayar, C. Süer, N. Dursun, Turkey

P.1.b.006 Intra-hippocampal L-thyroxine infusion precludes synaptic component of depotentiation following a depotentiating stimulus given shortly after a tetanus
Y. Bayar*, M. Youssef, N. Dursun, C. Süer, Turkey

P.1.b.007 An investigation of depotentiation of long-term potentiation in the dentate gyrus of the hippocampal formation in hypothyroid and hyperthyroid rats
N. Dursun*, C. Süer, Turkey

P.1.b.008 Depotentiation of post-tetanic enhancement induces abnormal Tau hyperphosphorylation in the hippocampus in vivo
E. Babur*, B. Tan, N. Dursun, C. Süer, Turkey
**NEURODEVELOPMENT**

**P.1.c.008**  
mGlu2 as a novel target underlying sex-differences in a ventral dentate gyrus (vDG)-medial amygdala (MeA) circuit controlling social behaviour: importance of early life experiences  

**P.1.c.009**  
Altered fetal steroidogenesis and dysregulated placental immune response in a developmental vitamin D deficient rat model of autism  
A. Ali*, X. Cui, D. Eyles, Australia

**P.1.c.010**  
Glucocorticoids reduce TPH2 expression in the newborn rat brain  
T.S. Kalinina*, V.V. Bulygina, D.A. Lanshakov, E.V. Sukhareva, G.T. Shishkina, N.N. Dygalo, Russia

**P.1.c.011**  
Dexamethasone upregulates levels of proapoptotic proteins proBDNF and cleaved caspase-3 in the frontal cortex and the hippocampus of neonatal rats  
V. Bulygina*, T.S. Kalinina, D.A. Lanshakov, N.N. Dygalo, Russia

**P.1.c.012**  
GABA-A α5 receptor potentiation in preadolescence prevents hyporeactivity to amphetamine induced by prenatal lipopolysaccharide treatment in rat females  
B. Batinic*, A. Santrač, I. Jančić, B. Marković, M. Milić, M. Savić, Serbia

**P.1.c.013**  
GPRIN1, a new 5-HT6 receptor partner involved in its constitutive activity and receptor-induced neuronal differentiation  
C. Pujol*, L. Runtz, M. Seveno, J. Bockaert, P. Marin, S. Chaumont-Dubel, France

**P.1.c.014**  
Inhibition of DYRK1A overdosage restores cognition in Down syndrome models through DYRK1A-interaction with major players of synaptic transmission  

**NEUROENDOCRINOLOGY**

**P.1.e.005**  
Lithium treatment and thyroid function – a retrospective study in patients with unipolar depression, bipolar and schizoaffective disorders  
G. Sobreira*, J. Oliveira, Portugal

**P.1.e.006**  
The effects of hypocalcaemia on prolactinoma cell populations  

**P.1.e.008**  
Is there an association between oxytocin plasma levels and women’s mental health?  
M. Serati*, S. Grassi, M. Redaelli, L. Pergoli, L. Cantone, V. Bollati, J.L. Barkin, G. Tiso, E.M. Colombo, M. Buoli, A.C. Altamura, Italy

**P.1.e.009**  
Testosterone application modulates resting-state connectivity in emotion regulation network  
M. Votinov*, L. Wagels, F. Hoffstaedter, S. Eickhoff, U. Habel, Germany

**NEURO-IMMUNE INTERACTION**

**P.1.f.011**  
Immunological features of hyperprolactinemia in schizophrenic patients being under long-term therapy with risperidone  
O. Lobacheva*, E.G. Kornetova, V.B. Nikitina, T.P. Veltugina, T.A. Menyaytseva, A.S. Boiko, Y.N. Borodyuk, A.V. Semke, Russia

**P.1.f.012**  
Anti-neuronal antibodies and their significance for psychiatric and cognitive symptomatology: a 3-year prospective case-control study  
M. Schou*, S.G. Sæther, O.K. Oranje, S.K. Reitan, A. Vaaler, D. Kondziella, Norway

**P.1.f.013**  
Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: an electronic hospital register-based study  
E.F. Osimo*, P.B. Jones, G.M. Khandaker, United Kingdom

**P.1.f.015**  
Identification of new formyl peptide receptor-2 (FPR2) agonists with anti-inflammatory properties  
**P.1.f.016** Changes in serum myostatin levels before and after electroconvulsive therapy in drug-resistant depressed patients  
C. Celik, A. Bolu, T. Oznur, M.S. Aydın*, Y. Tokgöz, O. Uzun, Turkey

**P.1.f.017** Fractalkine alters synaptic activity of rat principal cells in the basolateral amygdala  
J.E. Sowa*, K. Tokarski, G. Hess, Poland

---

**P.1.g** NEUROPHARMACOLOGY

**P.1.g.016** Effects of chronic administration of memantine on okadaic acid induced changes in hippocampus and medial septal nucleus  
G. Beselia*, M. Dashniani, Georgia

**P.1.g.017** Dopamine D2-agonist cabergoline increases brain-derived neurotrophic factor mRNA expression in the rat midbrain and demonstrates anxiolytic-like behavioural effects  
P. Anokhin*, T. Proskuryakova, V. Shokhonova, I. Shamakina, Russia

**P.1.g.018** Resveratrol prevents schizophrenia-like behaviour and neural plasticity abnormalities induced by maternal immune activation  
N. Moura, T. Pombo, F. Ferreira*, Brazil

**P.1.g.019** Possible long term consequences of a chronic oral treatment with methylphenidate on monoamine neurotransmission  
M. Di Miceli*, A. Omoloye, B. Gronier, United Kingdom

**P.1.g.020** Neuronal and peripheral markers of plasticity dynamics, change concomitantly after sub-anesthetic dose of ketamine in humans  
L. Colic*, C. McDonnell, M. Li, O. Speck, B.H. Schott, M. Bianchi, M. Walter, Germany

**P.1.g.021** Naloxonazine microinjections in the ventral periaqueductal grey matter column decreased the antinociception induced by copaiba tree oil intake  

**P.1.g.022** Serum concentrations of iNos and IL-33 in depressed patients with a history of suicide attempts  

**P.1.g.023** Glutamate levels measured by glutamate voltammetry in the rat prefrontal cortex after treatment with N-methyl-D-aspartate receptor antagonists  
I. Ionescu*, K. Allers, R. Arban, C. Dorner-Ciossek, L. Kussmaul, Germany

**P.1.g.024** Functional activation of Gi/o proteins coupled to multiple neurotransmitter receptors in postmortem human prefrontal cortical membranes  
Y. Odagaki*, M. Kinoshita, T. Ota, J.J. Meana, L.F. Callodo, J.A. Garcia-Sevilla, Japan

**P.1.g.025** mTOR signaling is involved in the promnesic effects of both 5HT6R agonist and antagonist  
R. Asselot*, F. Dauphin, M. Leger, T. Freret, V. Bouet, France

**P.1.g.026** Adjunctive aripiprazole in the treatment of risperidone/paliperidone-induced hyperprolactinemia. Influence of catechol-O-methyltransferase and MAOA polymorphisms  
A. Arnaiz, M. Zumarraga, O. Olivas, A. Arrue, M. Gaton, L. Erkoreka, M. Zamalloa, N. Basterreche*, Spain

**P.1.g.027** The effect of TC-2153, an inhibitor of striatal-enriched protein tyrosine phosphatase, on the 5-HT2A receptors  
E.A. Kulikova*, N.B. Illarionova, K.P. Volcho, T.A. Khomenko, N.F. Salakhutdinov, N.V. Khotskin, E.Y. Bazhenova, A.V. Kulikov, Russia

**P.1.g.028** Effect of brain-derived neurotrophic factor treatment on behavior and brain serotonin system in tumor necrosis factor-α knockout mice  
D. Bazovkina*, E. Kulikova, E. Bazhenova, V. Naumenko, A. Kulikov, Russia

**P.1.g.029** The selective orexin-2 antagonist JNJ-42847922(MIN-202) improves sleep in patients with primary insomnia  
S. Brooks*, P. Siebenga, R. Zuiker, G. Jacobs, I. Kezic, J. Van Gerven, R. Luthringer, P. De Boer, P. Van der Ark, The Netherlands
P.1.g.030  Analysis of genetic variants associated with antipsychotic treatment efficacy in healthy Armenian individuals

P.1.g.031  Evaluation of the effects of etifoxine (100 mg) and lorazepam (2 mg) on alertness and cognitive functions in elderly subjects
D. Deplanque*, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet, France

P.1.h.018  Memory impairments and changes of brain-derived neurotrophic factor gene expression in depressive-like state development
A.V. Gorlova*, D.A. Pavlov, E.A. Zubkov, A.N. Inozemtsev, V.P. Chekhonin, Russia

P.1.h.020  Activation of trace amine-associated receptor 1 reduces schedule-induced polydipsia in rats
A. Dolgorukova*, A. Dorotenko, L. Mus, R.R. Gainetdinov, I. Sukhanov, Russia

P.1.h.021  The trace amine-associated receptor 1 modulates nicotine behavioural effects
I. Sukhanov*, A. Dorotenko, A. Dolgorukova, M. Dorofeikova, R.R. Gainetdinov, Russia

P.1.h.022  Effects of exercise and environmental enrichment in serotonin transporter (5-HTT) knock-out mice
J. Rogers, F. Farzana, F. Cheng, S. Li, L. Lanfumey, P. Adlard, A. Hannan, T. Renoir*, Australia

P.1.h.023  Depressive behaviour induced by activation of hippocampus associated with changes in c-Fos and Bcl-xL expression in the CA1 and cortical neurons
N. Dygalo*, V.V. Bulygina, E.V. Sukhareva, T.S. Kalinina, D.A. Lanshakov, Russia

P.1.h.024  Altered serotonergic gene expression in the brain regions of male mice with anxiety/depression-like state and pathology of aggressive behaviour
D.A. Smagin*, I.L. Kovalenko, A.G. Galyamina, N.N. Kudryavtseva, Russia

P.1.h.025  Lack of serotonin 2B receptor gene drives depressive-like phenotype induced by chronic stress: a potential role for microglia?
I. D’Andrea*, L. Maroteaux, A. Roumier, France

P.1.h.026  Psychomotor disturbances and changes in the expression of neurotransmitter genes in the dorsal striatum of aggressive and defeated male mice
A.G. Galyamina*, D.A. Smagin, I.L. Kovalenko, T.G. Tolstikova, N.N. Kudryavtseva, Russia

P.1.h.027  Reduced aggression, social impairments, and cognitive inflexibility in neuronal nitric oxide (Nos1) knockdown mice
A. O’Leary*, F. Freudenberg, E. Candemir, L. Grünewald, A. Reif, Germany

P.1.h.028  Knockdown of Bcl-xL in the rat hippocampus increased immobility in the forced swim test
G.T. Shishkina*, D.A. Lanshakov, A.V. Bannova, N.P. Agarina, N.N. Dygalo, Russia

P.1.h.029  Abnormality of social behavior and dysfunction of autism related gene expression developing under chronic social defeat stress in male mice
N.N. Kudryavtseva*, I.L. Kovalenko, D.A. Smagin, A.G. Galyamina, V.N. Babenko, Russia

P.1.h.030  Comparing models of autism spectrum disorder based on pre- and postnatal valproate exposure: behavioral and histological assessment
V. Gedzun*, V. Dubynin, A. Malysh, N. Sarycheva, M. Svinov, Russia

P.1.h.031  Effect of trazodone on affective state behaviour in the chronic constriction injury rat model
B. Garrone*, A. Di Matteo, A. Amato, L. Pistillo, L. Durando, P. Di Giorgio, S. Tongiani, Italy

P.1.h.032  Age-related changes in negative affect and cognitive performance in Sprague-Dawley rats: possible role of the cell fate regulator FADD
E. Hernández-Hernández*, M.J. García-Fuster, Spain

P.1.h.033  Effect of prenatal administration of fluvoxamine on morphophysiological parameters and behavior of white rats
G. Gruzdev*, Y.A. Voronina, D.M. Manchenko, N.Y. Glazova, N.G. Levitskaya, Russia
Deviations from the physiological, ultradian glucocorticoid rhythm are accompanied by altered behavioural and fMRI responses to emotional stimulation

High angular resolution diffusion imaging correlates of depression in Parkinson’s disease: a connectometry study
M. Mayeli*, S. Sobhani, F. Ghazi Sherbaf, S. Mohammadi Jooyandeh, F. Rahmani, M.H. Aarabi, Iran

Effects of natural medicinal on emotional brain response
L. Colic*, L. Martens, L. Fensky, V. Teckentrup, A. Kühnel, M. Schultz, Y. Fan, M. Walter, Germany

Which white matter bundles are associated with treatment efficacy in deep brain stimulation of the ventral internal capsule for OCD and major depressive disorder?

Effects of natural medicinal on amygdala-centered resting state functional connectivity
L. Colic*, Y. Fan, L. Fensky, V. Teckentrup, A. Kühnel, L. Martens, M. Schultz, M. Walter, Germany

Meditation-associated change in the functional connectivity of the insula

Influence of serotonergic gene variants on serotonin transporter binding in ADHD

Non-invasive magnetic resonance imaging of human serotonin function: dose-dependent effects of citalopram
A. Schrantee*, P. Lucassen, J. Boolij, L. Reneman, The Netherlands

Monoamine oxidase A distribution volume as a correlate for electroconvulsive therapy – preliminary results

Amygdala reactivity to fearful faces correlates positively with impulsive aggression
S. Da Cunha-Bang*, P.M. Fisher, L.V. Hjordt, K.K. Holst, G.M. Knudsen, Denmark

Tryptophan catabolism affects the neural correlates of mood-congruent processing biases in bipolar depression
B. Vai*, M. Riberto, D. Ghiglino, S. Poletti, R. Bonsignori, G. Schuetze, M. Schwarz, C. Colombo, F. Benedetti, Italy

Investigation of cerebral cortex hemodynamic activations using fNIRS during mind reading task in subjects with autism spectrum disorder
B. Duman*, E. Kale, I. Yenihayat, B. Baskak, H. Devrimcı-Özgüven, Turkey

Brain correlates of impaired insight and social cognition in schizophrenia
M. Martin-Subero*, P. Salgado-Pineda, R. Salvador, P. Fuentes-Claramonte, S. Alonso-Lana, S. Sarró, E. Pomarol-Clotet, P. McKenna, Spain

Brain responses in the theory of mind network are modulated by intention type in schizophrenia
F. Bitsch*, P. Berger, A. Nagels, I. Falkenberg, B. Straube, Germany

Excitatory amino acid transporters 1 affects corticolimbic circuitry during implicit processing of negative emotional stimuli in bipolar disorder
M. Riberto*, S. Poletti, C. Lorenzi, B. Vai, S. Brioschi, F. Benedetti, Italy
P1.i.034  Assessment of the myelination of brain structures in patients with schizophrenia using the MRI method
D. Parshukova*, L.P. Smirnova, A.A. Seregin, E.M. Dmitrieva, V.L. Yamykh, A.V. Semke, S.A. Ivanova, Russia

P1.i.035  Cingulum bundle abnormalities and their association with psychopathology in recent-onset schizophrenia
W. Yoon*, J.S. Lee, Y.S. Kim, H.R. Kim, South-Korea

P1.i.036  Cortico-striatal-thalamo-cortical white matter structure in Tourette syndrome and ADHD
N. Forde*, M. Zwiers, S. Akkermans, J. Naaijen, J. Buitelaar, P. Hoekstra, The Netherlands

P1.i.040  Enhancing neuro imaging genetics through meta analysis: global collaborations in psychiatry by the ENIGMA consortium
M.A.B. McMahon*, P.M. Thompson, USA

P1.i.301  Application of machine learning for structural brain MRI in mood disorders: critical review from a clinical perspective
K.S. Na*, H.Y. Jung, S.H. Shim, South-Korea

P1.j.017  Pharmacological inhibition of bone resorption induces cognitive impairment in rats on high fat high fructose diet: metabolic correlations
M. Zhelyazkova-Savova*, S. Gancheva, Bulgaria

P1.j.018  Neurocognitive functions in remission vs. psychotic states: a comparative study between bipolar disorder and schizophrenia
D. Ceylan*, B.B. Akdede, E. Bora, C. Hıdırgöl, Z. Tunca, K. Alptekin, A. Ozerdem, Turkey

P1.j.019  Memory relation to perceptual processes during cognitive aging
M. Machavariani-Tsereteli*, T. Gagoshidze, Georgia

P1.j.020  Psychological and neural mechanisms of rotating leadership in teams: the impact of engagement and shared mental model
T. Casas Klett, R. Ni*, Switzerland

P1.j.021  Social-intellectual deprivation effects on prefrontal cortex functioning and the “Theory of Mind" development – study in Georgia
M. Metreveli*, T. Gagoshidze, Georgia

P1.j.022  Effects of lamotrigine in open-field, water maze and step-through tests in rats
D. Dimitrova*, L. Vasileva, E. Papagianni, D. Getova, Bulgaria

P1.j.023  Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome
A. Salvador*, Y. Worbe, C. Delorme, G. Coricelli, R. Gaillard, T.W. Robbins, A. Hartmann, S. Palminteri, France

P1.j.024  Association of sleep quality and neurocognitive dysfunction in patients with depression
E. Berdzenishvili*, S. Tabagua, Georgia

P1.j.025  L-Thyroxine suppresses depotentiation of post-tetanic enhancement in the perforant pathway – dentate gyrus synapses in a dose-dependent manner
C. Süer*, M. Youssef, N. Dursun, Turkey

P1.j.026  Donepezil improves cognitive deficit but not hypermobility induced by cholinergic and glutamatergic antagonists in mice
S. Wagner, E. Poiraud, B. Huyard, S. O’Connor, E. Andriambeloson*, France

P1.j.027  Lou/c/jall rats as a model of cognitive resilience in the field of Alzheimer’s disease
M. Leger*, B. Haelewyn, T. Freret, France

P1.j.028  Effects of donepezil on scopolamine-induced cognitive impairment and Alzheimer’s disease-like change in quantitative EEG analysis in rhesus monkeys
T. Nakako*, Y. Iwamura, A. Matsumoto, K. Matsumoto, M. Ikejiri, K. Ikeda, Japan

P1.j.029  Modulation of hippocampal cholinergic transmission and memory function by septohippocampal projections
N. Chkhikvishvili*, N. Pochkhidze, Georgia
P.1.j.030  Cognitive function in children and adolescents with ADHD receiving lisdexamfetamine dimesylate in a 2-year safety study
T. Banaschewski*, A. Zuddas, C. Bliss, B. Robertson, D. Coghill, Germany

P.1.j.031  Personality, stress, and multitasking
M. Van Schrojenstein Lantman*, V. Hoebregts, M. Mackus, J.C. Verster, A. Scholey, The Netherlands

P.1.j.032  Modulation of memory function and neurotransmitters activity in prefrontal cortex by projections from nucleus basalis magnocellularis
M. Burjanadze*, G. Beselia, L. Kruashvili, N. Chkhivikishvili, Georgia

P.1.j.043  Acute effects of low-dose ketamine on pain and emotional memory acquisition and consolidation in mice
M. Erdinc, I. Kelle, H. Akkoc, E. Uyar*, L. Erdinc, Turkey

**EPIDEMIOLOGY**

P.1.k.010  Comparison of clinical characteristics between single and repeated suicide attempters admitted to emergency room

P.1.k.011  Has deinstitutionalization affected inpatient suicide? Psychiatrist inpatient suicide rates between 1990 and 2013 in Israel
L. Levi*, N. Werbeloff, I. Pugachova, R. Yoffe, M. Large, M. Davidson, M. Weiser, Israel

P.1.k.012  Suicide attempts in Serbian elderly population – 10 year retrospective study
V. Djordjevic*, A. Rankovic, P. Vojvodic, G. Djokic, Serbia

P.1.k.013  Characteristics of suicide in Neamt County
M.M. Dumitru*, A. Papari, A.C. Papari, Romania

P.1.k.004  Descriptive analysis of demand in a mental health-primary care liaison department
B. Mata Sáenz*, L. Nuevo Fernández, L.M. Asensio Aguerri, L. Cabanillas Carrillo, L. Beato Fernández, Spain

P.1.k.005  Related factors with patients who didn’t come to visits after being referred by primary care
B. Mata Sáenz*, V. Muñoz Martínez, L. Nuevo Fernández, L.M. Asensio Aguerri, L. Beato Jiménez, L. Cabanillas Carrillo, Spain

P.1.k.007  Prevalence and characteristics of schizophrenia in 1st versus 2nd generation East-African immigrants in Israel – a 30-year retrospective study
G. Eger*, Y. Reuven, J. Dreher, P. Shvartzman, M. Weiser, S. Lev-Ran, Israel

P.1.k.008  Age-related pharmacotherapy of attention deficit hyperactivity disorder in adults in Slovenia from 2003 to 2015: a population-based study
M. Stuhec*, I. Locatelli, Slovenia

P.1.k.009  Is cesarean section associated with risk for autism spectrum disorder?
R. Gross*, Israel

P.1.k.012  Early life stress affects glutamatergic postsynaptic density genes: implications for novel treatment targets
E.F. Buonaguro*, S. Morley-Fletcher, C. Avagliano, L. Vellucci, S. Maccari, A. De Bartolomeis, Italy

P.1.k.013  The association between suicide attempts and Toxoplasma gondii infection
S. Shim*, H. Jung, J. Yang, K. Na, E. Kim, South-Korea

P.1.k.014  HLA-class II genetic signatures in autism spectrum disorders

P.1.k.015  Acute hypoxic stress in the critical periods of embryogenesis: the influence on the offspring development in the early postnatal period
E. Shvyreva*, A. Graf, M. Maslova, A. Maklakova, N. Sokolova, Russia

P.1.k.016  The role of C1473G polymorphism in mouse tryptophan hydroxylase-2 gene in the response of brain serotonergic system and behavior to short photoperiod
E.Y. Bazhenova*, N.V. Khotskin, I.E. Sorokin, D.V. Fursenko, A.V. Kulikov, Russia
P.1.I.017 Relationship between hippocampal subfield volumes and cortisol awakening response parameters in major depressive disorder
K. Doolin*, T. Frodl, V. O’Keane, Ireland

P.1.I.018 Neurochemical mechanism for alterations of sexual functioning in postmenopausal women
H.Y. Jung, W. Hahm, J.C. Yang*, G.W. Kim, South-Korea

P.1.I.019 Clinical characterisation of neurexin1 deletions and their role in neurodevelopmental disorders
J. Fitzgerald, M. Al-Shehhi, S. Lynch, S. Shen, L. Gallagher*, Ireland

P.1.I.020 Relevance of adult hippocampal cytogenesis for behavior in female rats and the role of female hormones

P.1.I.021 The effects of P38-MAPK inhibitor on long-term potentiation, long-term depression and depotentiation in the perforant pathway – dentate gyrus synapses
M. Yousef*, Turkey

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**AFFECTIVE DISORDERS (CLINICAL)**

**P.2.a.018** Attentional processing of emotional information in remitted recurrent major depressive disorder – preliminary results from the NEWPRIDE study
R.S. Van Kleef*, S.E. Nijmeijer, J.B.C. Marsman, C.L. Bockting, E. Van Velzen, A. Aleman, M.J. Van Tol, The Netherlands

**P.2.b.017** GSK-3beta rs334558 is associated with severe insomnia in patients with major depressive episode, but not with remission after antidepressant treatment

**P.2.b.018** Does pharmacotherapy play a role in changes of salivary aldosterone in patients with depressive disorder after clinical improvement?
L. Izakova*, N. Hlavacova, V. Segeda, D. Kapsdorfer, D. Jezova, Slovak Republic

**P.2.b.019** Cognitive performance in patients with major depressive disorder treated with vortioxetine compared with escitalopram and venlafaxine

**P.2.b.020** Cognitive performance and 12-month clinical outcome in first-episode of depression

**P.2.b.021** Is there enough ‘interest in and pleasure in’ the concept of depression – the development of the Leuven Affect and Pleasure Scale (LAPS)
K. Demyttenaere*, P. Mortier, G. Kiekens, R. Bruffaerts, Belgium

**P.2.b.022** A meta-analysis of dose escalation of antidepressant agents in major depressive disorder
L. Bartova*, M. Dold, R. Rupprecht, S. Kasper, Austria

**P.2.b.023** Effects of vortioxetine on composite scores across objective cognitive tests: results from 2 clinical studies in adults with major depressive disorder
H. Loft, W. Jacobson*, C.K. Olsen, USA

**P.2.b.024** Agomelatine in depressed patients with cardiovascular comorbidities: subgroup-analysis of the VIVALDI-studies
G. Laux*, B. Barthel, Germany

**P.2.b.025** Cognition predicts psychosocial functioning and psychological treatment adherence in depressive disorders
A. Costas*, I. Ramos Grille, G. Garrido García, E. Jovell Fernández, Spain

**P.2.b.026** The relation between major depressive disorder and comorbid generalized anxiety disorder – results from a European multicenter, cross-sectional survey
M. Dold*, L. Bartova, D. Souery, J. Mendlewicz, A. Serretti, J. Zohar, S. Montgomery, S. Kasper, Austria

**P.2.b.027** Serum lipidomic analysis for the discovery of biomarkers for major depressive disorder in drug-free patients
M.K. Kwack*, E.Y. Kim, B.S. Kim, South-Korea

**P.2.b.028** Depression and acute myocardial infarction
A. Spasovska Trajanovska*, Macedonia

**P.2.b.029** Gene polymorphisms of enzymes biotransformation of xenobiotics in patients with depressive disorders
L. Levchuk*, I.S. Losenkov, E.V. Lebedeva, E.D. Schastnyy, O.E. Perchatkina, N.A. Bokhan, Russia

**P.2.b.030** Cortical monoamine oxidase – a distribution in seasonal affective disorder compared to healthy controls

**P.2.b.031** Measuring change in depression using the LAPS – findings in the “Mosaic of Emotions” group experience with agomelatine
**P.2.c.002**  A potential protein marker of impaired glutamatergic transmission in patients with bipolar disorder
A.A. Seregin*, L.P. Smirnova, E.M. Dmitrieva, A.A. Letova, G.G. Simutkin, S.A. Ivanova, Russia

**P.2.d.016**  Neurotrophins, inflammation and oxidative damage as mediators of cognitive functioning in bipolar disorder
E. Mora*, M. Portella, G. Piñol-Ripoll, R. López, D. Cuadras, I. Forcada, M. Teres, E. Vieta, M. Mur, Spain

**P.2.d.017**  Predicting functional impairment in bipolar disorder: a pilot study with a machine learning approach
J.V. Pinto*, D. Librenza-Garcia, D.P. Baldez, A.R. Rosa, F. Kapczinski, M. Kauer-Sant’Anna, I.C. Passos, Brazil

**P.2.d.018**  Clinical correlates of early-onset bipolar I disorder
J.V. Pinto*, M. Kunz, F. Kapczinski, I.C. Passos, M. Kauer-Sant’Anna, Brazil

**P.2.d.019**  Antipsychotic use in acute mania: a retrospective study in an affective disorder specialized unit in Lisbon, Portugal
I. Coelho*, F. Gonçalves, A. Aleixo, M. Marinho, M. Nascimento, G. Pereira, G. Sobreira, A. Nobre, Portugal

**P.2.d.020**  Sexual dysfunction and mood stabilisers in bipolar disorder: a review
C. Gómez Sánchez-Lafuente*, R. Reina Gonzalez, M. Hernandez Abellán, Spain

**P.2.d.021**  Benefits and harms of atypical antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis
T. Nosaka*, K. Hagi, A. Pikalov, A. Loebel, Japan

**P.2.d.022**  Inflammatory cytokines influence cortical thickness in bipolar disorder
G. Leone*, S. Poletti, C. Locatelli, H.A. Drexhage, F. Benedetti, Italy

**P.2.d.023**  Lurasidone adjunctive to lithium or valproate in patients with bipolar I disorder: effectiveness of up to 20 weeks of treatment
A. Pikalov*, J. Tsai, Y. Mao, J. Cucchiaro, A. Loebel, USA

**P.2.d.024**  One-year course of illness and clinical management in a cohort of patients affected with schizoaffective and bipolar disorders.
A. Murru*, N. Verdolini, I. Pacchiarotti, L. Samalin, J. Undurraga, G. Guiso, J.M. Goikolea, E. Vieta, Spain

**P.2.d.025**  Deficits in cognitive emotional regulation strategies of remitted unipolar patients and remitted bipolar patients (after a depressive episode)
M.M. Minciucă*, R.S. Romosan, A.M. Romosan, L. Dehelean, Romania

**P.2.d.026**  IL-6 levels in bipolar patients with manic episode
T. Torres-Suarez, J. Ramirez-Bermudez*, A. Díaz, C. Rios, Mexico

**P.2.d.027**  Recurrence and recovery in aripiprazole once-monthly maintenance treatment of bipolar I disorder: a blinded, placebo-controlled, randomised study

**P.2.d.028**  Graph analysis of verbal fluency test discriminates between patients with bipolar disorder and healthy controls
K. Machalska*, A. Turek, A.A. Chrobak, A. Tereszko, M. Siwek, D. Dudek, Poland

**P.2.d.029**  Difficulties in emotion regulation for patients with bipolar disorder type I and alcohol addiction comorbidity: a comparative study
L. Yasmine*, U. Ouali, H. Rebbi, F. Nacef, Tunisian Republic
**P.2.e** **TREATMENT (BASIC)**

**P.2.e.004** Electroconvulsive therapy: changes in the proteomic profiling in non-responder patients with major depression

**P.2.e.005** Time-course antidepressant-like effect of repeated electroconvulsive shock as measured by the time spent immobile in the forced-swim test in rats
R. García-Cabrerizo*, M.J. García-Fuster, Spain

**P.2.e.006** Chronic stress exposure impairs GABAergic homeostasis in the hippocampus: restorative effect of the novel antipsychotic lurasidone
M.A. Riva*, A. Rossetti, M.S. Paladini, M. Colombo, R. Molteni, Italy

**P.2.e.007** Hepatotoxicity of agomelatine and other antidepressants versus selective serotonin reuptake inhibitors
S. Billioti de Gage*, C. Collin, T. Le Tri, A. Pariente, R. Dray-Spira, M. Zureik, France

**P.2.f** **TREATMENT (CLINICAL)**

**P.2.f.016** Pharmacological treatments and risk of re-hospitalisation due to unipolar depression in a nationwide cohort of 123,712 patients

**P.2.f.017** Impact of CYP2C19 genotype on escitalopram exposure and establishment of a dose algorithm for genotype-based individualization of escitalopram therapy
M. Jukic*, E. Molden, M. Ingelman-Sundberg, Sweden

**P.2.f.018** SAGE-217 in subjects with major depressive disorder: efficacy and safety results from open-label Part A of a phase 2A study
H. Gunduz-Bruce, R. Riesenber, A. Sankoh, H. Li, G. Nomikos, J. Doherty, I. Kaul, R. Arnold, P. Miller*, S. Kanes, USA

**P.2.f.019** Risk factors of delirium following electroconvulsive therapy: a systematic review
T. Tsuji*, T. Uchida, J. Hirano, S. Kirino, Y. Saito, K. Sakuma, M. Mimura, H. Uchida, Japan

**P.2.f.020** A baseline controlled study with fluvoxamine to evaluate the effect on polysomnography in depressed patients with insomnia
B. Zhang*, China

**P.2.f.021** Intravenous sodium valproate for the treatment of mixed symptoms in patients with bipolar disorder: a pilot study
G. Amodeo*, M. Olivola, A. Fagiolini, Italy

**P.2.f.023** Could cognitive remediation therapy increase psychological treatment adherence in depression disorders? The role of cognitive impairment (pilot study)
A. Costas*, I. Ramos Grille, G. Garrido García, J.M. Vendrell, E. Jovell Fernández, Spain

**P.2.f.024** Agomelatine in real-life. Efficacy, tolerability and impact on anhedonia: a pooled analysis of 8 non-interventional studies
M. Di Giannantonio*, Italy

**P.2.f.025** Escitalopram versus duloxetine in acute treatment of major depressive disorder: a meta-analysis and systematic review
B. Maneeton*, N. Maneeton, P. Woottiluk, S. Likhitsathian, V. Boonyanaruthee, M. Srisurapanont, Thailand

**P.2.f.026** Switching to vortioxetine from a selective serotonin reuptake inhibitor in patients with major depression in remission: focus on tolerability
P. Scarpellini*, A. Cerù, Italy

**P.2.f.027** Low and high dose aripiprazole augmentation in major depressive disorder: a randomised, open-label study

**P.2.f.028** Intravenous clomipramine for treatment resistant depression
M.A. Trusso*, I. Baldini, A. Fagiolini, Italy
P.2.f.029  Functional recovery in patients with major depressive disorder (MDD) – the role of cognitive symptoms in real life clinical practice
I. Gkolia, A. Galanopoulos*, I. Michopoulos, A. Douzenis, D. Kontis, N. Oikonomidis, E. Papalexi, I. Zervas, Greece

P.2.f.030  Sex and interaction of CYP1A2  *1F/*1F genotype with smoking impact mirtazapine pharmacokinetics: a population pharmacokinetic analysis

P.2.g  OTHER (BASIC)

P.2.g.002  Hevin in the nucleus accumbens controls emotional responses
M. Barrera Conde*, M. Mongredien, V. Vialou, Spain

P.2.h  OTHER (CLINICAL)

P.2.h.007  Effects of lithium on metabolic parameters and clinical response: a retrospective analysis of 820 mood disorder patients
M. Pinna, M. Manchia*, C. Visioli, L. Tondo, Italy, Canada

P.2.h.008  Clinical manifestation of unipolar depression in addition to patient gender
J. Arandjelovic*, O. Zikic, M. Stankovic, Serbia

P.2.h.009  Elevated hs-CRP plasma level as a biological marker in elderly depressed adults
R. Grigoras*, T. Purnichi, M. Grigoras, V. Matei, Romania

P.2.h.010  ACTH levels, rumination and vulnerability to depression in healthy reproductive-age women
M. Jovicic*, S. Andric Petrovic, M. Mihaljevic, K. Maksimovic, J. Radulovic, M. Adzic, N.P. Maric, Serbia

P.2.h.011  Mania associated with digoxin: case description and literature review

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**P.3.a PSYCHOTIC DISORDERS (BASIC)**

**P.3.a.005** Disrupting protein–protein interactions of neuronal nitric oxide synthase: implications in schizophrenia-related behaviours  
E. Candemir, N. Fattakhov, V. Frerichs, S. Arshad, A. O’Leary, L. Grünewald, M. Schneider, D.A. Slattery, A. Reif, F. Freudenberg*, Germany

**P.3.a.006** Depressive comorbid symptoms in old age patients diagnosed with schizophrenia  
J. Vicente*, C. Garcia, R. Mateos, Spain

**P.3.a.007** Enhanced evaluative fear learning in delusion-proneness  
A. Louzolo*, M. Ingvar, A. Olsson, P. Petrovic, Sweden

**P.3.a.008** The effect of genetic variant of the ANKK1 gene with cannabis misuse in incipient psychotic patients: a controlled study  
V. Sanchez-Gistau*, S. Arranz, M. Sole, A. Cabezas, L. Moreno, L. Martorell, J. Labad, E. Vilella, Spain

**P.3.b PSYCHOTIC DISORDERS (CLINICAL)**

**P.3.b.020** Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains  
I. Laszlovzky, A. Barabassy*, B. Szatmári, J. Harsányi, E. Szalai, G. Németh, Hungary

**P.3.b.021** Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia  
B. Szatmári, A. Barabassy*, I. Laszlovzky, J. Harsányi, E. Szalai, D. Réti-Györfy, G. Németh, Hungary

**P.3.b.022** Demographic and pharmacological profile of inpatients treated with intramuscular paliperidone palmitate in a psychiatric unit  

**P.3.b.023** Behavioural phenotypes and genetic vulnerability in patients with postpartum psychosis, a comparison with the functional psychoses  
S.P. Milos*, L. Dehelean, A. Romosan, R. Romosan, Romania

**P.3.b.024** Non organic hallucinatory behaviour and neurocognitive deterioration in patients with functional psychoses  
V.A. Olteanu*, L. Dehelean, A. Romosan, R. Romosan, Romania

**P.3.b.025** Association between prolactin levels and antipsychotic response in schizophrenia: focus on the reproductive status  
M. Solerdelcoll Arimany*, A. González-Rodríguez, J. Pinzon, R. Penadés, C. García-Rizo, V. Ruiz-Cortés, M. Torra, M. Bernardo, R. Catalán, Spain

**P.3.b.026** Predictive factors for the diagnostic switch from schizophrenia to bipolar disorder  
R. Bálint*, L. Dehelean, A. Romosan, R. Romosan, Romania

**P.3.b.027** Risk factors for low bone mineral density in patients taking antipsychotics for psychosis  
T. Yoo*, S.W. Kim, M. Jhon, South-Korea

**P.3.b.028** Aberrant salience inventory and first rank symptoms: assessing proneness to psychosis beyond diagnosis  
T. Tofani*, C. Appignanesi, B. Campone, C. Baschirotto, E. Corsi, E. Ciampi, L. Mallardo, M. Santella, L. Tatini, F. Pietrini, N. Meneghin, P. Marino, M. Casini, V. Ricca, A. Ballerini, Italy

**P.3.b.029** Mu-opioid receptor availability in schizophrenia patients: a PET study using [11C]-carfentanil  
A.H. Ashok*, T. Marques, E. Rabiner, O. Howes, United Kingdom

**P.3.b.031** Evaluation of olfactory function in patients with recent onset psychosis and at-risk mental state in an early intervention program  
S. Arranz*, E. Izquierdo, A. Cabezas, M. Solé, M. Algora, I. Moreno, V. Sanchez, Spain

**P.3.b.033** Dysfunction of categorisation of bodily sensations in delusional parasitosis  
A.A. Malyutina*, M.G. Vinogradova, Russia

**P.3.b.034** Healthcare resource use in schizophrenia sufferers – findings from the EuroSC cohort  
**P.3.b.035**  Health-related quality of life in outpatients with schizophrenia: what determines changes over time and how to measure them
C. Domenech*, C. Altamura, C. Bernasconi, R. Corral, H. Eikis, J. Evans, A. Malla, A. Nordstroem, M. Zink, J. Haro, Spain

**P.3.b.036**  Relationship between schizophrenia spectrum and pain perception disturbance
A.L. Perez Morenilla*, P. Ortega Orihuela, Spain

**P.3.b.037**  Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use

**P.3.c.005**  Pre-clinical evaluation of two novel benzamides, LB-102 and 103, for the treatment of schizophrenia

**P.3.c.006**  Association of polymorphism in the dopamine receptors and transporter genes with hyperprolactinemia in patients with schizophrenia

**P.3.c.007**  GPR52 agonists represent a novel approach to treat psychotic disorders and improve cognitive function
A.J. Grottick, N. Schüler, H. Rosenbrock, M. Von Heimendahl, R. Arban, S. Hobson*, Germany

**P.3.c.008**  Long-term antipsychotic treatment and corpus callosum volume: an MRI study in patients with schizophrenia
M. Trehout*, E. Leroux, N. Delcroix, S. Dollfus, France

**P.3.c.009**  Differential impact of clozapine, atypical and typical antipsychotics on the fronto-striato-thalamic tracts in schizophrenia: a DTI study
A. Vandevelde*, E. Leroux, M. Tréhout, S. Dollfus, France

**P.3.d.019**  The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
S.D. Ostergaard*, L. Foldager, O. Mors, P. Bech, C. Correll, Denmark

**P.3.d.020**  Impact of once-monthly paliperidone palmitate treatment on hospitalisation risk in patients with schizophrenia switching from oral antipsychotics
N. Li, J. Zhuo, W. Tan*, I. Turkoz, M. Mathews, Y. Feng, Singapore

**P.3.d.021**  Demographic and pharmacological profile in hospitalized patients treated with long-acting injectable aripiprazole
A. Ramirez Ojeda*, M. Márquez Márquez, M.Z. Pérez Sosa, C. Muñoz Cauqui, A. Florido Puerto, A. Piña Baena, Spain

**P.3.d.022**  Sustained remission and symptom stability in patients with schizophrenia receiving aripiprazole once-monthly: a 52-week, open-label, maintenance study
T. Peters-Strickland*, N. Jin, P. Such, P.M. Salzman, USA

**P.3.d.023**  Effect of time to treatment initiation with once-monthly paliperidone palmitate in hospitalised Asian patients with acute exacerbated schizophrenia
H. Li, Y. Li, Y. Feng, J. Zhuo, I. Turkoz, M. Mathews, W. Tan*, Singapore

**P.3.d.024**  Inflammatory markers and clinical outcome in treatment resistant schizophrenia inpatients treated with clozapine
E. Kalter*, T. Horovitz, D. Shlosberg, E. Berger, A. Weizman, S. Konas, Israel

**P.3.d.025**  Risperidone suppresses upregulation of pro-inflammatory genes in peripheral leukocytes of schizophrenia patients partly by increasing their promoter methylation
F. Zhu*, Y. Fan, X. Mu, W. Wang, X.C. Ma, China

**P.3.d.026**  Patient reported outcomes from schizophrenia patients treated with paliperidone palmitate 1-monthly for at least 6 months (picture study)
M. Vega, S. Arqués, B. Herrera*, M. Garcia-Dorado, Spain
P.3.d.027  Food craving evolution in schizophrenic patients starting treatment with clozapine
M. Garriga*, A. Mallorqui, L. Serrano, M. Salamero, E. Vieta, M. Bernardo, C. Garcia-Rizo, Spain

P.3.d.028  Potential biomarkers of tardive dyskinesia: a multiplex analysis of blood serum
A.S. Boiko*, E.G. Kornetova, S.A. Ivanova, A.J.M. Loonen, Russia

P.3.d.029  Antidepressant augmentation of antipsychotics in schizophrenia: a systematic review, meta-analysis and metaregression analysis
B. Galling*, C.U. Correll, Germany

P.3.d.030  Evenamide, a voltage-gated sodium channel blocker in the treatment of schizophrenia: results from a placebo-controlled study
R. Anand*, E.C. Forrest, R.D. Hartman, S.M. Graham, L. Faravelli, Switzerland

P.3.d.031  Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis
M. Krause, Y. Zhu, J. Schneider-Thoma, M. Huhn, G. Salanti, A. Chaimani, S. Leucht*, Germany

P.3.d.032  Deep brain stimulation in schizophrenia: a randomized pilot study testing anterior cingulated cortex vs. nucleus accumbens targets

P.3.d.033  Redox dysregulation in schizophrenia pathophysiology: add-on trial with N-acetyl-cysteine (NAC) in early psychosis patients

P.3.d.034  Paliperidone palmitate 3-monthly formulation in schizophrenia – baseline interim analysis of a naturalistic, 52-week, prospective study
L. Hargarter*, P. Bergmans, I. Usankova, P. Cherubin, Germany

P.3.d.035  Subset analyses by race of a phase 2 study of TAK-063 in subjects with acute exacerbations of psychotic symptoms
A.R. Mahableshwarkar, M. McCue, X. Dong, E. Hanson, J. Affinito, T.A. Macek*, USA

P.3.d.036  Are there differences in the antipsychotic load between deficit and non-deficit syndrome in first-episode schizophrenia?
A. López-Díaz*, I. Lara, P. Lorenzo-Herrero, J.L. Fernández-González, Spain

P.3.d.037  Effect of brexpiprazole on long-term remission in adults with schizophrenia: results of an open-label, long-term study
R. Baker*, N. Jin, E. Weiller, C. Weiss, USA

P.3.e.004  Effects of long-term treatment with risperidone and clozapine on mice isolated detrusor smooth muscle
M.H. Tanyeri, M.E. Buyukokuroglu, P. Tanyeri*, O. Mutlu, F. Akar, G. Ulak, B.F. Erden, Turkey

P.3.e.005  The involvement of GABAB receptors in antipsychotic-like effects of positive allosteric modulator of muscarinic acetylcholine M4 receptors
P. Clešík*, M. Woźniak, A. Pilc, J. Wierońska, Poland

P.3.e.006  Influence of haloperidol and clozapine on apoptosis and autophagy in an animal model of schizophrenia
D. Djorovic*, G. Jevtic, V. Radonjic, B. Filipovic, M. Aksic, N. Petronijevic, Serbia

P.3.f.010  MDR1 and CYP3A4 genes variants association with clinical response measured on a five-factor model in multiphasic schizophrenia and related disorders
Audit on baseline monitoring serum prolactin
A. Jayakumar*, V. Krishnan, United Kingdom

The relation between negative symptoms and reward alterations before and after antipsychotic treatment in first episode patients with schizophrenia
M.O. Nielsen*, S. Wuiff, E. Rostrup, B. Glenthøj, Denmark

Interpersonal problems and personality disorder in Korean criminal offenders with schizophrenia
I.S. Chee*, Y. Kim, J. Kwon, South-Korea

Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses in a general population sample

Psychiatric disorders in child and adolescent offspring of patients with schizophrenia and bipolar disorder: a four-year follow-up study

Do treatment goals impact treatment decisions among people recently diagnosed with schizophrenia?

Reward alterations in antipsychotic naïve first episode psychosis before and after treatment with a partial dopamine agonist

The influence of the introduction of paliperidone palmitate long-acting injection on oral prescription of schizophrenic patients
J. Uno*, Japan

Neurexin family genes (CNTNAP2 and NRXN1): their involvement in mathematics anxiety
R. Enikeeva*, A. Kazantseva, E. Khusnutdinova, A. Klich, Russia

Circulating microRNAs as potential biomarkers of differential susceptibility to traumatic stress

Complement alternative pathway factors in the pathogenesis of posttraumatic stress disorder
L. Hovhannisyan*, D. Avetyan, G. Mkrtchyan, A. Arakelyan, Rep. of Armenia

Fibroblast growth factor-antisense overexpression in medial prefrontal cortex regulates anxiety-like behaviour in rats
E. Eren Kocak*, F.O. Hokelekli, H. Karatas-Kursun, M. Yemisci, T. Dalkara, Turkey

Psychopathological correlates of hypersexual disorder: a case-control observational study
I. Pinucci*, C. Appignanesi, G. Castellini, M. Maggi, V. Ricca, Italy

Identification and comparison of workplace stressors in different profiles of health care workers in primary and secondary community health care
N. Trifunovic, A. Dzubur Kulenovic*, Z. Jatic, Bosnia and Herzegovina

The ‘Body keeps the score’ revisited: changes in lipid levels and coronary disease risk in veterans suffering from chronic PTSD
A. Dzubur Kulenovic*, Bosnia and Herzegovina

Effects of SSRIs on peripheral inflammatory cytokines in patients with first episode generalised anxiety disorder

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**P.4.b.011**  Subclinical signs in trauma-exposed non-psychiatric subjects: a risk factor
F. Vellante*, S.F. Sarchione, F. Gambi, G. Sepede, B. Brunetti, G. Martinotti, M.D.G. Di Giannantonio, Italy, Brazil

**P.4.b.012**  Functional connectivity of premotor, sensorimotor and insular regions in obsessive-compulsive disorder patients with and without sensory phenomena

**P.4.c**  TREATMENT (BASIC)

**P.4.c.003**  Natural medicine influences stress-induced activity of the anterior cingulate cortex and associated brain regions
L. Martens*, A. Kühnel, Y. Fan, L. Fensky, V. Teckentrup, L. Colic, M. Schultz, M. Walter, Germany

**P.4.c.004**  Reducing fear extinction deficits in a 5-HT2C receptor editing model of post-traumatic stress disorders
M. Regue*, V. Martin, L. Lanfumey, R. Mongeau, France

**P.4.d**  TREATMENT (CLINICAL)

**P.4.d.005**  Allostatic load and cognitive outcome after 12 weeks of alprazolam treatment in patients with anxiety disorders
C. Soria, C. Remedi, L. D’Alessio*, E. Roldán, Argentina

**P.4.d.006**  Neural plasticity following cognitive-behavioral therapy in panic disorder – the impact of comorbid depression

**P.4.d.007**  The effect of early maladaptive schema on the treatment outcomes of cognitive–behavioural group therapy for panic disorder
S.J. Lee*, S.H. Won, S.M. Chang, J.M. Woo, S.W. Lee, South-Korea

**P.4.e**  OTHER (BASIC)

**P.4.e.005**  Chronic stress targets adult hippocampal neurogenesis preferentially in the suprapyramidal blade of rat dorsal dentate gyrus

**P.4.e.006**  Brain activation induced by chronic psychosocial stress in mice
M. Laine, E. Sokolowska, M. Dudek, S. Callan, P. Hytylä, I. Hovatta*, Finland

**P.4.e.007**  Cold pressor pain in body focused repetitive behaviour disorders
S.A. Redden*, S.R. Chamberlain, J.E. Grant, USA

**P.4.f**  OTHER (CLINICAL)

**P.4.f.003**  Alcohol abuse in subjects developing or not post-traumatic stress disorder after trauma exposure
F. Fiori*, F. Vellante, F. Sarchione, M. Brunetti, G. Martinotti, G. Sepede, M. Corbo, M. Di Giannantonio, Italy

**P.4.f.004**  Interaction between word retrieval processing and affect in patients with obsessive compulsive disorder
J.C. Yang, S.H. Shim, B. Nam, South-Korea

**P.4.f.005**  Fragmented REM sleep contributes to slow dissolving of emotional distress and hyperarousal in insomnia
R. Wassing, F. Schalkwijk, E.J. Van Someren*, The Netherlands
**P.5.a**  
**DEMENTIA (BASIC)**

P.5.a.002  Ghrelin mimetic MK-677 alleviates amyloid beta-related pathology in 5XFAD mice, an animal model of Alzheimer’s disease  
S.M. Lee*, M.H. Hong, H.Y. Chung, M. Moon, South-Korea

**P.5.b**  
**DEMENTIA (CLINICAL)**

P.5.b.006  Neuropsychological assessment in illiterate patients with neurocognitive disorder  
G. Bastug, T. Cobanoglu-Tunali, M. Ezerbolat-Ozates, S. Kırıcı, E. Agtas, E. Ozel-Kızıl*, Turkey

P.5.b.007  Cognitive function associated with depression in patients with Alzheimer’s disease and the elderly without dementia  
D.H. Kim*, Y. Moon, K. Yoon, South-Korea

P.5.b.008  Gut bacteria and Alzheimer’s disease: from dysbiosis to beta-amyloid plaques  
S. Provasi*, C. Ferrari, C. Festari, M. Boccardi, G. Frisoni, A. Cattaneo, Italy

P.5.b.009  Cognitive impairment and plasma phoenixin level  
G. Gultekin*, G.C. Batun, M. Yuruyen, H. Yavuzer, F.E. Akcan, M. Emul, Turkey

**P.5.c**  
**NEUROLOGICAL DISORDERS (BASIC)**

P.5.c.003  Genetic variants of SNCA, risk of Parkinson’s disease and alpha-synuclein level in CD45+ blood cells  

P.5.c.004  Dopamine decreases SNCA gene expression in peripheral blood lymphocytes from Parkinson’s disease patients in vitro  
A. Lavrinova*, E. Litusova, I. Milyukhina, M. Nikolaev, S. Pchelina, A. Emelyanov, Russia

**P.5.d**  
**NEUROLOGICAL DISORDERS (CLINICAL)**

P.5.d.005  P300 parameters as markers for early stages of subcortical vascular neurocognitive disorder and treatment efficacy  
O.A. Levada*, N.V. Cherednichenko, A.S. Troyan, Ukraine

P.5.d.007  Behind the myths of antipsychotics for delirium prevention: the unbearable lightness of evidence  
S. Castro*, M.C. Ferreira, C. Rodrigues, S.S. Almeida, Portugal

P.5.d.008  Ten-day cognitive training program combined with transcranial direct current stimulation (tDCS) in stroke rehabilitation – a sham controlled study  

P.5.d.302  Psychological distress of myasthenia gravis  
B. Nam*, T. Kim, South-Korea

**P.5.f**  
**OTHER (CLINICAL)**

P.5.f.003  The effect of melatonin and zinc on primary insomnia in elderly patients  
**P.6.a**  
**ALCOHOL (BASIC)**

**P.6.a.005** Immuno-inflammatory mechanisms of brain damage in patients with delirium tremens  
*A. Berezkin*, Russia

**P.6.a.006** Functional inactivation of accumbens disrupts context-induced reinstatement of alcohol seeking in rats  
*P.C. Bianchi*, R.M. Leão, P. Palombo, P.E. Carneiro-de-Oliveira, C.S. Planeta, F.C. Cruz, France

**P.6.a.007** Effects of excessive alcohol drinking on metabolic processes in rats’ brain  
*G. Shayakhmetova*, O.I. Kharchenko, L.B. Bondarenko, V.M. Kovalenko, Ukraine

**P.6.a.008** Study of the effects of caffeinated/sugared energy drinks on ethanol craving, in rats  
*J.J. Romano*, C.Z. Nassis, G. Petri, J.F.R. Santos, Brazil

**P.6.b**  
**ALCOHOL (CLINICAL)**

**P.6.b.007** An fMRI study on the effect of cue reactivity on striatal reward anticipation in alcohol dependent patients  

**P.6.b.008** Gender differences in the alcohol-related alterations in cortical activity – a combined TMS-EEG study  
*O. Kaarre*, E. Kallioniemi, M. Köönönen, T. Tolmunen, V. Kekkonen, P. Kivimäki, N. Heikkinen, F. Ferreri, E. Laukkanen, S. Määttä, Finland

**P.6.b.009** Effect of the monoamine stabilizer (-)-OSU6162 on cognitive function in alcohol dependent patients  
*L. Khemiri*, P. Steensland, J. Guterstam, A. Carlsson, J. Franck, N. Jayaram-Lindström, Sweden

**P.6.b.011** Pharmacogenetic study of benzodiazepine tranquilizers’ safety during alcohol withdrawal syndrome treatment: focus on polymorphism 3435C>T of ABCB1  
*D.V. Ivashchenko*, K.A. Ryzhikova, Z.A. Sozaeva, M.S. Zastrozhin, E.A. Grishina, A.D. Aguzarov, L.M. Savchenko, E.A. Bryun, D.A. Sychev, Russia

**P.6.c**  
**DRUGS (BASIC)**

**P.6.c.008** The role of chronic stress on addictive vulnerability – focus on the nucleus accumbens  
*C. Lima*, P. Morgado, F. Marques, J. Cerqueira, N. Sousa, Portugal

**P.6.c.009** The effect of drugs of abuse on norepinephrine transmission in the bed nucleus of stria terminalis: a microdialysis study in freely moving rats  
*D. Jadzic*, E. Carboni, M. Mallai, R. Cadeddu, J. Samardzic, Italy

**P.6.c.010** Glucocorticoid receptor regulates rewarding properties of morphine  
*Ł. Marut*, U. Skupio, R. Przewlocki, Poland

**P.6.c.011** Methamphetamine administration during a window of vulnerability in young adulthood induced enduring hippocampal cell damage  
*C. Bis-Humbert*, R. Garcia-Cabrero, M.J. Garcia-Fuster, Spain

**P.6.c.012** Impact of repeated administration of cocaine on the expression of genes involved in cholesterol metabolism in the rat brain  
*J. AlSebaaly*, L. Rabbaa Khabbaz, E. Dugast, M. Solinas, N. Thiriet, France

**P.6.d**  
**DRUGS (CLINICAL)**

**P.6.d.009** Role of dopamine and opioid gene polymorphisms in efficacy of naltrexone and guanfacine combination for relapse prevention among opioid addicts  
*V. Palatkin*, A. Kibitov, E. Krupitsky, E. Blokhina, V. Brodyansky, E. Verbitskaya, E. Zvartau, Russia

**P.6.d.010** Predisposing biomarkers of addiction in the brain reward system  
*A. Just*, C. Meng, D.G. Smith, E.T. Bullmore, T.W. Robbins, K.D. Ersche, United Kingdom
P.6.d.011 SLC6A2 genotype variation and the modulatory effects of atomoxetine on inhibitory control in individuals with and without cocaine use disorder

P.6.d.012 Demographic and clinical profile of cannabis users in Singapore
A. Pezhummoottil Vasudevan Nair*, T. Guo Zheng, D. Kumar, G. Song, Singapore

P.6.d.013 Long-acting injectable aripiprazole as treatment for psychiatric patients comorbid with substance-related and addictive disorder: efficacy and safety
C. Montemitro*, G. Baroni, V. Cantelmi, B. Tittozzi, M. Pettoruso, M. Di Nicola, G. Ducci, M. Alessandrinii, M. Di Giannantonio, G. Martinotti, Italy

P.6.d.014 A phase 1b study of potential safety and pharmacokinetic interactions between cocaine and EMB-001, with exploratory efficacy measures

P.6.d.015 The effect of methylphenidate on executive functioning in patients with co-morbid ADHD and stimulant use disorder
C. Brynte*, M. Konstenius, N. Jayaram-Lindström, J. Franck, Sweden

P.6.e OTHER (BASIC)

P.6.e.003 Predicting adolescent smoking using fMRI – a possible predisposing role for inhibitory control and reward processing in addictive behaviours
L. Jollans*, R. Whelan, Ireland

P.6.e.004 Problematic internet use among adolescents – gender differences

P.6.f OTHER (CLINICAL)

P.6.f.004 Heritable vulnerability in the early psychiatric onset and addictive behaviors: the role of temperament
F. Perrini*, L. Tomassini, G. Battagliese, S. De Persis, I. Cuomo, R. Porrari, A. Valle, E. Amici, S. De Filippis, Italy

P.6.f.005 Higher emotional eating scores before a nutritional treatment in patients with obesity moderates the development of binge eating disorder
L. Mallardo*, A. Santangelo, E. Mannucci, B. Cresci, C. Rotella, G. Castellini, V. Ricca, Italy

P.6.f.006 Sexual addiction in Tunisia: an exploration of prevalence, socio-demographic characteristics and self esteem
C. Missaoui*, B. Amamou, A. Mhalla, S. Fathallah, F. Zaafrane, L. Gaha, Tunisian Republic
**P.7.a**  DISORDERS (BASIC)

**P.7.a.004**  Predicting autism spectrum disorder using blood-based gene expression signatures and machine learning  

**P.7.a.005**  Executive functions, attention and verbal fluency of children with attention deficit/hyperactivity disorder using methylphenidate  
*C. Minervino*†, L.F.P. Cruz, Brazil

**P.7.a.006**  Executive functions in children with neurodevelopment disorders  
*C. Minervino*†, E.E.L.D. Pereira, Brazil

**P.7.b**  DISORDERS (CLINICAL)

**P.7.b.008**  Executive functions in children with an attention deficit hyperactivity disorder, pervasive developmental disorder and language specific disorder  
*M.J. Candón Gamez*, S.L. Romero Guillena†, E. Regli Rojas, Spain

**P.7.b.009**  Prevalence of behavioral and emotional problems in school going adolescents in India  
*A. Gupta*†, C. Goel, India

**P.7.b.010**  A 7-year follow-up study of child and adolescent mental health emergencies  
*A. Fernandez-Quintana*†, R. Méndez-Iglesias, A. Novo-Ponte, C. Quiroga-Fernández, Spain

**P.7.b.011**  Knowledge of kindergarten and elementary schools teachers regarding attention deficit hyperactivity disorder  
*S. Almutairi*†, M. Almutairi, A. Al-Harbi, M. Alsuhaibani, N. Alkeaid, T. Albatti, Saudi Arabia

**P.7.b.012**  Brain derived neurotrophic factor signaling and clinical symptoms in anorexia nervosa  
*F. Rybakowski*†, M. Skibinska, M. Dmitrzak-Weglarz, A. Slopian, M. Tyszkievicz-Nwafor, Poland

**P.7.b.013**  Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study  
*C.U. Correll*†, C. Arango, M. Tocco, R. Goldman, J. Cucchiaro, L. Deng, A. Loebel, USA

**P.7.b.014**  Efficacy and safety of lurasidone in children and adolescent patients with bipolar I depression  
*R. Goldman*†, M. DelBello, L. Deng, J. Cucchiaro, A. Loebel, USA

**P.7.b.030**  Characteristics of nonsuicidal self-injury behaviours between two groups of Albanian adolescents: a community sample and clinical sample  
*B. Zenelaj*†, T. Jupe, E. Mitro, V. Alikaj, Albania

**P.7.b.031**  Characteristics of nonsuicidal self-injury behaviours between two groups of Albanian adolescents: a community sample and clinical sample  
*B. Zenelaj*†, T. Jupe, E. Mitro, V. Alikaj, Albania

**P.7.b.032**  Vortioxetine in pediatric patients: a new experience  
*L. Nuevo*†, V. Muñoz, L. Mella, M. Font, M. Novo, L. Asensio, B. Mata, E. Segura, Spain

**P.7.d**  TREATMENT (CLINICAL)

**P.7.d.006**  Methylphenidate long-term effects on psychiatric outcomes in a Sardinian ADHD population: preliminary results from the prospective ADDUCE project  
*E. Sanna*†, S. Carucci, R. Romaniello, S. El Kacemi, C. Balia, D. Coghill, A. Zuddas, Italy

**P.7.d.007**  A randomized, double blind, placebo-controlled, efficacy study of Omega 3/6 in children with mild to moderate inattentive ADHD – preliminary results  
*S. Carucci*†, R. Romaniello, G. Masi, P. Curatolo, A. Gagliano, A. Zuddas, Italy

**P.7.d.008**  Perampanel treatment in drug-resistant focal epilepsy with de novo mutation CACNA1H: characteristics and clinical outcome  
*C. Galati*†, E. Pironti, F. Cucinotta, M. Spanò, Italy

**P.7.d.009**  Perampanel treatment in early-onset epileptic encephalopathy with infantile movement disorders associated with de novo GRIN1 gene mutation  
*C. Galati*†, E. Pironti, F. Cucinotta, G. Di Rosa, Italy

**P.7.d.010**  Enduring effects of methylphenidate on sleep in children with attention-deficit/hyperactivity disorder: a double-blind randomized controlled trial  
*M.M. Solleveld*†, A. Schrantee, H.K. Baek, M.A. Bottelier, P.J. Lucassen, E.J.W. Van Someren, R.M. Rijsman, L. Reneman, The Netherlands
P.7.e.002  
Effects of metformin on behavior of adolescent rats with metabolic syndrome induced in early age  
O. Tkachenko*, A.K. Voronina, G.M. Shayakhmetova, I.S. Blazchuk, V.M. Kovalenko, Ukraine

P.7.f.003  
Successful use of clozapine in severe intractable aggressive and self-injurious behaviours in adults with autism and intellectual disabilities  
S. Sajith*, Singapore

P.7.f.004  
EKG parameters in children and adolescents treated with second-generation antipsychotics: a 24-months prospective follow-up study  
M. Lamberti*, A. Gagliano, A. Morello, L. Guerriero, A. Terrizzi, E. Germanò, M.P. Calabrò, E. Spina, A.M. Persico, Italy

P.8.b.005  
Evaluating stigmatic attitudes towards mentally ill patients and their underlying factors in Hungary  
T. Buchman-Wildbaum*, B. Paksi, E. Sebestyén, B. Kun, K. Felvinczi, A. Schmelowszky, Z. Demetrovics, R. Urbán, Hungary

P.8.b.006  
A review of pharmacotherapies for vulvodynia  
M.D.C. Ferreira*, C. Campos, P. Cabral, B. Santos, Portugal

P.8.b.007  
Vitamin D levels in inpatients  

P.8.b.008  
A study on functional gastrointestinal disease and quality of life in patients with mental health medicine  
D.H. Kang*, S.H. Jang, South-Korea

Updated programme:  
http://2017.ecnp.eu / ECNP app / congress info terminals
Free congress registration for European junior scientists (if abstract accepted for publication).
http://2018.ecnp.eu

BRAINSTORMING SESSION
07.45-08.45 | Room 341
An effective alcohol hangover treatment: friend or foe?
Chair: Gabriele Fischer, Austria
Experts: David Nutt, United Kingdom
         Joris Verster, The Netherlands

BRAINSTORMING SESSION
07.45-08.45 | Room 342B
How do smartphones and other ubiquitous technologies change patient care paradigms in movement disorders?
Chair: Gerard R. Dawson, United Kingdom
Experts: Valerie Legrand, France
         Serge Van Sint Jan, Belgium

BRAINSTORMING SESSION
07.45-08.45 | Room 343
Future perspective for treatment of bipolar disorder: stratification
Chair: Carmen Moreno, Spain
Experts: Iria Grande, Spain
         Gregor Hasler, Switzerland

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
**SYMPOSIUM**
**09.00-10.40 | Havane**

**Contribution of epistasis (gene-gene interactions) to the clinical and quantitative risk for the schizophrenia phenotype**

*Chairs: Kristin Nicodemus, United Kingdom  
  John L. Waddington, Ireland*

**S.26.01** | 09.00  
Concept and principles of epistasis: importance across multiple human disorders  
Scott Williams, USA

**S.26.02** | 09.25  
Experimental and quantitative approaches to the phenotypic study of epistasis in relation to schizophrenia  
John L. Waddington, Ireland

**S.26.03** | 09.50  
Clinical studies of epistasis at the level of cognition and other functional aspects of psychotic illness  
Kristin Nicodemus, United Kingdom

**S.26.04** | 10.15  
A co-expression gene set and associated polygenic score in relation to clinical response to antipsychotics  
Alessandro Bertolino, Italy

---

**SYMPOSIUM**
**09.00-10.40 | Grand Amphitheatre**

**TNM symposium – Digital applications in bipolar disorders: opportunities, risks and ethical implications**

*Chairs: Michael Bauer, Germany  
  Maria Faurholt-Jepsen, Denmark*

**S.28.01** | 09.00  
Digital phenotyping in experimental medicine and drug discovery  
Kate Saunders, United Kingdom

**S.28.02** | 09.25  
Smartphone-based monitoring and treatment in bipolar disorder – status, opportunities and challenges  
Maria Faurholt-Jepsen, Denmark

**S.28.03** | 09.50  
Can complex psycho-education programs for bipolar disorder fit in a SIMPLe app?  
Diego Hidalgo-Mazzei, Spain

**S.28.04** | 10.15  
Ethical considerations about recommending technology for patients with bipolar illness  
Michael Bauer, Germany
CLINICAL TREATMENT TRACK

SYMPOSIUM
09.00-10.40 | Maillot

**Neurofeedback in ADHD: evidence from different modalities**

Chairs: Martijn Arns, The Netherlands
Katya Rubia, United Kingdom

**S.29.01** The scientific background of neurofeedback to treat ADHD
Martijn Arns, The Netherlands

**S.29.02** EEG neurofeedback in ADHD: new meta-analyses and multicentre trials
Daniel Brandeis, Switzerland

**S.29.03** NIRS neurofeedback in patients with ADHD
Beatrix Barth, Germany

**S.29.04** fMRI neurofeedback in ADHD
Katya Rubia, United Kingdom

TRANSLATIONAL RESEARCH TRACK

SYMPOSIUM
09.00-10.40 | Room 532AB

**Myelination from cells to brain networks: a core mechanism of plasticity and connectivity**

Chairs: Sophia Frangou, USA
Tanja M. Sheldrick-Michel, Denmark

**S.30.01** Oligodendroglial myelin in cortical circuits: functional roles beyond the axon
Maarten Kole, The Netherlands

**S.30.02** Dysconnectivity in autism: from proteomics to mini brains
Tanja M. Sheldrick-Michel, Denmark

**S.30.03** Intra-cortical myelination during adolescence: linking MRI networks with gene transcription profiles
Kirstie Whitaker, United Kingdom

**S.30.04** Abnormalities in myelinoarchitecture in schizophrenia using high-field in vivo MRI
Sophia Frangou, USA

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
EDUCATIONAL UPDATE SESSION
09.00-10.40 | Bordeaux

Exercise and psychiatric disease: should patients take the challenge?

Moderator: Paul John Lucassen, The Netherlands

E.06.01 09.05 The benefits of exercise for brain plasticity: from rodents to humans
Henriette Van Praag, USA

E.06.02 09.50 The efficacy of exercise in the treatment of psychiatric disease
t.b.a.

AWARD CEREMONY
10.40-11.15 | Poster area (podium)
Presentation ECNP Travel Awards

COFFEE BREAK
10.40-11.15 | Poster area and exhibition

POSTER VIEWING
10.40-11.15 | Poster area

Posters that are on display can already be viewed during this time. It is not mandatory for poster presenters to be at their poster; the poster sessions will start at 12.15. See pages 150-193 for details.

PLENARY LECTURE
11.15-12.00 | Grand Amphitheatre

Chair: Andreas Reif, Germany

From genes to clinical phenotype in ADHD across the lifespan
Barbara Franke, The Netherlands

LUNCH
12.00-14.00 | Poster area and exhibition

POSTER SESSION
12.15-13.45 | Poster area

Poster presenters will be available at their paper poster for further explanation and discussion. See pages 150-193 for details.

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
RAPID-FIRE POSTER SESSION
12.15-12.45 | Poster area (podium)

Chair: Roger Adan, The Netherlands

RF.03.01 Cadherin-13, a risk factor for neurodevelopmental disorders, modulates serotonin system development via radial glia interaction
Andrea Forero, Germany

RF.03.02 Novel insights into the neurometabolic homeostasis of cocaine addiction: aberrant glutamatergic mechanisms in the nucleus accumbens
Etna Engeli, Switzerland

RF.03.03 Dynamic connectivity analysis of selective serotonin reuptake inhibitor effects, a pharmacological PET/MR study
Gregor Gryglewski, Austria

RF.03.04 Genetic variants within key nodes of the cascade of antipsychotic mechanisms: effects on treatment response and schizophrenia psychopathology
Stefano Porcelli, Italy

RF.03.05 Classification and prediction of neuro-pathological change of Alzheimer’s disease using machine learning and MRI
Alexander Kautzky, Austria

RF.03.06 Striatal hyperactivation associates with insulin resistance and reward delay discounting in adolescents with excess weight
Cristina Martín Pérez, Spain

AWARD CEREMONY
13.00-13.15 | Poster area (podium)
Presentation ECNP Poster Awards

TUESDAY | SESSIONS

CAREER DEVELOPMENT SESSION
13.15-13.45 | Poster area (podium)

How to get funding: writing a strong grant or fellowship application

Chair: t.b.a
Presenter: Per Svenningsson, Sweden

TOP PAPER SESSION
13.15-13.45 | Room 341
Highlights in anorexia nervosa – focus on translational research

Chair: Iiris Hovatta, Finland
Presenter: Odile Viltart, France

TOP PAPER SESSION
13.15-13.45 | Room 342B
Highlights in psychotic disorders

Chair: t.b.a.
Presenter: Pascal Steullet, Switzerland

PLENARY LECTURE
14.00-14.45 | Grand Amphitheatre

Cognitive and functional remediation in affective disorders

Chair: Henricus G. Ruhe, The Netherlands
Presenter: Anabel Martinez-Aran, Spain

COFFEE BREAK
14.45-15.00 | Poster area and exhibition
SYMPOSIUM
15.00-16.40 | Havane

TNM symposium – Common mechanisms and therapeutic avenues for Down syndrome and other genetic developmental disorders

Chairs: Mara Dierssen, Spain
       Marie-Claude Potier, France

S.31.01 15.00 Boosting plasticity through neurorehabilitation with brain stimulation and cognitive training
         Roi Cohen Kadosh, United Kingdom

S.31.02 15.25 Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes
         Victor Faundez, USA

S.31.03 15.50 Translating molecular advances in Down syndrome and fragile X syndrome into therapy
         Mara Dierssen, Spain

S.31.04 16.15 Fragile X syndrome: from molecular pathology to therapy
         Barbara Bardoni, France

SYMPOSIUM
15.00-16.40 | Grand Amphitheatre

Causes and consequences of inflammation in bipolar disorder

Chair: Iria Grande, Spain

S.33.01 15.00 Role of inflammation in neuropsychiatric research domains
         Lucile Capuron, France

S.33.02 15.25 Targeting mitochondrial inflammation in bipolar disorder
         Ana Andreazza, Canada

S.33.03 15.50 Relationships between inflammation, elevated body mass index, and depressive relapse in bipolar disorder
         David Bond, USA

S.33.04 16.15 Inflammation and white matter integrity in bipolar disorder
         Francesco Benedetti, Italy

TRANSLATIONAL RESEARCH TRACK
**CLINICAL TREATMENT TRACK**

**S.34**  
**SYMPOSIUM**  
**CLINICAL TREATMENT TRACK**  
**SYMPOSIUM**  
15.00-16.40 | Bleu  
**Sexual side effects of antidepressant and antipsychotic drugs: clinical challenge and underlying mechanisms**  
**Chairs:** Christian Broberger, Sweden  
Anita Clayton, USA  
- **S.34.01**  
  15.00  
  Iatrogenic hyperprolactinaemia, antipsychotics and sexual dysfunction  
  Angel Luis Montejo Gonzalez, Spain  
- **S.34.02**  
  15.25  
  Effects of antidepressants on sexual function and satisfaction – implications for drug development  
  Anita Clayton, USA  
- **S.34.03**  
  15.50  
  Actions of SSRIs and antipsychotics on the network properties of neuroendocrine dopamine neurons: implications for sexual side effects  
  Christian Broberger, Sweden  
- **S.34.04**  
  16.15  
  Sexual dysfunction and antipsychotics: new findings from the QUALIFY study  
  Dieter Naber, Germany  

**CLINICAL TREATMENT TRACK**

**S.35**  
**SYMPOSIUM**  
**Melatonin receptors in neuropsychopharmacology: a preclinical and clinical update**  
**Chairs:** Stefano Comai, Italy  
Nava Zisapel, Israel  
- **S.35.01**  
  15.00  
  Neuropsychopharmacological properties of novel melatonin MT1 receptor ligands  
  Stefano Comai, Italy  
- **S.35.02**  
  15.25  
  Anxiolytic, hypnotic and analgesic properties of melatonin MT2 receptor partial agonists  
  Gabriella Gobbi, Canada  
- **S.35.03**  
  15.50  
  Melatonin receptors as a target to treat alcohol addiction  
  Valentina Vengeliene, Germany  
- **S.35.04**  
  16.15  
  Current melatonergic therapies for insomnia  
  Nava Zisapel, Israel  

**EDUCATIONAL TRACK**

**EDUCATIONAL UPDATE SESSION**

**E.07**  
**EDUCATIONAL UPDATE SESSION**

**Synthetic cannabinoids: a growing problem?**  
**Moderator:** Valerie Curran, United Kingdom  
- **E.07.01**  
  15.05  
  Synthetic cannabinoids: taking stock of the problem  
  Gal Shoval, Israel  
- **E.07.02**  
  15.50  
  Synthetic cannabinoids: clinical aspects and therapy options  
  Liana Fattore, Italy  

**Updated programme:**  
http://2017.ecnp.eu / ECNP app / congress info terminals
P.1.a.029  Genetics of specific clinical phenotypes of bipolar disorder: a focus on mania with psychosis

P.1.a.030  Distribution of C4 copy number variations in bipolar disorder, schizophrenia and systemic lupus erythematosus
C.M. Mariaselvam*, A. Sundaresh, M. Bennabi, C. Manier, R. Krishnamoorthy, M. Leboyer, V.S. Negi, R. Tamouza, France, India

P.1.a.031  Interactive effects of DRD2 C957T polymorphism, stressful life events and gender on impulsivity and general intelligence
K. Klaus*, M. Vaht, K. Pennington, J. Harro, United Kingdom

P.1.a.032  Up-regulated micro-RNAs in schizophrenia
H. Ghazaryan*, M. Petrek, A. Arakelyan, Rep. of Armenia

P.1.a.033  Genetic and clinical evidence of mitochondrial dysfunction in autism spectrum disorder and intellectual disability
A. Valiente Pallejà*, G. Muntané, M. Cortés, R. Martínez-Leal, H. Torrell, E. Vilella, L. Martorell, Spain

P.1.a.034  Role of Ten-Eleven Translocation 3 (TET3) in brain function

P.1.a.035  RNA signature and prediction to treatment response in first episode schizophrenia

P.1.a.036  Increased DNA methylation in the parvalbumin gene promoter in schizophrenia – relationship with symptoms and drug treatment
G.P. Reynolds*, H. Fachim, L. Zeng, J. Yang, United Kingdom

P.1.a.037  Maternal depression during pregnancy: implications for baby epigenetic signature and stress response system

P.1.a.038  Association of SGK1 gene with schizophrenia
E.G. Poltavskaya*, O.Y. Fedorenko, A.V. Semke, S.A. Ivanova, Russia

P.1.a.039  Histamine H1 receptor level in peripheral blood lymphocytes of schizophrenic patients as possible diagnostic marker of olanzapine treatment efficacy

P.1.a.040  Genetic analysis of the endocannabinoid signalling in association with anxious and depressive phenotype
J. Lazary*, G. Juhasz, G. Bagdy, Hungary

P.1.a.041  Incomplete replication of association between DRD2 C957T and cognition in schizophrenia
S. Spitoni*, A. Drago, Italy

P.1.b.009  L-Thyroxine suppresses the mitogen-activated protein kinases activation by a depotentiating stimulus given short after a tetanus in hippocampus in vivo
B. Tan*, E. Babur, N. Dursun, C. Süer, Turkey

P.1.b.010  A possible GABAergic biomarker for adult autism spectrum disorder
J. McCracken*, USA

P.1.b.011  Heart rate variability discriminates between sleep-EEG stages in healthy adults; proposal of a standard rule of assessment during sleep
T. Mikoteit*, M. Adamczyk, E. Balbi, V. Spoormaker, M. Hatzinger, E. Holsboer-Trachsler, A. Steiger, M.A. Pawlowski, Switzerland

P.1.b.012  In vivo real-time monitoring of corticostriatal synaptic plasticity
C.A. Cordeiro*, T. Koster, L. Kuhl, J. Folgering, T. Cremers, The Netherlands
P.1.b.013 Repetitive microinjection of orexin-A accelerates regulation of sleep homeostasis and recovery from barbiturate anesthesia-induced deep sleep
N. Maglakelidze*, E. Chkhartishvili, O. Mchedlidze, M. Babilodze, V. Tsomaia, N. Rogava, S. Dzadzamia, E. Chijavadze, N. Nachkebia, Georgia

P.1.c NEURODEVELOPMENT

P.1.c.015 Early life experience contributes to developmental programming of depressive-like behavior, neuroinflammation and oxidative stress
G.Z. Réus*, G. Cruvinel, A.B. De Moura, A.C. Darabás, A.P. Strassi, M. Michels, F. Dal-Pizzol, J. Quevedo, Brazil

P.1.c.016 Survival effect of embryonic proteoglycans in Alzheimer’s disease via simultaneous activation of neurogenesis and angiogenesis in adult brain

P.1.c.017 Modeling molecular and cellular phenotypes in schizophrenia-specific cortical neurons
M. Jung*, A. Puls, J. Schiller, A. Klemenz, I. Giegling, D. Rujescu, Germany

P.1.c.018 Perinatal and early childhood prognosis factors in children with neurodevelopmental disorders
L. Kobylinska*, C. Anghel, F. Rad, I. Mihaiescu, I. Dobrescu, Romania

P.1.c.019 Functional brain network connectivity in prenatal alcohol exposed neonates

P.1.c.020 Cadherin-13, a risk factor for neurodevelopmental disorders, modulates serotonin system development via radial glia interaction

P.1.d GLIA-NEURON INTERACTION

P.1.d.003 The role of astrocytic glucocorticoid receptor in morphine withdrawal and conditioned place aversion
L. Kudla*, U. Skupio, L. Marut, M. Tertil, J. Barut, A. Wawrzczak-Bargiela, R. Przewlocki, Poland

P.1.e NEUROENDOCRINOLOGY

P.1.e.010 Peroxiredoxin-1 and peroxiredoxin-3 as indicators of sickness behaviour in patients with varying levels of depression severity
E.A. Ogłodek, M.J. Just, K. Just*, D.M. Moś, A.D. Grzesińska, A. Araszkiewicz, Poland

P.1.e.011 Increased interleukin-1β and interleukin-10 activity as a trait marker of depression

P.1.e.012 Antipsychotics induce hyperprolactinemia: incidence and interest of switch to aripiprazole
B. Walid*, M. Ilyes, B.S. Rim, H. Kilani, Tunisian Republic

P.1.e.013 Mechanism of cortisol production in adrenal cortical cells under the non-stress and stress conditions: role of cyclic AMP and calcium in vitro study
N. Kuwabara*, T. Kurihara, M. Yoshie, K. Tamura, M. Kutsukake, E. Tachikawa, Japan

P.1.e.014 Anorexia nervosa and insulin sensitivity: a systematic review and meta-analysis
A. Ilyas, C. Hubel, K. Ismail, J. Treasure, G. Breen, C. Kan*, United Kingdom

P.1.f NEURO-IMMUNE INTERACTION

P.1.f.009 Medial septal NMDA receptor inhibition affects stress-induced brain expression and plasma concentration of interleukin 6 in rats
M. Podlacha*, I. Majkutewicz, D. Myslinska, A. Wadolowska, G. Jerzemowska, K. Plucinska, E. Kurowska, J. Rucinski, D. Wrona, Poland

P.1.f.014 Central and peripheral effects of lipopolysaccharide administration in rats
A. Wadolowska*, D. Myslinska, M. Podlacha, J. Rucinski, I. Majkutewicz, Z. Ciepielewski, D. Zelesławska, E. Jurkowlaniec, Poland

P.1.f.018 The effect of electroconvulsive therapy (ECT) on serum tryptophan metabolites
IgG antibodies with nuclease activity in serum of patients with schizophrenia
E. Ermakov*, L. Smimova, S. Ivanova, O. Zaharova, V. Buneva, G. Nevinsky, Russia

Peripheral inflammation in fibromyalgia syndrome
N. Groven*, E.A. Fors, V.C. Iversen, L.R. White, S.K. Reitan, Norway

Proton pump inhibitors deteriorate clinical signs of experimental autoimmune encephalomyelitis

Inflammation in schizophrenia: implications for pathophysiology and treatment
L. Castanheira*, C. Ferreira, L. Ferreira, E. Fernandes, Portugal

β2-microglobulin: a biomarker for bipolar disorder and schizophrenia?

Microbiota abnormalities in autism spectrum disorders: a pilot comparison in a cohort of adult patients and healthy controls
A. Gaman*, G. Iamandi, S. Le Fresne, J. Dubreucq, A. Teruel Martinez, D. Monnet, N. Simohammed, E. Murzi, J. Houenou, M. Cazaubiel, J. Dore, M. Leboyer, France

Establishment of a predictive profile of relapse in patients with major depressive disorder – a pilot study
M. Santos*, S. Carvalho, L. Lima, J. Mota-Pereira, P. Pimentel, D. Maia, D. Correia, S. Gomes, A. Cruz, M. Medeiros, Portugal

Prolyl endopeptidase is involved in the degradation of neural cell adhesion molecules
K. Jaako*, A. Noortoots, A. Aonurm-Helm, A. Zharkovsky, Estonia

The application of TCM to the treatment of psychiatry diseases: in vitro anti-oxidation and anti-inflammatory effect of Free and Easy Wanderer
C. Hong*, T. Efferth, Germany

Modified cinnamic acid derivatives as effective mito- and neuroprotective substances
M. Neganova*, V. Semenov, M. Semenova, D. Mischenko, O. Redkozubova, S. Klochkov, E. Shevtsova, Russia

Behavioural and hippocampal morphological changes induced by short ketamine treatment in a genetic rat model displaying depressive-like behaviour
G. Treccani*, M. Ardalan, N. Liebenberg, F. Chen, L. Musazzi, A. Bettega, M. Mikkelsen, M. Popoli, G. Wegener, J. Nyengaard, H. Müller, Denmark

Effects of antipsychotic drugs on the epigenetic modification of BDNF gene expression in the hippocampus of chronic restraint-stressed rats
M.K. Seo, Y.H. Kim, A.J. Choi, G.M. Kim, J. Lee*, J.G. Lee, S.W. Park, South-Korea

Endogenous opioids scale social threat learning in humans
J. Haaker*, J. Yi, P. Petrovic, A. Olsson, Germany

The effect of mitoprotective agent allomargaritarine on seizure activity in pilocarpine-induced status epilepticus
S. Klochkov*, M. Neganova, N. Chepurnova, E. Shevtsova, Russia

Lumateperone (ITI-007): a novel investigational agent with broad therapeutic potential across multiple neuropsychiatric disorders

Scopolamine-induced convulsions in fasted mice after food intake: determination of M1 and M2 muscarinic receptor expressions in brain regions
P.1.g.042  Efficacy of bremelanotide in The RECONNECT Studies
A. Clayton*, J. Lucas, R. Jordan, C. Spana, USA

P.1.g.043  Aβ1-42 impairs mGluR5-gated spike timing-dependent long-term potentiation by disrupting CB1 receptors
J. Lee*, J.H. Kwag, South-Korea

P.1.g.044  Neuroscience-based nomenclature in Ukraine
O. Zubatiuk*, E. Nosova, Ukraine

P.1.g.045  Endocannabinoid neurotransmission inhibits the formation of nitric oxide in the bed nucleus stria terminalis during acute restraint stress in rats
L. Gomes-de-Souza*, L.A. Oliveira, R. Benini, W. Costa-Ferreira, C.C. Crestani, Brazil

P.1.g.046  New insights on the binding profile of loxapine on dopaminergic and serotonergic receptors
P.M. Llorca*, D. Drapier, L. Zimmer, F. Ferreri, France

P.1.g.047  Impact of antipsychotic drugs on neuronal model cells proteome
U. Jankowska*, B. Skupien-Rabian, B. Swiderska, M. Dziedzicka-Wasylewska, S. Kedracka-Krok, Poland

P.1.h.034  Molecular and epigenetic consequences of pre- and postnatal trauma in a mouse model
S. Frey*, R. Steigleder, J. Distler, O. Kratz, G. Moll, Y. Golub, Germany

P.1.h.035  Gender specific behavioral alterations are associated with gut dysbiosis in mice exposed to multifactorial early-life adversity

P.1.h.036  Do statins impair learning and memory after long-term treatment – comparative experimental study
M. Georgieva-Kotetarova*, I. Kostadinova, D. Delev, I. Kostadinov, H. Zlatanova, I. Kandilarov, Bulgaria

P.1.h.037  Behavioural and peripheral effects of the central nucleus of the amygdala stimulation are more pronounced in high responder rats
J. Ruciński*, D. Myslinska, A. Wadolowska, I. Majkutewicz, M. Podlacha, Z. Ciepielowski, E. Kurowska, E. Jurkowianiec, Poland

P.1.h.038  Antinociceptive, antiallodynic and antihyperalgesic activities of NLX-112 in acute, tonic and neuropathic pain models in mice
A. Furgała*, K. Salat, M. Kołaczkowski, J. Sniecikowska, M.A. Varney, A. Newman-Tancredi, Poland

P.1.h.039  Searching for the relationship between the serotonergic system and abnormal aggression induced by post-weaning social isolation
C. Miskolczi*, E. Sipos, L. Biró, S. Ferenczi, J. Haller, E. Mikics, Hungary

P.1.h.040  50 kHz ultrasonic vocalization as a marker of positive affect in mania models: mixed effects induced by ouabain
E. Wendler, C. Souza, A. Dornellas, M. Wöhr, R. Schwarting, R. Andreatini*, Brazil

P.1.h.041  Pharmacological inhibition of gut leakiness prevents the long-term effects of early-life stress in rats
M. Damaudéry*, M. Rincel, A. Minni, M. Olier, C. Monchaux de Oliveira, Y. Maytime, E. Gauthier, I. Grit, A. Costa, A. Lepinay, S. Layé, L. Ferrier, P. Parnet, V. Theodorou, France

P.1.h.042  Awakenings in cataleptic rats by ultrasounds: a new animal model for paradoxical kinesia and its possible mechanisms
L. Tonelli*, M. Wöhr, R.K.W. Schwarting, L. Melo-Thomas, Germany

P.1.h.043  Mesenchymal stem cells secretome: a new therapeutic tool for Parkinson’s disease regenerative medicine?
B. Mendes-Pinheiro*, F.G. Teixeira, S. Anjo, B. Manadas, L. Behie, N. Sousa, A.J. Salgado, Portugal

P.1.h.044  Pharmacological stimulation of 5-HT7 receptor exerts widespread beneficial effects in a mouse model of Rett syndrome
D. Vigli*, L. Cosentino, E. Lacivita, M. Leopoldo, G. Laviola, B. De Filippis, Italy
P.1.h.045  Differential role of NMDA receptor subunits in the development of PTSD-like symptoms
L. Biro*, E. Sipos, C. Miskolczi, M. Toth, J. Haller, E. Mikics, Hungary

P.1.h.046  A novel method to study behavioral strategy in probabilistic learning in group housed mice
L. Szumiec*, J. Rodriguez Parkitna, Poland

P.1.h.047  Activation of the nigrostriatal dopaminergic pathway increases prepulse-inhibition of the startle response in female but not in male Long Evans rats
A. Casado*, S. Baerentzen, C. Kjaerby, M. Palner, Denmark

P.1.h.048  Treatment with an ethyl-acetate fraction of Trichilia catigua (catuaba) alleviates the memory impairment caused by global cerebral ischemia in rats
D. Velasquez Oliveira*, Brazil

P.1.h.049  Down syndrome model characterization: adult and post-natal neurogenesis enhancement with selective α5 GABA-A modulator and recombinant human IGF-1
C. Albac*, R. Bartesaghi, N. Créau, J. Delabar, M. Potier, France

P.1.h.050  Aggressive behavioral changes in mice following chronic treatment with caffeine
M. Sarkhouh*, H. Alaradi, K. Seyadi, H. Bakhsh, S. Mahdi, M. Mubarak, A. Kamal, Bahrain

P.1.i.037  Do metabolic parameters of posterior cingulate gyrus in multiple sclerosis correlate with the duration of the disease?
A. Zacharzewksa-Gondek*, T.M. Gondek, A. Pokryszko-Dragan, M. Sąsiadek, J. Bladowska, Poland

P.1.i.038  Neurocognition and neuroimaging features in offspring of parents with bipolar disorder: a comparative high risk study
G.S. Can*, G. Ulas, A. Ildiz, E. Neslihan, E. Ada, A. Ozerdem, Turkey

P.1.i.039  The analysis of TMS brain mapping of plastic changes in scapular-arm replantation patients

P.1.i.041  Novel insights into the neurometabolic homeostasis of cocaine addiction: aberrant glutamatergic mechanisms in the nucleus accumbens

P.1.i.042  A multicenter positron emission tomography study of GABA receptor availability in adults with autism

P.1.i.044  Evolution of default-mode network alteration in OCD-patients following a cognitive behavioral therapy
C. Tezenas*, M. Morgièvre, L. Mallet, K. N'Diaye, France

P.1.i.045  The effects of long-term psychosocial adversity on dopaminergic function and the acute stress response
M. Bloomfield*, R. McCutcheon, T. Dahoun, M. Kempton, L. Valmaggia, T. Freeman, V. Glover, J. Pruesner, C. Morgan, S. Kapur, O. Howes, United Kingdom

P.1.i.046  Early and recent stress affects white matter microstructure in unipolar patients
V. Aggio*, S. Poletti, E. Mazza, I. Bollettini, S. Brioschi, C. Colombo, F. Benedetti, Italy

P.1.i.047  A novel social perception task for testing the social interaction model in pharmaco-fMRI protocols with selective serotonin reuptake inhibitors
N. Beinhölzl*, N. Naor, H. Okon-Singer, A. Buchenau, U. Scharrer, E. Molloy, A. Villringer, J. Sacher, Germany

P.1.i.048  Reduced gray matter in subcortical brain regions in MDD: preliminary results of an ultra-high field 7 Tesla MRI Study
P.1.i.049  Blunted neural response to implicit negative facial affect in anorexia nervosa
J. Leppanen*, V. Cardi, Y. Paloyelis, A. Simmons, K. Tchanturia, J. Treasure, United Kingdom

P.1.i.050  Effects of cardiovascular fitness on hippocampal volume and vasculature in young adults
A. Kaiser*, A. Schrantee, M.M. Solleveld, L. Reneman, P.J. Lucassen, The Netherlands

P.1.i.051  Disruption of white matter structural integrity in young adults with depressive symptoms: a diffusion tensor imaging study
K. Same*, M.H. Aarabi, M. Mayeli, F. Rahmani, Iran

P.1.i.052  Does brain magnetic resonance spectroscopy allow the detection of metabolite changes during immunomodulatory therapy in multiple sclerosis?
T.M. Gondek*, A. Zacharzewskas-Gondek, A. Pokryszko-Dragan, M. Sasiadek, J. Bladowska, Poland

P.1.i.053  Associations between central chemokine levels and glial activation in first episode psychosis – a positron emission tomography study

P.1.i.054  Response inhibition in misophonia
N. Eijsker*, A. Schröder, G. Van Wingen, D. Denys, The Netherlands

P.1.j.035  Effects of a glucose drink on executive brain functioning and perceived workload
M. Mackus*, M. Van Schrojenstein Lantman, V. Hoebregts, P. Jackson, J.C. Verster, A. Scholey, The Netherlands

P.1.j.036  A comparison of assessment of cognitive functioning on phones and tablets

P.1.j.037  Effect of GABA PAM drugs on the Oppel-Kundt illusion visual processing in patients with schizophrenia spectrum disorders
E. Dirzius*, G. Zukauskaite, D. Leskauskas, A. Bulatov, Lithuania

P.1.j.038  Influence of erythropoietin derivatives and their mutated forms on measurement of S100B protein in focal ischemia of rat prefrontal cortex
F. Shakova*, I.A. Zakharova, T.I. Kalinina, G.A. Romanova, S.G. Morozov, Russia

P.1.j.039  Endophenotype status and neuro-hemodynamic correlates of spatial working memory in obsessive compulsive disorder

P.1.j.040  Social cognition in autism spectrum disorder is associated with brain serotonin transporter availability
A. Tangen*, M. Andersson, K. Nyström, S. Bölte, C. Halldin, L. Farde, J. Lundberg, J. Borg, Sweden

P.1.j.041  Explorative analysis of the association between trail making test error types and brain connectivity in first episode psychosis
E. Bourama*, B. Dvoracek, I. Stamou, K. Sedlakova, I. Fajnerova, L. Farde, J. Lundberg, J. Borg, Sweden

P.1.j.042  Intact perception of illusions in patients with schizophrenia
M. Roinishvili*, L. Grzeczkowski, A. Shaqiri, M. Okruashvili, E. Chkonia, A. Brand, F. Mast, M. Herzog, Georgia

P.1.j.033  Early recognition and treatment of delirium using the confusion assessment method for the intensive care unit in cardiac surgical intensive care unit
F. Zanobini*, M. Nitti, G. Giubbolini, F. Giubbolini, A. Fagiolini, Italy

P.1.j.034  Probing translation: investigating the effect of a serotonin 5-HT6 antagonist compound on cognitive performance of aged rats
Risk factor gene BIN1 induces late onset Alzheimer disease presymptomatic phenotypes in a BAC transgenic mouse model


Rapid memory replay of life-like episodic sequence of events precedes their verbal recall from long-term memory

X. Viñals*, I. Rodríguez, I. Sols-Balcells, A. Ben-Yakov, L. Fuentemilla, Spain

Acute escitalopram administration improves Stop-signal inhibitory control in healthy volunteers

N. Skandali*, J. Rowe, V. Voon, J. Deakin, T. Robbins, B. Sahakian, United Kingdom

The examining of changes in basal ganglia and cerebellar networks at rest in children with attention deficit hyperactivity disorder

S. Gengeç Benli*, S. Içer, S. Ozmen, Turkey

Genetic variation in the Estonian population: a pharmacogenomic study of adverse drug reactions using electronic health records

K. Krebs*, T. Tasa, M. Kals, R. Mägi, T. Esko, A. Metspalu, J. Vilo, L. Milani, Estonia

The introduction of psychotherapy in psychiatric outpatients as part of the treatment in the last four years in a Greek hospital

G. Lyrakos*, V. Spinaris, I. Spyropoulos, Greece

Proposed cellular mechanisms for the effects of aripiprazole on the contractility of gastric smooth muscles

N. Prissadova*, I. Stefanova, D. Getova, A. Krustev, H. Badakov, Bulgaria

Obestatin effect on pain sensitivity, caused by chemical and thermal stimulus in BALB/c white mice

A.A. Galakhova*, E.E. Khirazova, A.A. Guseva, Russia

H1 histamine receptor antagonist exerts antitumor effect against primary and commercial human glioblastoma cell lines


Learning deficits and hippocampal neurogenesis in rats overexpressing the dopamine transporter

N. Bernhardt*, M. Lieser, H. Edemann Callesen, A. Garthe, C. Winter, Germany

Chronic magnesium supplementation increases hippocampal neurogenesis and decreases proliferation in myocardium in ACTH-treated rats

J. Petrovic*, M. Labudović-Borović, N. Puškaš, D. Stanić, B. Batinić, B. Plečaš-Solarović, V. Pešić, Serbia

Tracking the ventral striatum temporal response during social feedback in anorexia nervosa

P.1.I.028  Expression of selected signaling proteins in hippocampus of knock-out mice devoid of alpha1A-or alpha1B-adrenergic receptor subtypes
K. Chorążka*, J. Kuśmierczyk, A. Zelek-Molik, G. Kreiner, M. Bagińska, I. Nalepa, Poland

P.1.I.029  Ghrelin: a potential role in the physiological adaptations to long term food restriction and nutritional recovery?
P. Duriez*, E. Berreby, V. Tolle, O. Viltart, France

P.1.I.030  Sexual dimorphic effect of the invalidation of GHS-R on GH ultradian secretion and meal pattern
A. Labarthe, P. Zizzari, O. Fiquet, J. Veldhuis, E. Egecioglu, M. Bohlooly, J. Epelbaum, V. Tolle*, France

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
Disruption of mGluR5-Homer1 interactions modulates glutamatergic signaling and promotes rapid antidepressant effects
T. Serchov, A. Holz*, F. Mülsch, C. Normann, D. Van Calker, K. Biber, Germany

Neuroimmune mechanisms of resilience/susceptibility to stress
M.S. Paladini*, A.C. Rossetti, L. Rubini, G. Racagni, M. Papp, M.A. Riva, R. Molteni, Italy

Anti-depressant-like effects of cannabidiol and cannabidiolic acid in genetic rat models of depression

Childhood trauma affects tryptophan metabolism in mood disorder
R. Bonsignori*, S. Poletti, M. Riberto, G. Schüetze, C. Locatelli, M. Schwarz, F. Benedetti, Italy

The relationship between chronotype and problematic drinking according to gender in mood disorder
J.Y. Kong*, South-Korea

Elevated cytokine plasma levels in patients with major depressive disorder
A. Mrad*, Tunisian Republic

Early screening during pregnancy for maternal psychopathology reduced post-partum depressive symptoms and improved mother–infant attachment
E. Petri*, O. Bacci, L. Palagini, S. Banti, C. Borri, C. Foghi, D. Marazziti, M. Mauri, Italy

Blood epitranscriptomic biomarkers to predict suicidal behavior

Dynamic connectivity analysis of selective serotonin reuptake inhibitor effects, a pharmacological PET/MR study

Depression severity and cognitive symptoms are independent predictors of functioning in patients with depression
K.G. Larsen*, J.M. Haro, D. Saragoussi, L. Hammer-Helmich, Denmark

Assessment of impulsivity with self-report scales and behavioral tasks in symptomatic and remitted patients with major depression
C. Oğüt*, K. Başar, Turkey

Efficacy of venlafaxine extended-release compared with placebo in major depressive disorder patients by severity of anxiety symptoms
G. Lyndon*, R. Prieto, D. Wajsbrot, C. Allgulander, B. Bandelow, United Kingdom

A real-world study on time-to-initiation and dose optimization of major depressive disorder treatment in the United States
R. Prieto Lopez*, Y. Yeh, X. Gao, I. Chopra, C. Sounthonevat, R. Chambers, E. Pappadopulos, M. Boucher, A. Shelbaya, Spain

Dysthymia and double depression in a mental health unit
A. De la Cruz Dávila, I. Veiga Ramos*, M.T. Ríos Vilas, C. Quinteiro Rouco, Spain

Sleep quality in mothers with postpartum depression and maternity blues: a preliminary study
L. Del Matto*, G. Costoloni, C. Caterini, F. Salvaro, S. Bolognesi, A. Goracci, A. Fagiolini, Italy

Aerobic exercise decreases cortisol awakening reaction in depressed inpatients
**P.2.b.046** Non-invasive brain stimulation for the treatment of depression: systematic review and meta-analysis of randomised, sham-controlled trials  
J. Mutz*, D. Edgcumbe, V. Thoma, C.H.Y. Fu, United Kingdom

**P.2.b.047** Time perception and binge watching among medical students with depressive symptoms  
M. Boudali, M. Hamza*, S. Halayem, A. Bouden, A. Belhadj, Tunisian Republic

---

**P.2.d** **BIPOLAR DISORDERS (CLINICAL)**

**P.2.d.030** Symptoms and functioning in aripiprazole once-monthly maintenance treatment of bipolar I disorder: a blinded, placebo-controlled, randomised study  

**P.2.d.031** High prevalence of cesarean sections in women with bipolar disorder  

**P.2.d.032** Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response?  
A. Pikalov*, J. Goldberg, C. Siu, Y. Mao, J. Tsai, A. Loebel, USA

**P.2.d.033** Social cognition and exposure to trauma in individuals with bipolar disorder  
C. Gama*, D.S. Martins, L.S. Czepielewski, M.H. De Sousa, J. Bucker, M. Kauer-Sant’Anna, M. Kunz, Brazil

**P.2.d.034** Possible links between antipsychotic dosage equivalency and clinical features in bipolar patients  
M. Nascimento*, F. Bacelar, A. Nobre, Portugal

**P.2.d.035** Functional impairment in adult bipolar disorder with ADHD  
I. Torres*, M. Garriga, B. Sole, C.M. Bonnin, E. Vieta, J.M. Goikolea, A. Martinez-Aran, Spain

**P.2.d.036** A Homer1 gene variant influences brain white matter structure and lithium effects in bipolar disorder  
A. Vitali*, E. Mazza, C. Lorenzi, S. Poletti, I. Bollettini, F. Benedetti, Italy

**P.2.d.037** Tract-based fractional anisotropy mediates the relationship between illness duration and cognitive performances in bipolar disorder  
E.M.T. Melloni*, S. Poletti, I. Bollettini, S. Brioschi, C. Locatelli, F. Benedetti, Italy

**P.2.d.038** The serum S100B as a potential marker in bipolar spectrum disorder  

**P.2.d.039** Impact of childhood trauma and affective temperament on resilience in bipolar disorder  
B.G. Unübol*, S. Kesebir, Turkey

**P.2.d.040** Potential genes behind the difference between bipolar I and bipolar II disorder  

**P.2.d.041** The impact of psycho-educational group program on drug attitude and global functioning of real patients with bipolar disorder  

**P.2.d.042** Predominant polarity in bipolar disorder – is there a genetic base?  

**P.2.d.043** Effect of the inflammatory biomarker C-reactive protein on response to lurasidone treatment in patients with bipolar depression  
A. Pikalov*, C. Raison, C. Siu, J. Tsai, K. Koblan, A. Loebel, USA
P.2.d.044 Bipolar disorder and white matter microstructure: ENIGMA bipolar disorder fractional anisotropy DTI results

TREATMENT (BASIC)

P.2.e.008 Evaluation of inhaled loxapine treatment in psychiatric patients with acute agitation
D.R. Mendez Mareque*, V. Alter Labandeira, A. Lopez Cortiña, B. Salazar Laya, D. Rey Souto, A. Nuñez Boquete, J. Crespo Iglesias, A. Nuñez Perez, Spain

P.2.e.009 Ketamine exerts anxiogenic and antidepressant effects dependent on serotonin and AMPA receptors in mice
M. Erdinc, I. Kelle, H. Akkoc, E. Uyar*, L. Erdinc, Turkey

P.2.e.010 Differential susceptibility of the alpha(1)-adrenergic receptor subtypes to antidepressant drugs action: in vitro study
J. Kusmierczyk*, P. Chmielarz, K. Rafa-Zablocka, M. Kowalska, I. Nalepa, Poland

P.2.f.033 Positive clinical predictors of response to repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression
E. Pirdogan Aydın*, E. Türkylmaz Uyar, M. Dalkiran, A. Genç, Ö.A. Özer, K. Oğuz Karamustaloglu, Turkey

P.2.f.034 Effects of adjunctive aripiprazole in patients with major depressive disorder with inadequate response to standard antidepressant therapy
J.S. Lee*, S.G. Kim, South-Korea

P.2.f.035 JNJ-42847922/MIN-202, a selective orexin 2 receptor antagonist, demonstrates beneficial effects on mood and sleep in patients with major depressive disorder
K. Recourt*, G. Van Amerongen, G. Jacobs, R. Zuiker, R. Luthringer, P. Van der Ark, J. Van Gerven, The Netherlands

P.2.f.036 Safety and efficacy of ketamine infusion in treatment-resistant depression with multiple medical comorbidities: a case report

P.2.f.037 Effect of long-term valproate treatment on bone metabolism in patients with bipolar disorder: a pilot study
A. Cuomo*, G. Costoloni, A. Goracci, F. Ferretti, A. Fagioli, Italy

P.2.f.038 Antidepressant efficacy and safety in depression treatment with heart failure patients: a review of randomized controlled trials
E. Moreira*, S. Martins, J. Silva-Cardoso, L. Fernandes, Portugal

P.2.f.039 SSRI outcome depends on the environment: citalopram amplifies the influence of sociodemographic characteristics on mood in the STAR*D study
A. Viglione*, S. Poggini, G. Matte Bon, F. Chiarotti, A. Giuliani, I. Branchi, Italy

P.2.f.040 The effect of 10-day theta-burst stimulation on symptom severity and cognition in major depression – a pilot study
Net effect of serotonin reuptake inhibitors on suicidality in depression is beneficial rather than harmful already during the first week of treatment

Discontinuation of hypnotic medication in trazodone once daily versus venlafaxine extended release users
J. Hubenak*, E. Cermakova, Czech Republic

Do SSRIs cause an initial increase in anxiety in depressed patients participating in placebo-controlled trials?

Longitudinal investigation of subjective and objective cognitive side effects of electroconvulsive therapy – a pilot study
J.Z. Petersen*, M.B. Jørgensen, H.M. Jensen, L.V. Kessing, K.W. Miskowiak, Denmark

Comorbidity of depression and panic disorder affects suicide attempts in patients with mood disorders
V. Liaugaudaite*, A. Podlipskyte, N. Mickuviene, Lithuania

Should we consider sleep disturbances as predictors of suicidal behavior?
G. Serafini*, M. Pompili, P. Girardi, M. Amore, Italy

Toxoplasma gondii seroprevalence in a cohort of Italian psychiatric inpatients with mood or psychotic disorders: a preliminary communication
C. Del Grande*, E. Schiavi, I. Maschi, M. Barbuti, G. Maccariello, B. Pinto, G. Massimetti, F. Bruschi, L. Dell’Osso, Italy

“Fat burners”, when the flames reach the mood: mania episode induced by dietary supplements
A. Trabsa*, A. Palma, D. Sanagustin, L. González, E. Monteagudo, M. De Dios, V. Pérez, Spain

Depression symptoms and obstructive sleep apnea in coronary artery disease patients
A. Juskiene*, G. Varoneckas, A. Podlipskyte, Lithuania

Depressive symptoms in elderly indigenous people of the Xukuru do Ororuba ethnic group, Brazil
K. Petribu*, F. Lima, S. Brotto, D. Leao, M. Arruda, S. Araujo, Brazil

The nitric oxide synthase activity as a biomarker of major depressive episode and response to antidepressant treatment
E. Loeb*, B. Feve, P. Chanson, L. Becquemont, E. Corruble, France

Updated programme:
http://2017.ecnp.eu / ECNP app / congress info terminals
P.3.a

PSYCHOTIC DISORDERS (BASIC)

P.3.a.009 Cannabidiol rescues glutamatergic, memory and social interaction deficits following prenatal infection: a follow-up in female offspring
A.L. Osborne*, N. Solowij, I. Babic, X.F. Huang, K. Weston-Green, Australia

P.3.a.010 Sex differences in a neurodevelopmental animal model of schizophrenia: focus on white matter structures and myelin

P.3.a.011 Lactational immune activation model: from trans-diagnostic risk to trans-diagnostic prevention
M. Arad, Y. Piontkewitz, N. Albelda, N. Wolff, I. Weiner*, Israel

P.3.b

PSYCHOTIC DISORDERS (CLINICAL)

P.3.b.038 Hand functions in patients with schizophrenia: comparison with bipolar disorder and healthy subjects
M. Hacioglu Yildirim, E.A. Yildirim, E. Carpar*, T. Coskun, D. Ipekcioglu, G. Canturk, Turkey

P.3.b.039 Spatio-temporal perception and boundaries of self: evaluation of peripersonal space in schizotypy traits
G. Di Cosmo*, F. Fiori, F. Ferré, A. Salone, M. Corbo, M. Costantini, G. Martinotti, L. Marzetti, M. Di Giannantonio, Italy

P.3.b.040 Obstetric complications and cognitive function in schizophrenia

P.3.b.041 Clinical, cognitive and imaging evidence of a neurodevelopmental continuum in offspring of probands with schizophrenia and bipolar disorder

P.3.b.042 The longitudinal trajectory of serum brain-derived neurotrophic factor (BDNF) levels in psychotic patients: a prospective observational study

P.3.b.043 Two-year follow-up of patients with a first psychotic episode: comparison between affective and non-affective psychoses and predictors of functioning
C. Torrent, M. Reinares, A. Martinez-Aran*, B. Cabrera, M. Parellada, I. Corripio, M. Cuesta, M. Bernardo, E. Vieta, Spain

P.3.b.044 Speech graph analysis of verbal fluency tests distinguish between patients with schizophrenia and healthy controls
A. Turek*, K. Machalska, A.A. Chrobak, A. Tereszko, M. Siwek, D. Dudek, Poland

P.3.b.045 Psychosis in Wilson’s disease: an unusual presentation of bipolar affective disorder
L.F. Black, J.F.G. Underwood*, United Kingdom

P.3.b.046 Comparison of serum tumor necrosis factor-like weak inducer of apoptosis levels in patients with schizophrenia and healthy control subjects
U. Ozkal*, G. Gultekin, S. Incir, N. Konuk, N. Kocabasoglu, H.M. Emul, Turkey

P.3.b.047 Stress-induced prefrontocortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis
C. Schifani*, H.H. Tseng, M. Kenk, E. Navas, A. Tagore, P.M. Rusjan, S. Houle, R. Mizrahi, Canada

P.3.b.048 S100B protein and psychopathology in acute phase paranoid schizophrenia patients

P.3.b.049 Cholinergic neurotransmission and cognition in medication-free subjects with psychosis
W.A.M. Vingerhoets*, G. Bakker, M. Van der Pluijm, O. Bloemen, M. Caan, J. Booij, T. Van Amelsvoort, The Netherlands
P.3.b.050  Effects of metabolic alterations on cognitive functioning in schizophrenia
M. Spangaro*, M. Bosia, M. Bechi, M. Buonocore, R. Cavallaro, Italy

P.3.b.051  Add-on aripiprazole for atypical antipsychotic induced clinically significant hyperprolactinemia

P.3.b.053  Validation of the international classification of functioning, disability and health core set for schizophrenia from the perspective of psychologists
L. Nuño, M. Barrios, E. Rojo, J. Gómez-Benito, G. Guilera, A. Mateu*, Spain

P.3.b.054  Polypharmacy in a sample of psychiatric inpatients
A. Fernandez-Quintana*, M. Vidal Millares, M. García Mahía, Spain

P.3.b.055  Break and recovery points of fusion differentiate schizophrenia from bipolar disorder patients

P.3.b.056  CB1-5-HT2A heteromers and neurological soft signs in schizophrenia patients: human studies in pro-neurons of the olfactory epithelium
L. Galindo*, P. Robledo, E. Moreno, A. Cuenca-Arroyo, D. Guinart, R. De La Torre, V. Perez-Sola, Spain

P.3.c.010  Modulation of sub-chronic ketamine-induced locomotor sensitisation by midbrain dopamine neuron firing

P.3.c.011  Evolution of patients with paranoid schizophrenia treated with paliperidone injection
P. Nechita*, G. Craciun, D.C. Nechita, M. Mutica, M.C. Pirlog, A. Ciubara, Romania

P.3.c.012  Clozapine and levomepromazine induce the cytochrome P450 isoenzyme CYP3A4, but not CYP1A1/2, in human hepatocytes
P. Danek*, A. Basinska-Ziobron, W.A. Daniel, J. Wójcikowski, Poland

P.3.c.013  Follow-up 30 cases of patients treated with aripiprazole depot along 18 months continuation or discontinuation
P. De Jaime Ruiz*, Spain

P.3.d.038  Aripiprazole LAI vs. paliperidone LAI in inpatients with psychosis comorbid with substance use disorder: clinical and QoL effects at 1-year follow-up
I. Cuomo*, G.D. Kotzalidis, S. De Persis, F. Perrini, E. Amici, S. De Filippis, Italy

P.3.d.039  Safety and tolerability of brexpiprazole in adults with schizophrenia: results of an open-label, long-term study

P.3.d.040  A study comparing weight gain from ALKS 3831 to olanzapine in early-illness young adults with schizophrenia, schizophreniform, or bipolar I disorder
M. David*, A. Simmons, Y. Jiang, C. Graham, B. Silverman, Ireland

P.3.d.041  Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966

P.3.d.042  Theta burst stimulation on medial prefrontal cortex in schizophrenia patients with impaired social cognition: a pilot 1H-MRS study
F. Briend*, C. Nathou, F. Kauffmann, N. Delcroix, L. Lecardeur, O. Etard, S. Dollfus, France
**P.3.d.043** Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia


**P.3.d.044** Efficacy of high-frequency neuronavigated repetitive TMS in auditory verbal hallucinations: a double-blind controlled study in patients with schizophrenia


**P.3.d.045** Effect of brexpiprazole on prolactin: an analysis of short- and long-term trials in schizophrenia

J. Ivkovic*, A. Lindsten, V. George, H. Eriksson, M. Hobart, Denmark

**P.3.d.046** Effect of dopamine D2 receptor and serotonin 2A receptor gene polymorphisms on response to risperidone in schizophrenia

A. Charanraj Goud*, D.G. Shewade, R. Raj Kumar, A. Surendiran, India

**P.3.d.048** The effect of ethnicity and immigration on treatment resistance in schizophrenia

V. De Luca*, Canada

**P.3.d.049** Efficacy of metacognitive training compared with a psychosocial rehabilitation program on social cognitive processing in schizophrenia

E. Varga*, S. Endre, D. Molnár, T. Tényi, R. Herold, Hungary

**P.3.d.050** Subjective experience and attitude towards treatment after switching from oral to LAI antipsychotics in schizophrenia: an observational 24-month study

L. Tatini*, F. Pietrini, G. Talamba, E. Calderani, L. Poli, F. Chiarello, P. Marino, C. Baschirotto, M. Santella, L. Mallardo, V. Ricca, A. Ballerini, Italy

**P.3.d.051** Hospitalisation rate in individuals with schizophrenia treated with long acting injectable atypical antipsychotics in Latin America – the REALAI study

R. Rodriguez, L. Palmeira, J. Ramos, B. Soares*, F. Guarniero, J. Diaz, Brazil

**P.3.d.052** A major challenge for clinicians: discussing rechallenge with clozapine through a case series

S. Hun Senol*, G. Gurcan, A. Ertugrul, A.E. Anil Yagcioglu, Turkey

**P.3.d.053** Antipsychotic-induced hyperprolactinemia in a sample of psychotic patients

A. Fernandez-Quintana*, M.C. García Mahía, Spain

**P.3.d.054** Lipid profile of patients taking antipsychotics

W. Bouali*, R. Ben Soussia, I. Marrag, F. Ellouze, K. Hajji, Tunisian Republic

**P.3.d.055** Effects of sertindole on EEG activity in patients with schizophrenia

M. Debicka, A. Kroć*, A. Wierzbicka, L. Wolkow, W. Jernajczyk, A. Wichniak, Poland

**P.3.d.056** Low-dose clozapine induced severe and persistent sinus tachycardia: review of two cases

M. Yalcin*, O. Odabasi, E.E. Bestepe, Turkey

**P3.e** OTHER (BASIC)

**P.3.e.007** Does genetics of obesity overlap with pharmacogenetics of antipsychotic induced weight gain? A molecular pathway analysis

H. Corfitsen*, B. Krantz, A. Drago, Denmark

**P.3.e.008** Referential deficits as a clinical marker of formal thought disorder

D. Cokal*, G. Sevilla, S. Watson, W.S. Jones, M. Douglas, H. Spencer, D. Turkington, N. Ferrier, W. Hinzen, United Kingdom

**P.3.e.009** Epigenetic signature of early trauma: differences in the FKBP5 DNA methylation levels among psychotic patients, their healthy siblings and controls

M. Mihaljevic*, D. Franic, I. Soldatovic, S. Andric, B. Stankovic, B. Zukic, S. Pavlovic, M. Adzic, N. Maric, Serbia

**P.3.f** OTHER (CLINICAL)

**P.3.f.019** Metabolic syndrome and schizophrenia: the role of substance abuse

C. Ferreira*, L. Castanheira, L. Ferreira, Portugal
P.3.f.020  The association of simvastatin use with decreased IL-6 in schizophrenia may suggest a new alternative add-on treatment  
_P. Belmonte-de-Abreu*, Brazil_

P.3.f.021  Genetic variants within key nodes of the cascade of antipsychotic mechanisms: effects on treatment response and schizophrenia psychopathology  

P.3.f.022  Subjective interview quality metrics predict scoring performance in the administration of the PANSS  
_S. Negash, B. Echevarria, L. Stein, E. Prochnik, M. Ropacki*, USA_

P.3.f.023  What is the best methodology for external review of recorded interviews and ratings in schizophrenia clinical trials?  
_D. Daniel*, A. Kott, USA_

P.3.f.024  Within person variance as a quality metric – an exploratory analysis identifying outlier sites in schizophrenia clinical trials  
_A. Kott*, X. Wang, G. Sachs, D. Daniel, Czech Republic_

P.3.f.025  Gender differences in the relationship between executive functions and delusion-like experiences – preliminary studies  
_A. Tereszko*, W. Janeczko, K. Słowik, K. Brzezicka, K. Prochwicz, M. Siwek, D. Dudek, Poland_

P.3.f.026  Global functioning and quality of life in primary versus secondary negative symptoms in schizophrenia  
_A. Toma*, O. Capatina, Romania_

P.3.f.027  Course of negative symptom subdomains in schizophrenia: a one year follow-up study  
_O. Capatina*, I. Miclutia, Romania_

P.4.a.013  The role of annexins family proteins in posttraumatic stress disorder  
_D. Avetyan*, G. Mkrtchyan, Rep. of Armenia_

P.4.a.014  Study of synaptic plasticity changes in posttraumatic stress disorder  
_G. Mkrtchyan*, D. Avetyan, Rep. of Armenia_

P.4.a.015  Sense of coherence as a coping mechanism for women with anxiety living in deprivation  
_O. Remes*, N. Wainwright, P. Surtees, L. Lafortune, K.T. Khaw, C. Brayne, United Kingdom_

P.4.a.016  Administration of para-chlorophenylalanine reduces both expression and acquisition of context-conditioned fear  
_S.M. Hagsäter*, E. Johansson, R. Pettersson, E. Eriksson, Sweden_

P.4.a.017  From uncertainty to checking: the role of metacognitive monitoring in obsessive compulsive disorder (OCD)  
_A. Baptista*, K. N’Diaye, L. Mallet, France_

P.4.b.013  Secondary traumatisation and some related outcomes in firefighters  
_G. Bastug*, A. Ergul Topcu, O.F. Ergun, E.T. Ozel-Kizil, Turkey_

P.4.b.014  The prevalence of posttraumatic stress disorder and mental health of Korean Vietnam War veterans 40 years after the war  

P.4.b.015  The prefrontal-amygdala circuit in trait anxiety and generalized anxiety disorder. Testing the boundaries between healthy and pathological worries  
P.4.b.016 Will early intervention with SSRI versus benzodiazepines reduce the risk of developing posttraumatic stress disorder?
I. Frankova*, Ukraine

P.4.b.017 The evaluation of motor cortex excitability measures in patients with obsessive–compulsive disorder
S. Simsek*, Turkey

P.4.b.018 Distinct contributions of obsessive and compulsive symptoms for whole-brain functional connectivity in obsessive-compulsive disorder

P.4.c TREATMENT (BASIC)

P.4.c.005 Prevalence of anxiety and depressive symptoms in a Canadian medical cannabis use cohort
M. Van Ameringen*, W. Simpson, J. Turna, B. Patterson, P. Lucas, Canada

P.4.d TREATMENT (CLINICAL)

P.4.d.009 A neural model for the anxiolytic effects of deep brain stimulation in patients with obsessive compulsive disorder
E. Fridgeirsson*, M. Figee, J. Luigjes, G. Wingen, D. Denys, The Netherlands

P.4.d.010 Comparison of serotonin reuptake inhibitor (SRI) alone versus SRI plus bright light therapy combination for obsessive compulsive disorder
K. Turgut*, M. Boysan, A. Aydin, M. Ak, Turkey

P.4.d.011 Panicolytic effect of naltrexone: a randomised clinical trial
A. Franceschi Biagioni*, R.C.R. Freire, A.G. Nardi, N.C. Coimbra, Italy, Brazil

P.4.d.012 Enhancing inhibition processes during cognitive-behavioral therapy in obsessive-compulsive disorder with repetitive transcranial magnetic stimulation
G. Grassi*, S. Pacini, C. Cecchelli, S. Pallanti, Italy

P.4.e OTHER (BASIC)

P.4.e.008 Sex-dependent differences in oxytocin receptor gene methylation between posttraumatic stress disorder patients and trauma-exposed healthy controls

P.4.e.009 Facilitation of contextual fear extinction by orexin-1 receptor antagonism is associated with the activation of specific amygdala cell subpopulations
A. Flores*, C. Herry, R. Maldonado, F. Berrendero, Spain

P.4.e.010 Sucrose intake test as a tool to study vulnerability/resilience towards acute stress
N. Sala*, L. Musazzi, P. Tornese, M. Popoli, Italy

P.4.f OTHER (CLINICAL)

P.4.f.006 Cardiovascular reactions to psychosocial stress, Type D personality and trait anxiety in patients with coronary artery disease
J. Gecaite*, J. Burkauskas, J. Brozaitiene, N. Mickuviene, Lithuania

P.4.f.007 Subcortical brain volumes as endophenotypes of social anxiety disorder – preliminary findings from the Leiden Family Study on social anxiety disorder
J.M. Bas-Hoogendam*, H. Van Steenbergen, N.J.A. Van der Wee, P.M. Westenberg, The Netherlands
P.5.a  DEMENTIA (BASIC)

P.5.a.003  Effects of dimethyl fumarate treatment on adult neurogenesis in the streptozotocin-induced rat model of sporadic Alzheimer’s disease
E. Kurowska*, I. Majkutewicz, M. Podlacha, D. Myslinska, B. Grembecka, J. Rucinski, E. Jurkowlaniec, Poland

P.5.a.004  The impact of phospholipase D functional ablation in physiology and in an Alzheimer’s disease model in Caenorhabditis elegans
F. Bravo*, J. Silva, G. Di Paolo, A. Castro, T. Oliveira, Portugal

P.5.b  DEMENTIA (CLINICAL)

P.5.b.010  Comparative study of the effects of supportive educational programs: for family caregivers of the elderly with dementia

P.5.b.011  Association of hemoglobin levels and cognitive function in Alzheimer’s disease and mild cognitive impairment
H. Kim*, K.J. Lee, South-Korea

P.5.b.012  Antidepressants and anxiolytics in cognitive impairment: conclusions of a longitudinal study
C. Cenalmor Aparicio*, S.M. Cabello de Alba, T. Crespo Generelo, J.D. Vaquerizo Serrano, J. Olazarán Rodríguez, Spain

P.5.b.013  Classification and prediction of neuropathological change of Alzheimer’s disease using machine learning and MRI
A. Kautzky*, R. Seiger, A. Hahn, P. Fischer, W. Krampla, S. Kasper, G. Kovacs, R. Lanzenberger, Austria

P.5.c  NEUROLOGICAL DISORDERS (BASIC)

P.5.c.005  Patient-specific and in vitro models for the analysis of late-onset Alzheimer’s disease
T. Ehrhardt*, M. Jung, C. Hartmann, I. Giegling, D. Rujescu, Germany

P.5.c.006  Behavioral impairments after intranasal administration of alpha-synuclein oligomers in aged mice
I. Kalinin*, O.A. Solovieva, A.T. Proshin, M.A. Gruden, V.V. Sherstnev, Russia

P.5.d  NEUROLOGICAL DISORDERS (CLINICAL)

P.5.d.009  Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson’s disease

P.5.d.010  Implications of comorbidity and acute illness severity in elderly patients with delirium
S. Martins*, E. Pinho, R. Correia, E. Moreira, L. Lopes, L. Azevedo, L. Fernandes, Portugal

P.5.d.011  Antipsychotics without psychosis: exploratory study in Portuguese nursing homes
A.R. Ferreira*, E. Moreira, J. Guedes, M.R. Simões, L. Fernandes, Portugal

P.5.d.012  Anterograde amnesia following a hanging attempt: a case report
Y. Goren*, A. Glik, A. Steinmetz, G. Zalsman, T. Fischel, Israel

P.5.d.301  Four-year course of impulsive and compulsive behaviours in Parkinson’s disease: the Norwegian ParkWest study
A. Erga*, G. Alves, O. Tysnes, K. Pedersen, Norway
**ALCOHOL (BASIC)**

**P.6.a.009** Neural correlates of the anticipation of a sip of beer in young adult males  
M.M. Groefsema*, M. Luijten, R.C.M.E. Engels,  
The Netherlands

**P.6.a.010** Two binges of ethanol a day induces epigenetic modulations and astrogliosis in adolescent rats  

**P.6.a.011** Neuroactive steroid hormones – potential targets for personalized therapy of alcohol dependence  
T. Shushpanova*, N.A. Bokhan, A.I. Mandel, T.P. Novozheeva, A.V. Solonsky, Russia

**ALCOHOL (CLINICAL)**

**P.6.b.013** Neuropsychological correlates of as-needed pharmacotherapy in alcohol dependence: double-blind placebo control study with the opioid antagonist nalmefene  

**P.6.b.014** The effects of combined transcranial direct current stimulation and alcohol attentional retraining as a treatment for alcohol dependent inpatients  
T. Den Uyl*, T.E. Gladwin, J. Lindenmeyer, R.W. Wiers,  
The Netherlands

**P.6.b.015** Affective temperaments in alcohol dependence: influence of depression  
C. Guldner, M. Mohamed, M.C. Bourdel, X. Laqueille, A. Dervaux*, France

**P.6.b.016** Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder  

**P.6.b.017** Adversities in childhood and alcohol dependence disorder in adults  
M. Gonçalves*, J. Teixeira, C. Ferreira, A. Feijão, L. Nascimento, Portugal

**DRUGS (BASIC)**

**P.6.c.013** The effect of chronic toluene inhalation on hippocampus-dependent memory and the ultrastructure of the rat hippocampus  
N. Pochkhidze*, M. Zhvania, N. Japaridze, M. Dashniani, G. Lobzhanidze, Georgia

**P.6.c.014** ACTH4-10 analogue Semax and adamantane derivative hemantane produce significant reduction of withdrawal signs in morphine-dependent rats  
M. Konstantinopolsky*, L.G. Kolik, Russia

**P.6.c.015** Chronic restraint stress-induced sensitization to cocaine: role of coflin in nucleus accumbens  
D. Rigoni*, M. Avalos, A. Guzmán, M. Bisbal, L. Cancela, F. Bollati, Argentina

**P.6.c.016** BDNF alterations in nucleus accumbens shell during morphine withdrawal  
H. Geoffroy*, N. Marie, F. Noble, France

**P.6.c.017** Obsession in obsessive-compulsive disorder and cocaine addiction  
P. Smith*, K. N’Diaye, F. Vorspan, L. Mallet, France

**P.6.c.018** Matricaria chamomilla extract decreases morphine withdrawal symptoms and morphine self-administration in rats  
Z. Jamali*, Iran

**P.6.c.301** Synthetic cannabinoids: a new addiction matrix  
A. Scocard*, A. Benyamina, S. Coscas, L. Karila, France

**P.6.b.301** Intranasal oxytocin in alcohol use disorder: an ongoing randomized placebo-controlled trial  
**P.6.d**  
**DRUGS (CLINICAL)**

**P.6.d.016** The relationship between suicidal behaviour and family history of suicidal behavior and psychiatric disorders  
T. Oznur, C. Celik, A. Bolu, M.S. Aydin*, E. Kızilay, S. Atik, K.N. Ozmenler, O. Uzun, Turkey

**P.6.d.017** Assessment of depression and anxiety among methadone maintenance treatment program patients  
A. Vasylyeva*, V. Yarovoy, Ukraine

**P.6.d.018** Alcohol use disorders in patients with cannabis dependence seeking treatment  
A. Dervaux*, M. Bourdel, M. Krebs, X. Laqueille, France

**P.6.d.019** Patients with cannabis dependence seeking treatment: gender differences  
A. Dervaux*, M. Krebs, M. Bourdel, X. Laqueille, France

**P.6.d.020** Opioid maintenance therapy for the treatment of opioid use disorders in outpatients with or without schizophrenia  
J.F. Bouton, X. Laqueille, M.C. Bourdel, A. Dervaux*, France

**P.6.d.021** Six-month follow up of patients with dual pathology in a community mental health setting  
A. Novo Ponte*, A. Fernandez Quintana, C. Quiroga Fernandez, M.C. Garcia Mahia, Spain

**P.6.d.022** Predicting screen failure rates of human abuse potential studies  
L. Webster, R. Ashwin, E. Hansen, R. Turncliff*, K. Rooney, USA

**P.6.d.023** Can cytokines serve as biomarkers of current cocaine use?  
T. Milpied, F. Vorspan*, B. Etain, C. Marie-Claire, France

**P.6.e**  
**OTHER (BASIC)**

**P.6.e.005** Neural activity in response to smoking-related and neutral pictures in three different states in smokers  
C. Steinegger*, E. Engeli, M. Kirschner, M. Stepien, C. Paulson, M. Herdener, L.M. Hulka, Switzerland

**P.6.e.006** Relationship between cyberaddiction and social anxiety among students in medicine: about 188 students  
B. Amamou*, A. Ben Hawala, A. Mhalla, F. Zaafrane, L. Gaha, Tunisian Republic

**P.6.f**  
**OTHER (CLINICAL)**

**P.6.f.007** Relationship between cocaine craving and plasma leptin levels in addicted patients: a preliminary study  
G. Baroni*, C. Montemitro, S. Andreoli, M. Di Nicola, L. Leggio, L. Janiri, G. Martinotti, Italy

**P.6.f.008** Relation between food addiction and nutritional status in patients candidates for bariatric surgery  
M. Fuentes*, G. Gabler, J. Silva, P. Olguin, A. Rodriguez, Chile

**P.6.f.009** Feasibility and validity of mobile cognitive testing in patients with substance use disorders  

**TUESDAY INDUSTRY INFORMATION**

Updated programme:  
http://2017.ecnp.eu / ECNP app / congress info terminals
DISORDERS (BASIC)

P.7.a.007 Psychosocial determinants of poor quality of life of children with congenital heart disease
A. Sydorenko*, Ukraine

P.7.a.008 Understanding the role of the amygdala in attention-deficit/hyperactivity disorder: association between brain structure, function and delay aversion
J. Van Dessel*, M. Moerkerke, E. Sonuga-Barke, J. Lemiere, S. Van der Oord, M. Danckaerts, Belgium

P.7.a.009 In a quest for autism spectrum disorders subgroups
B. Pop, A. Isac*, Romania

DISORDERS (CLINICAL)

P.7.b.015 Effectiveness of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study
M. Tocco*, C. Arango, C.U. Correll, R. Goldman, J. Cucchiaro, L. Deng, A. Loebel, USA

P.7.b.016 Striatal hyperactivation associates with insulin resistance and reward delay discounting in adolescents with excess weight

P.7.b.017 Genes involved in the genetics of ADHD are enriched in mutations associated with verbal memory in schizophrenia
I. Albertsen, A. Drago*, Denmark

P.7.b.018 EEG theta/beta ratio correlates positively with inattention and memory problems in ADHD and controls
H. Kiiski*, M. Bennett, C. Kelly, K. Grogan, L. Rai, A. Sweeney, E. Mihelj, R. Boyle, A. Aleni, J. Bramham, R. Whelan, Ireland

P.7.b.019 Social and executive functions related to autistic symptomatology in adults with high-functioning autism

P.7.b.020 Diagnostic stability of autism spectrum disorders with the DSM-5 diagnostic criteria
M. Solerdelcoll Arimany*, A. Blázquez, R. Calvo, E. Varela, O. Puig, L. Lázaro, Spain

P.7.b.021 How saliva is useful for identification of antioxidants and vaspin in anorexia nervosa

TREATMENT (CLINICAL)

P.7.d.011 Medium-term efficacy data of medications in children and adolescents with autism spectrum disorder: an 18 months retrospective follow up study
J. Boi*, F. Donno, S. Petza, F. Cera, C. Balia, S. Carucci, A. Zuddas, Italy

P.7.d.012 Testing the efficacy of a smartphone application in improving medication adherence among children with ADHD
O. Weisman*, Y. Schonherz, T. Harel, M. Efron, M. Elazar, D. Gothelf, Israel

P.7.d.013 ADHD medications and the risk of epileptic seizures: a pharmacoepidemiological study using nationwide register data
I. Brikell*, L. Ghirardi, Z. Chang, B.M. D’Onofrio, R. Kuja-Halkola, H. Larsson, Sweden

P.7.d.014 Efficacy of guanfacine extended release in children and adolescents with ADHD and comorbid oppositional defiant disorder
M. Huss, J. Newcorn, D. Connor, A. Hervás, T. Werner-Kiechle*, B. Robertson, Switzerland

P.7.d.015 Study 329 suggests paroxetine to exert an antidepressant effect in children and adolescents
A. Lisinski*, F. Hieronymus, S. Nilsson, E. Eriksson, Sweden

P.7.d.016 Can we predict onset of tic disorder during methylphenidate treatment? A neuroimaging study
H. Yılmaz*, N.B. Özbaran, T. Bildik, S. Erermiş, S. Köse, Z. Yüncü, M.C. Çalli, Turkey
**P.7.e** OTHER (BASIC)

**P.7.e.003** Psychiatric symptoms – single manifestation of left thalamic tumor in adolescent – case report

F. Rad*, A. Buica, A. Stan, G. Grigore, C. Anghel, L. Kobylinska, I. Dobrescu, Romania

**P.7.f** OTHER (CLINICAL)

**P.7.f.005** Physiologically based pharmacokinetic model development for trazodone: application to paediatric dose projection

P. Coppola*, R. Picollo, A. Ke, F. Garofolo, S. Tongiani, Italy

**P.7.f.006** Cognitive characterization of offspring of patients with schizophrenia, bipolar disorder and a community control with ADHD traits


---

**P.8.a** OTHER TOPICS (BASIC)

**P.8.a.001** Role of ghrelin in metabolic and neuroendocrine adaptations to undernutrition in a mouse model of chronic food restriction

E.Y. Berreby*, A. Labarthe, P. Zizzari, P. Durriez, M. Mequinion, E. Egecioglu, M. Bohlooly, J. Epelbaum, O. Viltart, V. Tolle, France

---

**P.8.b** OTHER TOPICS (CLINICAL)

**P.8.b.009** Pokémon Go: is it a potential tool for mental health?

M. Van Ameringen*, W. Simpson, J. Turna, B. Patterson, K. Pullia, Canada

**P.8.b.010** Bodily pain perception in heart failure patients is associated with health-related quality of life impairment that endures for five years

J. Burkauskas*, N. Kazukauskiene, I. Duoneliene, N. Mickuviene, J. Brozaltiene, Lithuania

**P.8.b.011** Facial emotion recognition ability in psychiatrists, psychologists and psychological counselors

M. Dalkiran*, G. Gultekin, Turkey

**P.8.b.012** Adult attention deficit and hyperactivity disorder in violent prisoners

A. Nivoli, L. Folini, M. Antonioli*, A. Lepretti, P. Milia, L. Lorettu, Italy

---

**Updated programme:**

http://2017.ecnp.eu / ECNP app / congress info terminals
Introduction

All participants of the 30th ECNP Congress are welcome to attend the industry sessions.

ECNP invites industry to participate in the congress in three ways:

- Industry sessions (satellite symposia and the expert science exchange)
- Exhibition
- Group registration

Programmes of the satellite symposia have been approved by the Scientific Programme Committee of the congress and granted accreditation for two European CME credits by the European Accreditation Committee in CNS (EACIC).

Abstracts from speakers of the satellite symposia will be published after the congress in a supplement to the ECNP journal European Neuropsychopharmacology. They are available on http://2017.ecnp.eu, congress information terminals at the venue, and the ECNP app.

The satellite symposia are scheduled on Saturday, Sunday and Monday. The expert science exchange sessions take place on Sunday, Monday and Tuesday. See page 206-208 for the detailed schedule. The programme of these sessions can be found on pages 209-217.
List of partners

The following companies and organisations have confirmed their participation in the 30th ECNP Congress.

In alphabetical order:

**ABP - Brazilian Psychiatric Association**
*Stand number: 13*

The Brazilian Psychiatric Association (ABP) organises and hosts the XXXV Brazilian Congress of Psychiatry (CBP), the main event in psychiatry in Latin America. Under the theme “The Future of Psychiatry within the Neurosciences”, the 35th edition will take place on 25-28 October 2017 in São Paulo.

[www.abp.org.br](http://www.abp.org.br)

**ANGELINI**
*Stand number: 4*

Angelini is a privately held international company. Founded in Italy in 1919, Angelini has branches in 20 countries and employs 5,000 people. Pharma is the group’s core business, representing over 50% of the company’s € 1.5 billion 2015 revenue. Angelini focuses its research and commercial activities mainly on infection, pain and inflammation, and CNS diseases and disorders.

[www.angelini.it](http://www.angelini.it)

**CINP - International College of Neuropsychopharmacology**
*Stand number: 25*

The International College of Neuropsychopharmacology (CINP) is a truly worldwide membership organisation established over 50 years ago. Membership is on an individual basis. We offer members the opportunity to become part of this knowledgeable group of scientists, to participate at our meetings, and to publish in our own IJNP.

[www.cinp.org](http://www.cinp.org)

**concentris research management gmbh**
*Stand number: 14*

concentris is specialised in the management of EU-funded research projects. We carry out the non-scientific tasks of funded research projects and provide support and consultancy services for scientists and researchers at universities, in businesses and research institutes from the first project idea to the successful completion.

[www.concentris.de](http://www.concentris.de)

**DGPPN – The German Association for Psychiatry, Psychotherapy and Psychosomatics**
*Stand number: 21*

From anxiety disorder to obsessive-compulsive disorder, from science to care – the DGPPN Congress gathers all the expertise in psychiatry and psychotherapy in one place. Thanks to its broad range of topics, renowned experts and excellent continuing education opportunities, it has established itself as a central forum for the field of mental health.

[www.dgppnkongress.de](http://www.dgppnkongress.de)

**EBC – European Brain Council**
*Stand number: 24*

The European Brain Council (EBC) is a non-profit organisation gathering patient associations, major brain-related societies and companies. Its mission is to promote brain research in order to improve the quality of life of those living with brain disorders in Europe. 165 million Europeans have a brain disorder, costing more than € 800 billion annually.

[www.braincouncil.eu](http://www.braincouncil.eu)
EPA – European Psychiatric Association  
Stand number: 26

With active individual members in as many as 88 countries and 40 National Society/Association Members who represent more than 78,000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. EPA’s activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development.  
www.europsy.net

EUFAMI
Stand number: 20

EUFAMI is an international NGO based in Belgium committed to improving the care and welfare for people with mental illness. Our mission is to represent at the European level all family members of persons that are affected by mental illness and to protect their rights and interests.  
www.eufami.org

FENS – Federation of European Neuroscience Societies
Stand number: 19

FENS is the voice of European neuroscience. With 43 neuroscience member societies across 33 European countries, FENS as an organisation represents 24,000 European neuroscientists with a mission to advance European neuroscience education and research. FENS promotes neuroscience research to policy-makers, funding bodies and the general public, both regionally and internationally.  
www.fens.org

GAMIAN-Europe
Stand number: 23

GAMIAN-Europe (Global Alliance of Mental Illness Advocacy Networks-Europe), a patient-driven pan-European organisation, represents the interests of persons affected by mental illness and advocates for their rights. Its main objectives are advocacy, information and education, anti-stigma and discrimination, patients’ rights, co-operation, partnerships and capacity building.  
www.gamian.eu

Gedeon Richter Plc.
Stand number: 7
Satellite symposium: C.08

Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company. It has manufacturing subsidiaries in five countries and markets its products in one hundred countries. Its latest achievement in R&D is the original antipsychotic compound, cariprazine, already marketed in the US for the treatment of bipolar mania and schizophrenia.  
www.richter.hu

H. Lundbeck A/S
Stand number: 2 and 3
Satellite symposia: C.01, C.03, C.04, C.05 and C.09
Expert science exchange: CE.01 and CE.03

Lundbeck – improved treatment and a better life for people living with psychiatric and neurological disorders. A global pharmaceutical company specialised in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research in neuroscience with focus on depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.  
www.lundbeck.com

Janssen
Stand number: 5
Satellite symposium: C.10

At Janssen, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We collaborate with the world for the health of everyone in it. Follow us at www.twitter.com/janssenEMEA.  
www.janssen.com/EMEA
LivaNova
Stand number: 18
Expert science exchange: CE.05

LivaNova exists at the intersection of advancing technology and transforming lives for people impacted by difficult to treat depression, drug resistant epilepsy, cardiopulmonary diseases and cardiac rhythm disorders. We develop Vagus Nerve Stimulation, the first approved adjunctive long-term treatment option, offering sustained efficacy & increased quality of life with unique safety and guaranteed compliance.  
www.livanova.com

Lucimed
Stand number: 16

Lucimed is a Belgian company that manufactures the Luminette, a pair of light therapy glasses used to fight seasonal affective disorder (SAD) and circadian disorders (sleep, jet-lag, shift work). The Luminette was born in 2006 after four years of university research in Liège, Belgium.  
www.myluminette.com

Lundbeck Institute
Stand number: 2

Our mission is to develop and cascade unbiased, evidence-based medical education in psychiatry and neurology from leading experts to health care professionals and create a forum to facilitate knowledge-sharing. Since 1997 we have been committed to providing expert, international, interactive seminars, thereby building a valued legacy in medical education.  
www.lundbeck.com

Monsenso
Stand number: 28

Monsenso is an innovative technology company offering an mHealth solution to help optimise the treatment of mental disorders. Our mission is to help clinicians, researchers, and individuals overcome the burden of mental illness.  
www.monsenso.com

NbN – Neuroscience-based Nomenclature
Stand number: 11

The Neuroscience-based Nomenclature (NbN) is an ECNP-led international collaboration established to align the nomenclature of psychotropic drugs with the neuroscience underlying them. The new nomenclature encompasses all medications with CNS indications and is now available to clinicians for free download on the iOS App Store and the Google Play Store.  
http://nbnomenclature.org

NEUROFIT
Stand number: 15

NEUROFIT, your worldwide preferred partner (CRO) in the evaluation of treatments for central and peripheral nervous system disorders. We offer a comprehensive validated list of in vitro and in vivo models fully adapted to your needs. Our goal is to accelerate the development of your programs by providing cost-effective methods.  
www.neurofit.com

Otsuka Pharmaceutical Europe Ltd
Stand number: 3
Satellite symposium: C.03 and C.09
Expert science exchange: CE.01

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka’s 45,000 employees ensure that patients have access to innovative products and medical devices in our therapy areas of central nervous system disorders, endocrinology, nephrology, gastroenterology and oncology.  
www.otsuka-europe.com

Pfizer Inc.
Expert science exchange: CE.02

At Pfizer, we apply science and our global resources to bring therapies that extend and significantly improve people’s lives. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products.  
www.pfizer.com
**Porsolt**  
*Stand number: 9*

Porsolt provides efficacy and safety pharmacology, covering the drug development process from early screening through to regulatory submission. Porsolt also provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiples species and multiple disease areas, tailored solutions and bespoke model development.  
[www.porsolt.com](http://www.porsolt.com)

**PRA Health Sciences**  
*Stand number: 17*

Over the last 30 years, PRA Health Sciences has built the most comprehensive, high-end Early Development Services group in the world. Our pharmacology experts deliver innovative solutions from state-of-the-art facilities in Europe and North America. PRA also operates GLP-compliant laboratories close to the clinical units, enabling us to quickly analyse time-critical samples.  
[https://prahs.com](http://https://prahs.com)

**Pronexus Analytical AB**  
*Stand number: 12*

Pronexus Analytical is a preclinical CRO offering services in CNS pharmacology, neurochemistry and bioanalysis, with a focus on PK/PD studies and in vivo microdialysis in experimental models of CNS and metabolic disorders. The bioanalytical services include UHPLC-MS/MS, HPLC, and immunoassays for measuring disease biomarkers and drug levels in biological samples.  
[www.pronexus.se](http://www.pronexus.se)

**Recordati S.p.A**  
*Stand number: 7  
Satellite symposium: C.08*

Recordati is a European specialty pharmaceutical group dedicated to partnering, discovering and developing innovative, value-added products. Recordati is committed to the research and development of treatments for rare diseases, new specialties within the urological area and in psychiatry commercialising cariprazine, a novel atypical antipsychotic drug for the treatment of schizophrenia.  
[www.recordati.com](http://www.recordati.com)

**Servier**  
*Stand number: 1  
Satellite symposium: C.07*

Servier is at the forefront of research and education in the neurosciences, with heavy investment in neuropharmacology for the treatment of brain diseases: depression, Alzheimer’s and Parkinson’s diseases, and schizophrenia. The most recent result of our research is agomelatine, an antidepressant indicated in the treatment of patients with major depressive episodes.  
[www.servier.com](http://www.servier.com)

**Shire**  
*Expert science exchange: CE.04*

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialised conditions. We strive to develop best-in-class products across our core therapeutic areas, including haematology, immunology, neuroscience, ophthalmics, lysosomal storage disorders, gastrointestinal/internal medicine/endocrine, hereditary angioedema, and oncology.  
[www.shire.com](http://www.shire.com)
**Sooma Medical**  
*Stand number: 27*

Sooma Medical develops non-invasive neuromodulation devices for treatment of neurological and psychiatric disorders. The treatment utilises a mild form of brain stimulation known as transcranial direct current stimulation (tDCS). Patients in over 25 countries have benefited from Sooma Depression Treatment since it was approved in 2014.  
www.soomamedical.com

**Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.**  
*Satellite symposium: C.02*

Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. Sumitomo Dainippon Pharma Co., Ltd. is among the top-ten listed pharmaceutical companies in Japan operating globally. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.  
www.ds-pharma.com  
www.sunovion.com

**Sunovion Pharmaceuticals Europe Ltd.**  
*Stand number: 6*

Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.  
www.sunovion.eu

**The Lancet**  
*Stand number: 8*

The Lancet is the world’s leading, independent general medical journal, publishing original primary research and review articles of the highest standard. Since its inception in 1823, the journal has sought to address urgent topics in health and society, initiate debate, put science into context, and influence decision makers around the world.  
www.thelancet.com

**WFSBP Congress 2019 – 14th World Congress of Biological Psychiatry**  
*Stand number: 22*

During the upcoming World Congress of Biological Psychiatry in Vancouver, worldwide opinion leaders will share with us the recent innovations in their respective fields which impact on diagnosis, treatment and quality of life of our patients. High scientific level sessions will be organised: plenary lectures, symposia, interactive workshops and debates.  
www.wfsbp-congress.org

**Wisepress Medical Bookshop**  
*Stand number: 10*

Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of the ECNP Congress available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter: @WisepressBooks.  
www.wisepress.com
Overview Saturday

SATURDAY 2 SEPTEMBER

C.01 | 12.15-14.00
Satellite symposium
Bleu

THINC-it™: from mood to cognition

Educational financial support by H. Lundbeck A/S

C.10 | 12.15-14.00
Satellite symposium
Bordeaux

Continuous treatment in schizophrenia: addressing the controversies

Educational financial support by Janssen Pharmaceutical Companies

C.03 | 14.45-16.30
Satellite symposium
Bordeaux

Improvement of functional outcomes in schizophrenia – the role of long-acting injectable antipsychotics

Educational financial support by Otsuka Pharmaceutical Europe Ltd. & H. Lundbeck A/S

C.04 | 14.45-16.30
Satellite symposium
Bleu

Functional consequences of major depressive disorder

Educational financial support by H. Lundbeck A/S

Overview Sunday

SUNDAY 3 SEPTEMBER

CE.01 | 09.00-11.00
Expert science exchange
Room 241

Appropriate treatment choice in recent-onset schizophrenia: applicability and usefulness of a novel e-health tool

Organised by Otsuka Pharmaceutical Europe Ltd. & H. Lundbeck A/S

CE.02 | 15.00-17.00
Expert science exchange
Room 241

Great debates on optimizing treatment for MDD

Organised by Pfizer Inc.

C.05 | 17.15-19.00
Satellite symposium
Bordeaux

Treatment-resistant schizophrenia (TRS) – clinical presentation, neurobiology and treatment considerations

Educational financial support by H. Lundbeck A/S

C.07 | 17.15-19.00
Satellite symposium
Havane

The depressed patient’s perspective in achieving remission

Educational financial support by SERVIER

C.08 | 17.15-19.00
Satellite symposium
Maillot

Treatment of schizophrenia negative symptoms in the light of current therapeutic possibilities

Educational financial support by Gedeon Richter Plc. & RECORDATI S.p.A
Overview Monday & Tuesday

MONDAY 4 SEPTEMBER

CE.03 | 09.00-11.00
Expert science exchange
Room 241

From cognitive function to daily functioning in depression

Organised by H. Lundbeck A/S

CE.04 | 15.00-17.00
Expert science exchange
Room 241

Addressing comorbid adult ADHD in psychiatric patients

Organised by Shire International GmbH

C.02 | 17.15-19.00
Satellite symposium
Maillot

Rethinking the spectrum of mood disorders: implications for diagnosis and management

Educational and financial support provided by Sunovion Pharmaceuticals and Sumitomo Dainippon Pharma

C.09 | 17.15-19.00
Satellite symposium
Bordeaux

Can we improve functioning in our patients with schizophrenia? The potential role of D2 partial agonists

Educational financial support by Otsuka Pharmaceutical Development & Commercialization Inc. & H. Lundbeck A/S

TUESDAY 5 SEPTEMBER

CE.05 | 09.00-11.00
Expert science exchange
Room 241

Redefining treatment goals for difficult to treat depression

Organised by LivaNova

Saturday 2 September

C.01

SATellite SYMposium
12.15-14.00 | Bleu

THINC-it™: from mood to cognition

Chair: Raymond Lam, Canada

C.01.01
Functional impairment in patients with major depressive disorder
Raymond Lam, Canada

C.01.02
The validation of THINC-it™
Roger McIntyre, Canada

C.01.03
Cognitive function and mood study: cognitive dimensions in depression and functional correlates
Bernhard Baune, Australia

Educational financial support provided by H. Lundbeck A/S

C.10

SATellite SYMposium
12.15-14.00 | Bordeaux

Continuous treatment in schizophrenia: addressing the controversies

Chair: Henry Nasrallah, USA

C.10.01
Long-term treatment in schizophrenia: what defines treatment success in the clinical and real-world setting?
Istvan Bitter, Hungary

C.10.02
What are the biological and clinical hazards associated with psychotic relapses in the long-term management of schizophrenia?
Henry Nasrallah, USA

C.10.03
Personal and social functioning: do patients benefit from continuous antipsychotic treatment in schizophrenia?
Jose Olivares, Spain

Educational financial support provided by Janssen Pharmaceutical Companies
**SATELLITE SYMPOSIUM**

**C.03**

**14.45-16.30 | Bordeaux**

**Improvement of functional outcomes in schizophrenia – the role of long-acting injectable antipsychotics**

*C.03.01*

Towards understanding functional outcome in psychotic disorders and the influence of treatment

*Ashok Malla, Canada*

*C.03.02*

The priorities and preferences of patients with schizophrenia

*John F.P. Bridges, USA*

*C.03.03*

Optimisation of care in schizophrenia for relapse prevention with long-acting injectable antipsychotics

*Robin Emsley, South Africa*

*C.03.04*

Towards functional improvement in schizophrenia

*Stephan Heres, Germany*

*Educational financial support provided by Otsuka Pharmaceutical Europe Ltd & H. Lundbeck A/S*

**SATELLITE SYMPOSIUM**

**C.04**

**14.45-16.30 | Bleu**

**Functional consequences of major depressive disorder**

*C.04.01*

Addressing cognitive dysfunction in major depressive disorder

*Judith Jaeger, USA*

*C.04.02*

Functional consequences of major depressive disorder

*Lene Hammer-Helmich, Denmark*

*C.04.03*

How can we improve functional outcomes in major depressive disorder?

*Christopher Bowie, Canada*

*Educational financial support provided by H. Lundbeck A/S*

**Sunday 3 September**

**EXPERT SCIENCE EXCHANGE**

**CE.01**

**09.00-11.00 | Room 241**

**Appropriate treatment choice in recent-onset schizophrenia: applicability and usefulness of a novel e-health tool**

*CE.01.01*

An e-health tool for treatment choice in recent-onset schizophrenia: why, what, and how?

*Robin Emsley, South Africa*

*09.00*

*CE.01.02*

From theory to practice (part I) – Applicability of the e-health tool in clinical practice: initial pharmacological treatment in recent-onset schizophrenia

*John M. Kane*

*09.20*

*CE.01.03*

From theory to practice (part II) – Applicability of the e-health tool in clinical practice: what if the patient doesn’t do well or relapses following initial antipsychotic treatment?

*Christoph Correll, USA*

*09.40*

*CE.01.04*

An e-health tool for treatment choice in recent-onset schizophrenia: why, what, and how?

*Robin Emsley, South Africa*

*10.00*

*CE.01.05*

From theory to practice (part I) – Applicability of the e-health tool in clinical practice: initial pharmacological treatment in recent-onset schizophrenia

*John M. Kane*

*10.20*

*CE.01.06*

From theory to practice (part II) – Applicability of the e-health tool in clinical practice: what if the patient doesn’t do well or relapses following initial antipsychotic treatment?

*Christoph Correll, USA*

*10.40*

*Organised by Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S*
Sunday 3 September

**CE.02**  EXPERT SCIENCE EXCHANGE  
15.00-17.00 | Room 241

**Great debates on optimizing treatment for MDD**

*Debaters:* Roger McIntyre, USA  
Stephen M. Stahl, USA

Session 1: 15.00-16.00  
Session 2: 16.00-17.00

*Please note both sessions will be identical.*

*Organised by Pfizer Inc.*

**C.05**  SATELLITE SYMPOSIUM  
17.15-19.00 | Bordeaux

**Treatment-resistant schizophrenia (TRS) – clinical presentation, neurobiology and treatment considerations**

*Chair:* John M. Kane, USA

**C.05.01**  Clinical presentation of treatment-resistant schizophrenia (TRS)  
John M. Kane, USA

**C.05.02**  When the drugs don’t work: the neurobiology of TRS and implications for new therapies  
Oliver Howes, United Kingdom

**C.05.03**  Current treatment algorithms and options for TRS  
James MacCabe, United Kingdom

**C.05.04**  Discussion and Q&A  
John M. Kane, USA

*Educational financial support provided by H. Lundbeck A/S*

**C.07**  SATELLITE SYMPOSIUM  
17.15-19.00 | Havane

**The depressed patient’s perspective in achieving remission**

*Chair:* Stephen M. Stahl, USA

**C.07.01**  Diversity in depressed patients and in their psychiatrists  
Koen Demyttenaere, Belgium

**C.07.02**  Restoring functioning: the cornerstone for remission  
Malcolm Hopwood, Australia

**C.07.03**  Sharing my patients’ experiences  
Göran Hajak, Germany

*Educational financial support provided by SERVIER*

**C.08**  SATELLITE SYMPOSIUM  
17.15-19.00 | Maillot

**Treatment of schizophrenia negative symptoms in the light of current therapeutic possibilities**

*Chair:* Andrew Cutler, USA

**C.08.01**  Negative symptoms of schizophrenia: a burden for patients, caregivers and society  
Silvana Galderisi, Italy

**C.08.02**  Treatment of schizophrenia negative symptoms: mono- or add-on therapy?  
Wolfgang Fleischhacker, Austria

**C.08.03**  Antagonist or partial agonist, selective or nonselective drugs – which one is adequate?  
Andrew Cutler, USA

*Educational financial support provided by Gedeon Richter Plc. & RECORDATI S.p.A*
Monday 4 September

**CE.03**  
**EXPERT SCIENCE EXCHANGE**  
09.00-11.00 | Room 241

**From cognitive function to daily functioning in depression**

*Chair: John Harrison, United Kingdom*

**CE.03.01**  
09.00  
*What is the cognitive basis for patient functioning in depression?*  
*Alessandro Serretti, Italy*

**CE.03.02**  
09.20  
*How is cognitive dysfunction in depression described by patients?*  
*John Harrison, United Kingdom*

**CE.03.03**  
09.40  
*Measuring daily functioning in depression*  
*Tracy Greer, USA*

**CE.03.04**  
10.00  
*Does cognition predict functioning in depression?*  
*Josep Maria Haro, Spain*

**CE.03.05**  
10.20  
*Functional recovery in depression: going beyond the MADRS*  
*Eduard Vieta, Spain*

**CE.03.06**  
10.40  
*Assessing and monitoring the function of patients with depression in clinical practice*  
*Danielle Cha, Canada*

Organised by **H. Lundbeck A/S**

---

**CE.04**  
**EXPERT SCIENCE EXCHANGE**  
15.00-17.00 | Room 241

**Addressing comorbid adult ADHD in psychiatric patients**

*CE.04.01*  
15.00  
*Prevalence of ADHD comorbidity in psychiatric patients*  
*Ylva Ginsberg, Sweden*

*CE.04.02*  
15.20  
*Differential diagnosis of ADHD in comorbid psychiatric illness*  
*Larry Klassen, Canada*

*CE.04.03*  
15.40  
*Managing ADHD in comorbid patients*  
*Anthony Rostain, USA*

*CE.04.04*  
16.00  
*Prevalence of ADHD comorbidity in psychiatric patients*  
*Ylva Ginsberg, Sweden*

*CE.04.05*  
16.20  
*Differential diagnosis of ADHD in comorbid psychiatric illness*  
*Larry Klassen, Canada*

*CE.04.06*  
16.40  
*Managing ADHD in comorbid patients*  
*Anthony Rostain, USA*

*Organised by Shire International GmbH*

---

Updated programme:  
http://2017.ecnp.eu / ECNP app / congress info terminals
**C.02**

**SATELLITE SYMPOSIUM**
17.15-19:00 | Maillot

**Rethinking the spectrum of mood disorders: implications for diagnosis and management**

Chair: Roger McIntyre, Canada

C.02.01 Addressing patients needs across the spectrum of mood disorders
Allan Young, United Kingdom

C.02.02 Psychopharmacological interventions in mixed states: available evidence and clinical reality
Peter Haddad, United Kingdom

*Educational and financial support provided by Sunovion Pharmaceuticals and Sumitomo Dainippon Pharma*

**C.09**

**SATELLITE SYMPOSIUM**
17.15-19.00 | Bordeaux

**Can we improve functioning in our patients with schizophrenia? The potential role of D2 partial agonists**

Chair: Philip Gorwood, France

C.09.01 Improvement of patient functioning is an unmet need in schizophrenia
Sofia Brissos, Portugal

C.09.02 Antipsychotic side effects may have a negative impact on patient functioning
Greg Mattingly, USA

C.09.03 D2 partial agonists: their pharmacology and potential role in schizophrenia
Ofer Agid, Canada

C.09.04 Can D2 partial agonists improve functioning in clinical practice?
Christoph Correll, USA

*Educational financial support provided by Otsuka Pharmaceutical Development & Commercialization Inc. & H. Lundbeck A/S*

*This symposium is not open to French healthcare providers*
Introduction

ECNP has organised an exhibition to allow companies and organisations working in the field of clinical neuroscience to educate participants about their services, products, and/or literature. You are invited to visit these stands, where a wide variety of relevant information is presented.

The exhibition can be visited from Sunday to Tuesday, 09.00-17.00.

List of exhibitors

<table>
<thead>
<tr>
<th>COMPANY/ORGANISATION</th>
<th>STAND</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABP - Brazilian Pyschiatric Association</td>
<td>13</td>
</tr>
<tr>
<td>ANGELINI</td>
<td>4</td>
</tr>
<tr>
<td>CINP - The International College of Neuropsychopharmacology</td>
<td>25</td>
</tr>
<tr>
<td>concentris research management gmbh &amp; ECNP</td>
<td>14</td>
</tr>
<tr>
<td>DGPPN - The German Association for Psychiatry, Psychotherapy and Psychosomatics</td>
<td>21</td>
</tr>
<tr>
<td>EBC - European Brain Council</td>
<td>24</td>
</tr>
<tr>
<td>EPA - European Psychiatric Association</td>
<td>26</td>
</tr>
<tr>
<td>EUFAMI</td>
<td>20</td>
</tr>
<tr>
<td>FENS - Federation of European Neuroscience Societies</td>
<td>19</td>
</tr>
<tr>
<td>GAMIAN-Europe</td>
<td>23</td>
</tr>
<tr>
<td>Gedeon Richter Plc.</td>
<td>7</td>
</tr>
<tr>
<td>H. Lundbeck A/S</td>
<td>2,3</td>
</tr>
<tr>
<td>Janssen</td>
<td>5</td>
</tr>
<tr>
<td>LivaNova</td>
<td>18</td>
</tr>
<tr>
<td>Lucimed</td>
<td>16</td>
</tr>
<tr>
<td>Lundbeck Institute</td>
<td>2</td>
</tr>
<tr>
<td>Monsenso</td>
<td>28</td>
</tr>
<tr>
<td>NbN – Neuroscience-based Nomenclature</td>
<td>11</td>
</tr>
<tr>
<td>NEUROFIT</td>
<td>15</td>
</tr>
<tr>
<td>Otsuka Pharmaceutical Europe Ltd</td>
<td>3</td>
</tr>
<tr>
<td>Porsolt</td>
<td>9</td>
</tr>
<tr>
<td>PRA Health Sciences</td>
<td>17</td>
</tr>
<tr>
<td>Pronexus Analytical AB</td>
<td>12</td>
</tr>
<tr>
<td>RECORDATI S.p.A</td>
<td>7</td>
</tr>
<tr>
<td>SERVIER</td>
<td>1</td>
</tr>
<tr>
<td>Sooma Medical</td>
<td>27</td>
</tr>
<tr>
<td>Sunovion Pharmaceuticals Europe</td>
<td>6</td>
</tr>
<tr>
<td>The Lancet</td>
<td>8</td>
</tr>
<tr>
<td>WFSBP Congress 2019 - 14th World Congress of Biological Psychiatry</td>
<td>22</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>10</td>
</tr>
</tbody>
</table>

Floor plan exhibition
The European Accreditation Committee in CNS (EACIC) has granted a total of **28.5 CME credits** for Saturday-Tuesday:

- Saturday 2 September: 3 CME credits
- Sunday 3 September: 8.5 CME credits
- Monday 4 September: 8.5 CME credits
- Tuesday 5 September: 8.5 CME credits

**US CME credits**
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The scientific programme of the 30th ECNP Congress is eligible for a maximum of **28.5 AMA PRA Category 1 creditsTM**.

**Satellite symposia**
ECNP requires that all organisers of satellite symposia at the congress obtain accreditation for European CME. Each satellite symposium has been granted accreditation for **two European CME credits** by EACIC.

**How to apply**
Physicians should only claim CME credit commensurate with the extent of their participation in the activity. Requesting CME credits involves verifying their identity as participant in the 30th ECNP Congress.

Participants can obtain a certificate of participation for claiming credit free of charge by completing an evaluation form about the congress. The evaluation form will be online from the first day of the congress until 1 November 2017. Physicians can also record their participation at the CME accreditation stand at the exhibition during the congress.
Apply online
Participants requesting CME credits are required to complete an online evaluation form about the congress on the EACIC website: www.eacic.eu.

- Click on the 30th ECNP Congress banner (on the top of the homepage).
- Choose the option ‘First-time user’.
- Please provide your family name and first name as printed on your badge.
- Or choose ‘I am returning user’ if you have already started the evaluation of the 30th ECNP Congress.
- Log on or register.
- Choose option 1 (‘I want to evaluate the congress sessions’) or 2 (‘I want to evaluate a satellite symposium’).
- Complete the online evaluation form.
- Press ‘save’.

The CME certificate will be automatically e-mailed to the address provided.

The deadline to fill in the online evaluation form is 1 November 2017.

For more information, visit the CME accreditation desk at the poster area or contact:

European Accreditation Committee in CNS (EACIC)
Scientific secretariat: Dr Daniel Souery
47, avenue Jacques Pastur
1180 Brussels
Belgium
T: +32 4 79 98 74 40
eacic@ulb.ac.be
www.eacic.eu

FOR MEMBERS
ECNP greatly values the engagement and contribution of its members at ECNP Congresses. Please find below, for easy reference, an overview of special privileges and ‘places to be’ for members during the 30th ECNP Congress.

Members’ & Faculty lounge
Location: Level 3

Opening hours:
Saturday 09.00-18.30
Sunday-Monday 08.00-18.00
Tuesday 08.00-17.30

The Members’ & Faculty lounge offers a relaxed atmosphere in which ECNP members and congress faculty can take a moment for themselves between sessions or engage in conversation with one another during the congress. The lounge is equipped with wireless internet, power outlets, a computer with printer, and coffee and tea throughout the day.

General Assembly of ECNP members
Monday 4 September 12.15-13.15 | Havane, Level 3

The annual general meeting of members is ECNP’s highest deliberative body and the embodiment of one of the College’s most fundamental member privileges: the right to vote and help shape ECNP’s future.

Brainstorming sessions
Sunday-Tuesday 07.45-08.45

Nine small focused sessions organised by ECNP members on a topic of their choice. The brainstorming sessions are open to all participants.

Become a member
If the above inspires you to become a member of ECNP please visit www.ecnp.eu/membership. Just fill in the form and pay to immediately enjoy all the member benefits.
The future of neuroscience in Europe relies on the field’s ability to attract and retain talented junior researchers. To underline this, ECNP has developed a range of junior scientist* benefits at this congress, including the ability to:

- Register for the congress free of charge or at a reduced rate.
- Win a Travel Award.
- Learn practical skills at the Career development sessions.
- Attend the two New findings symposia (incorporated in the scientific programme).
- Join us at Bar Arlequin for a ‘science-on-the-rocks’ on Monday evening.

See page 136 for other benefits that we offer to junior scientists throughout the year.

Awards
If you have submitted an abstract, you might have won a Travel Award! After the congress, you will receive € 500 to support your travel costs to the congress.

At the congress, you will also have the chance to win a Poster Award (not exclusively for junior scientists). These awards are given on-site to the posters of the highest scientific excellence, presented in the most effective way. The award consists of € 500 and a commemorative certificate.

Career development sessions
Sunday-Tuesday 13.15-13.45 | Poster area (podium)

These training sessions each feature an engaging expert in the field, specifically invited to share with you their wealth of knowledge and experience. The topics are especially interesting for junior scientists.

---

New findings symposia
As part of the programme of the congress, 16 junior scientists who participated in the 2017 ECNP Workshop in Nice have been invited to give a presentation. Don’t miss the opportunity to attend these sessions (S.12 and S.16).

Science-on-the-rocks
This special junior scientist evening will take place on Monday 4 September from 19.00-20.30 at Bar Arlequin at the Palais des Congrès de Paris. Gitte Knudsen and Damiaan Denys, members of the Executive Committee, will give short talks on their personal perspective on how to combine clinical work, research and personal life.

Be there, the first two drinks will be offered by ECNP! A voucher can be picked up at the ECNP Plaza (for a maximum of 100 people on a first come, first served basis).

---

* ECNP’s definition of a ‘junior scientist’ for the 30th ECNP Congress is:

- Not older than 40 years (on the first day of the meeting).
- Pre-doctoral or doctoral student.
  or
  Post-doc (within first four years of employment after having received their PhD).
  or
  Resident (MD’s in training within first five years after becoming MD).
CONGRESS COMMITTEES

ECNP would like to thank the following people for their invaluable input in establishing the scientific programme for the congress, the review process of the abstracts for lectures and poster presentations, and other activities:

Executive Committee (2017-2019)
Celso Arango, Spain, president
Guy Goodwin, United Kingdom, past-president
Gitte M. Knudsen, Denmark, president-elect
Laurence Lanfumey, France, vice-president
Eduard Vieta, Spain, treasurer
Martien Kas, The Netherlands, secretary

Councillors:
Elisabeth Binder, Germany
Damiaan Denys, The Netherlands
Suzanne Dickson, Sweden
Catherine Harmer, United Kingdom
Stefano Pallanti, Italy
Gil Zalsman, Israel
Co-opt members:
Gerry Dawson, United Kingdom
Joop van Gerven, The Netherlands
Mark Millan, France

Executive Director:
Alexander Schubert, The Netherlands

Scientific Programme Committee (SPC)
Astrid Linthorst, United Kingdom, chair
Gil Zalsman, Israel, chair Educational Committee
Andreas Meyer-Lindenberg, Germany, editor-in-chief
European Neuropsychopharmacology
Nicoletta Brunello, Italy
Suzanne Dickson, Sweden
Kevin Fone, United Kingdom
Philip Gorwood, France
Lucianne Groenink, The Netherlands
Shitij Kapur, United Kingdom
Evgeny Krupitsky, Russia
Carmen Moreno, Spain
Florence Noble, France
Marie-Claude Potier, France
Andreas Reif, Germany
Eduard Vieta, Spain
Guido van Wingen, The Netherlands

Field editor European Neuropsychopharmacology
Jaanus Harro, Estonia, overall review

Scientific Advisory Panel members (2017-2020)
Roger Adan, The Netherlands
Laura Airas, Finland
Pino Alonso, Spain
Frank Bellivier, France
Anton Y. Bespalov, Germany
István Bitter, Hungary
Michael Bloomfield, United Kingdom
Jan Booij, The Netherlands
Jan K. Buitelaar, The Netherlands
Jocelyne Caboche, France
Josefina Castro-Fornies, Spain
Annamaria Cattaneo, United Kingdom
Ginetta Collo, Italy
Andrea Danese, United Kingdom
Andrea de Bartolomeis, Italy
Suzanne L. Dickson, Sweden
Katharina Domshke, Germany
Filippo Drago, Italy
Anne Eckert, Switzerland
Angelika Erhardt, Germany
Mia Ericson, Sweden
Karen Ersche, United Kingdom
David P. Finn, Ireland
Gabriele Fischer, Austria
Kevin C.F. Fone, United Kingdom
Barbara Franke, The Netherlands
Christine Freitag, Germany
Vibe G. Frokjaer, Denmark
Silvana Galderisi, Italy
Alexander Gerhard, United Kingdom
Mark A. Geyer, USA
Philip Gorwood, France
Iria Grande, Spain
Edna Grünblatt, Switzerland
Antoni Gual, Spain
Gregor Hasler, Switzerland
Martin Hatzinger, Switzerland
Judith Homberg, The Netherlands
Iiris Hovatta, Finland
Michal Hrdlicka, Czech Republic
Evgeny Krupitsky, Russia
Marion Leboyer, France
Klaus-Peter Lesch, Germany
Stefan Leucht, Germany
Paul John Lucassen, The Netherlands
Anabel Martinez-Aran, Spain
David Mataix-Cols, Sweden
ECNP MEETINGS AROUND THE CONGRESS

**Brain Day**
This year’s ECNP Brain Day was held on 1 September at the Paris headquarters of the Economic, Social and Environmental Council (ESEC). The goal of the Brain Day is to bring the latest developments in brain research to the general public. Leading French experts gave a series of interactive presentations on the theme of disorders of the brain and health economics.

**ECNP-ISCTM Joint Meeting**
The International Society for CNS Clinical Trials Methodology (ISCTM) held its autumn conference directly before the 30th ECNP Congress, on 31 August-2 September. The second day of the conference (1 September) was a joint meeting with ECNP. Panels of international experts considered topics on outcomes in treatment studies, clinician reported outcomes in multinational CNS trials, and drug development for negative symptoms in schizophrenia.

**Targeted Network Meetings (TNMs)**
The Targeted Network Meetings (TNMs) are small meetings of a maximum of 30 participants held just after the ECNP Congress every year.

Set up to help to develop ideas as a group with the best supporting scientific advice, TNM sessions can cover topics ranging from results already obtained by an ECNP Network, strategies for future projects, potential translational developments or critical assessments of gaps and unmet needs in a specific area.

Three TNMs will be held on Wednesday 6 September at the ECNP Congress venue in Paris, organised by the following ECNP Networks:

- Schizophrenia Network
- Neuroimaging Network
- Child and Adolescent Neuropsychopharmacology Network
Accreditation
Visit the CME accreditation desk at the poster area or look at page 221 for more details.

App
With our specially developed ECNP app you will have the most up-to-date congress information at your digital fingertips. As well as all the details about the congress, the app will also have information about ECNP in general. The app is available for Apple and Android.

Badges
Each registered participant will receive a name badge upon arrival. For organisational and security reasons, we request that all participants and exhibitors wear their badges at all times during the congress activities. Lost badges can be replaced at the registration desk at a cost of € 25 per badge (French VAT included).

Certificate of attendance
Certificates of attendance will be sent to you after the congress to the e-mail address provided in your registration. It is also possible to download the certificate of attendance via the ECNP website for registered participants that have attended the congress*. A link to download the certificate will be available after the congress.

* The certificate of attendance is not available for group- and on-site registrations. If you would like to have a certificate of attendance and you are part of a group, or have registered on-site, please go to the ECNP Plaza (level 3).

Certificate of poster presentation
After the congress poster presenters can obtain a certificate of poster presentation via the ECNP website. The certificate is only available for presenting authors. Co-authors can be listed on the certificate at the request of the presenting author.

Children at the congress
Children are not permitted in the session rooms, poster area or in the exhibition area at the venue. Childcare services are provided by the 30th ECNP Congress. For more information, please visit http://2017.ecnp.eu/general/childcare_services or go to the registration desk.

Cloakroom
The cloakroom is free of charge for congress participants. It is located on Level 0, close to the main entrance.

Opening hours:
Saturday 09.00-21.30
Sunday 07.00-19.30
Monday 07.00-21.00
Tuesday 07.00-18.00

Coffee and lunch
Coffee, tea and lunch are included in the registration fee and are available to all congress participants at the poster area and exhibition on Sunday, Monday and Tuesday:

10.40-11.15 Coffee break
12.00-14.00 Lunch
14.45-15.00 Coffee break

To buy a small snack or beverage, you can find a cash bar on Level 3.

Congress supplement to the ECNP journal European Neuropsychopharmacology (ENP)
All abstracts accepted for publication are published in the congress supplement to ENP. Participants who pre-ordered the supplement will receive their copy by regular mail after the congress. A copy can also be ordered on-site at the registration desk for € 55 (Dutch VAT included).

Disabled persons
The congress venue is equipped with facilities for the disabled. However, if you have any special needs or disabilities, please let the registration secretariat, CPO HANSER SERVICE, know. The staff will be available at the registration desk during the congress opening hours.
ECNP Plaza
The place to be if you want to take a break between sessions or meet up with others during the congress. The ECNP Plaza offers a variety of features and services:

- Find out all about ECNP membership.
- Learn more about current and future ECNP activities and initiatives.
- Find printed copies of our most recent publications.

Furthermore, you can simply come by to relax in our lounge area. You can find us on Level 3 during the following opening hours:

- Saturday 09.00-18.30
- Sunday-Monday 08.00-18.00
- Tuesday 08.00-17.30

Electricity and power outlets
The normal electricity supply is 230 volts. Power outlets are available at several plug-and-charge areas throughout the venue for you to charge electronic devices.

First aid
First aid service is available at Level 3 of the Palais des Congrès de Paris. The telephone number within the venue is: +33 (0)1 40 68 15 03. From outside the venue: 112.

The nearest hospital is:
American Hospital of Neuilly
63, boulevard Victor Hugo
92200 Neuilly-sur-Seine
France
+33 (0)1 46 41 25 25

Insurance
The organisers will not accept liability for individual medical, travel or personal insurance. It is highly recommended that all participants carry proper health and travel insurance.

Language
The official language of the 30th ECNP Congress is English. No translation will be provided.
Speakers’ secretariat* (Level 3, Room 351)
Saturday 09.00-19.00
Sunday-Monday 07.15-18.00
Tuesday 07.15-15.00
Wednesday for TNMs 07.00-14.00

*For speakers of the Educational update sessions
(interactive sessions with multiple choice questions):
Saturday 13.00-16.30
Sunday-Monday 12.00-14.00 & 16.30-18.00
Tuesday 12.00-14.00

Patient art
Every year, ECNP supports a patient artist whose work is of an especially inspiring nature and uses his/her art for our congress-related communication material. The main illustration of the 30th ECNP Congress was kindly made available to us by Personimages (www.personimages.org).

Presentations online
For those who missed a session or would like to review a presentation, all symposium presentations approved for release by their presenters are posted as webcast on the ECNP website after the congress.

Press
ECNP welcomes the press to the 30th ECNP Congress. ECNP places a high priority on informing the public about important news and developments related to the science and treatment of disorders of the brain. The college is happy to facilitate any contacts with ECNP specialists. Tom Parkhill, ECNP press officer, is available to assist, please contact him by e-mail at press@ecnp.eu.

Journalists can pick up press releases, and a press information pack, from the press room (Room 201). This press pack will also contain contact information and news on any additional press activities.

The press room is accessible for registered press only. ECNP also offers a press interview room. Further information is available at the press room.

Printing on-site
Printing on-site is possible at the ECNP Plaza. You can print short e-mails (no attachments) there.

Programme look up
Special terminals are available for searching through the online programme, looking up speakers and abstracts, exhibition information and floor plans. The terminals are located on Level 2 and 3 at the ECNP Plaza, exhibition and Foyer Bleu.

Recording, filming and photography
Audio and video/DVD recording and taking pictures with flash are prohibited during the congress sessions. The only photography which is allowed during session is photography of slides, which is permitted only for reference purposes (to respect the speaker’s copyright, reproduction is strictly forbidden). Photography of posters is allowed under similar terms. No (professional) filming crews or photographers are allowed under any circumstances in the session rooms of the ECNP scientific programme or poster area, except those hired by the 30th ECNP Congress Foundation. Persons in possession of a filming pass (press) are allowed to film and photograph at the designated filming areas (Hall Maillot and the ECNP Plaza).

Session rooms
It is not allowed to bring drinks or food inside the session rooms. When a session room is fully seated, it is not permitted to enter the room or stand at the back of the room due to security regulations.

Smoking
The 30th ECNP Congress is a non-smoking congress.

Taxis
Taxis are usually stationed outside the main entrance of the congress venue.

WIFI
Free wireless internet is available throughout the congress venue.

Network name: ECNP2017
Password: ECNP2017

At the designated plug-and-charge areas in the venue and at the ECNP Plaza you can charge your electronic devices.
PROJECTS AND INITIATIVES
In addition to its meetings, ECNP supports a variety of projects and initiatives designed to enhance the research infrastructure of neuroscience in Europe, and supporting the advancement of important objectives in this field.

- **ECNP Networks:** to facilitate research groups to apply for EU grants and to build common databases accessible to European researchers for conducting studies into the main psychiatric conditions.

- **ECNP Medicines Chest:** to assist clinical researchers in obtaining access to pharmacological compounds.

- **ECNP Junior Scientists Initiative:** to attract and retain junior researchers in the field.

- **ECNP Research Internship:** to provide short-term research internship opportunities for junior researchers in applied and translational neuroscience.

- **Neuroscience-based Nomenclature (NbN):** to rationalise the naming conventions of psychotropic medications.

- **CDE incentives:** lower registration fees for the ECNP Congress, for people from a country with a developing economy (CDE). Also, abstract-submitters from a European CDE country may receive a CDE Grant: free registration to the congress and a grant (€ 500) to cover travel expenses to the congress.

- **Non-MD:** lower registration fees for the ECNP Congress, specifically for those engaged in basic research. It excludes those with medical training.

- **Awards:**
  - **ECNP Neuropsychopharmacology Award**
    For individual achievements in basic science and clinical research.
  - **ECNP Poster Award**
    For outstanding posters of the highest scientific calibre.

ECNP Travel Award
To encourage the attendance of junior scientists at the ECNP Congress.

MEMBERSHIP
ECNP welcomes membership applications from scientists in neuroscience and related disciplines and (with the exception of corresponding members) residing in Europe.

Full membership information can also be found online at: www.ecnp.eu/membership

The top reasons for becoming an ECNP member:

Benefits related to the ECNP Congress
- Significantly reduced registration fees for the ECNP Congress.
- Exclusive access to the Members’ and Faculty lounge at the ECNP Congress.
- ECNP members can bring one junior scientist to the ECNP Congress for € 100.
- The possibility to host a brainstorming session at the next congress

Access to the latest information and research
- Free online subscription to the ECNP journal *European Neuropsychopharmacology.*
- Ability to join an ECNP Network.
- Access to the ECNP members’ website.
- Access to a member directory (‘find a member’), to connect to a wide network of ECNP members.

More opportunities
- Input into ECNP policy, by means of voting at the General Assembly.
- Serve on an ECNP committee and help shape ECNP’s future.
- Apply for an invitation to the ACNP Annual Meeting.
Scientific and organising secretariat
30th ECNP Congress
ECNP Office
Bolognalaan 28
3584 CJ Utrecht
The Netherlands
T: +31 88 75 69 555
F: +31 88 75 59 900
paris2017@ecnp.eu
http://2017.ecnp.eu

Registration and hotel
30th ECNP Congress
CPO HANSER SERVICE GmbH
T: +49 30 300 66 90
F: +49 30 305 73 91
registrationsecretariat@ecnp-congress.eu

Congress venue
Palais des Congrès de Paris
2 Place de la Porte Maillot
75017 Paris
France
www.viparis.com

© Copyright ECNP, August 2017
For the science and treatment of disorders of the brain

31ST ECNP CONGRESS 6-9 OCTOBER 2018 BARCELONA

REGISTER RIGHT NOW at the ECNP Plaza or registration (Level 0) and you will receive 20% DISCOUNT for the next ECNP Congress!

http://2018.ecnp.eu